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Summary 
 
Breast cancer is the most common female cancer in the UK and, despite earlier detection 
and improved treatments, remains the second most common cause of cancer death in 
women. Although therapies exist for breast cancer, including endocrine therapy for 
oestrogen receptor (ER) positive tumours, resistance to current treatment remains a major 
problem. The molecular mechanisms of endocrine resistance have yet to be fully 
elucidated and in order to improve treatment for patients this needs to be addressed. 
Clinically breast cancer presents as several distinct diseases with different outcomes and 
molecular profiles. Over the past decade, through the use of molecular profiling, the 
number of different subtypes of breast cancer has grown and understanding the pathways 
driving each subtype may allow a stratified approach to therapy, allowing patients to 
receive the treatment which will be of most benefit. 
The Nuclear Factor kappa B (NF-κB) pathways regulate the transcription of a wide range 
of genes involved in the immune response, inflammation, proliferation and apoptosis. 
Many of these processes are hallmarks of cancer and NF-κB has been hypothesised to have 
a role in tumorigenesis. The aim of the current study was to investigate the role of both 
NF-κB pathways in the pathogenesis and recurrence of breast cancer.  
Immunohistochemistry was employed to assess key components of the canonical and non-
canonical NF-κB pathways on a tissue microarray (TMA) of 544 patients with full clinical 
follow up and clinical information including ER status, subtype, necrosis, apoptosis and 
angiogenesis. Nuclear expression of p65 phosphorylated at serine 536 was associated with 
angiogenesis and shorter recurrence free interval. Cytoplasmic expression of IKKα was 
associated with cell death (apoptosis and necrosis) and a shorter recurrence free interval 
was also observed for those with high expression. These observations between phospho-
p65/IKKα and recurrence free interval, when subdivided by ER status, remained 
significant in ER positive tumours but were negated in ER negative tumours. When split 
further into subtype, a diverging role for each was observed with phospho-p65 associating 
with recurrence in luminal B tumours and IKKα with luminal A tumours. Other members 
of the NF-κB pathways (p65, IKKβ, NIK and RelB) were not associated with recurrence 
free interval. When these results were tested in an independent cohort, IKKα remained 
significant on recurrence free interval and breast cancer specific survival in ER positive 
tumours however phospho-p65 was only marginally associated with breast cancer specific 
survival. Variability of phospho-p65 is a major issue in IHC studies and therefore an 
alternative marker of the canonical NF-κB pathway is required. Analysis of expression in 
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this second cohort also revealed that high levels of IKKα in the cytoplasm were associated 
with recurrence on tamoxifen. This marker may therefore be able to be employed as a 
diagnostic tool to predict patients who are likely to display endocrine resistance and may 
represent a therapeutic strategy in combination with endocrine therapy, or for patients after 
endocrine resistance has occurred. 
Further examination of the pathways in breast cancer cell lines also demonstrated a 
difference between ER positive and ER negative breast cancer. In ER negative MDA-MB-
231 cells phosphorylation of p65 (from the canonical NF-κB pathway) and 
phosphorylation of p100 (from the non-canonical NF-κB pathway) was apparent even in 
untreated control cells, suggesting constitutive activation. Expression was however found 
to be inducible in ER positive MCF7 cells. 
In order to investigate whether kinases involved in activation of each pathway, IKKβ in the 
canonical pathway and IKKα in the non-canonical NF-κB pathway, had potential as targets 
in breast cancer, we examined the phenotypic impact of silencing their expression in breast 
cancer cell lines. Silencing IKKβ induced apoptosis and decreased cell viability in both 
MCF7 and MDA-MB-231 cells but reduction in expression of IKKα only impacted on cell 
viability and apoptosis in ER positive MCF7 cells. This data, consistent with results from 
the clinical specimens, has therefore revealed that inhibitors of IKKα are likely to be most 
beneficial in the treatment of ER positive tumours. 
These results suggest that the NF-κB pathways are associated with recurrence in patients 
with ER positive tumours with each pathway possibly associating with recurrence in 
different subtypes. Additional studies in a larger cohort, including patients receiving 
aromatase inhibitors are required, accompanied by extensive mechanistic studies to further 
explore the roles of IKKα and IKKβ in breast cancer. These observations highlight that 
different subgroups of breast cancer may have different signalling pathways driving 
progression and therefore patients are likely to benefit from different therapeutic strategies. 
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1.1   Breast cancer epidemiology, pathology and prognostic factors 
 
1.1.1   Breast cancer incidence, mortality and survival 
Breast cancer is the most common female cancer in the UK with more than 49,500 women 
diagnosed in 2010 [1]. The number of cases increases by around 1% each year but a peak was 
seen around 1988 after the introduction of the screening programme due to the detection of 
undiagnosed cancers (Figure 1.1A). The aim of the breast screening programme is to reduce 
mortality rates by earlier detection via mammography before any symptoms are apparent. 
Although earlier detection and improved treatments has resulted in a decrease in the number 
of deaths (Figure 1.1B) breast cancer still remains the second most common cause of cancer 
death in women in the UK with nearly 12,000 deaths attributed in 2010 [2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Incidence and mortality rates of breast cancer in women in the UK over 
time. A: Incidence rates per 100,000 women from 1975-2010 [1]. B: Mortality rates per 
100,000 women, from 1971 to 2011 [2]. The arrow has been added to indicate the 
introduction of the screening programme in 1988. 
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Breast cancer has, however, one of the highest survival rates of the most common cancers in 
the UK. In Scotland the relative survival of women diagnosed in 1998-2002 after 1 year was 
96.1%, after 3 years was 88.1%, for 5 years was 82.8% and the 10 year survival rate was 
76.4% [3]. The survival rate varies with age, Table 1.1 shows the relative survival for each 
age range. 
 
 
 
Years survival 
Age range (years) 
15-44 45-54 55-64 65-74 75-84 85-99 
1 year 98.1% 98.5% 97.8% 95.4% 88.9% 83.2% 
3 year 89.6% 93.3% 93.1% 89.2% 79.3% 65.9% 
5 year 82.6% 86.5% 86.7% 78.2% 69.4% 56.3% 
10 year 73.9% 80.5% 80.7% 72.0% 63.9% 46.1% 
 
Table 1.1: Survival rates of breast cancer in Scotland by age range. The percentage 
survival at 1 and 3 years for patients diagnosed between 2003 and 2007, and the 5 and 10 
year survival for patients diagnosed between 1998 and 2002 are shown (Information from 
[3]). 
 
 
 
 
1.1.2   Breast cancer risk factors 
There are several factors that have been found to increase the risk of breast cancer. Many of 
these factors are linked to exposure to the hormone oestrogen, which plays a role in the 
progression of the disease [4].  
 
1.1.2.1   Age 
The risk of developing breast cancer increases with age and older age is the largest risk factor 
other than female gender. Most breast cancers (over 80%) occur in women over the age of 50. 
For women under the age of 29 the risk is 1 in 2000, the risk increases to 1 in 50 up to age 49, 
1 in 22 up to age 59 and 1 in 13 up to age 69 [5]. 
 
1.1.2.2   Socioeconomic class and geographical variation 
Breast cancer is one of the few cancers where the risk appears to be higher in the more 
affluent social classes [5].  However, once a woman develops breast cancer, it is those in the 
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lower socioeconomic classes that have higher cancer mortality rates, as a result of better 
access to screening and treatment [6-7]. It has been reported that the highest incidence rates of 
breast cancer were found in Western Europe and lowest in Eastern Africa [8], however, those 
diagnosed in developed countries have better survival outcome, again likely due to better 
access to screening and treatment. 
 
1.1.2.3   Puberty and menopause 
An increased risk of breast cancer has been reported in women who had earlier menarche 
(initiation of menses) and earlier onset of regular menses [9]. As well as an increase in risk for 
every year younger at menarche, every year older at menopause has also been found to 
independently increase the risk of breast cancer [10]. Oestradiol serum levels at menopause 
have also been found to influence the risk of breast cancer, with a higher risk in those with 
elevated levels [11]. 
 
Additionally, postmenopausal women who are obese have around a 31% increased risk 
compared to those with a healthy body mass index [12].  As well as an increased body mass 
index, larger waist-hip ratio and weight gain in adulthood also result in a greater risk of breast 
cancer [12]. 
 
1.1.2.4   Childbearing age, parity and breastfeeding 
Several reproductive factors have been reported as being associated with the risk of breast 
cancer. Younger age at first child bearing decreases the risk, the parity (number of births) also 
affected the risk of breast cancer with those with higher parity having a decreased risk [13]. 
Recent studies have investigated these risk factors in different subgroups of patients 
depending on hormone receptor status. It was found that earlier time of menarche and longer 
time between menarche and first full-term childbirth was associated with increased risk in 
both hormone receptor-positive and hormone receptor-negative groups, however only weakly 
in the hormone receptor-negative group. Age at first birth was only associated with a 
decreased risk in the hormone receptor-positive group [14].  
 
1.1.2.5   Hormone replacement therapy 
Hormone replacement therapy (HRT) is widely used after the menopause to alleviate 
symptoms of menopause and prevent osteoporosis [15]. The Collaborative Group on 
Hormonal Factors in Breast Cancer reanalysed data from several studies and found that for 
every year of HRT use the risk of breast cancer increases but was limited to women who were 
currently receiving HRT or had so in the past 5 years [16]. The Million Women Study also 
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investigated the use of HRT and breast cancer incidence and again found that current users of 
HRT were more likely to develop breast cancer than women who had never used HRT [17]. 
There was an increased risk for women prescribed oestrogen only HRT, but the highest risk 
was with oestrogen-progestagen combination. This study estimated there were 20,000 extra 
cases of breast cancers in the UK that decade due to HRT, 15,000 of which were associated 
with oestrogen-progestagen [17]. 
 
1.1.2.6   Family history 
One of the most well known risk factors for breast cancer is family history. If a woman has a 
mother or sister with breast cancer before the age of 50 this increases her risk 2 fold or more 
and if there are multiple affected relatives this increases further. It is thought up to 10% of all 
breast cancers are due to an inherited mutation [18].  
 
For decades it has been known that in families with a strong history of breast cancer, in 
particular those arising in young women, this disease clustering is likely due to the inheritance 
of a highly penetrant dominant susceptibility allele which confers a high risk of developing 
breast cancer [19]. The first susceptibility gene was mapped to the q arm of chromosome 17 
in 1990 [20] and the candidate gene identified 4 years later [21]. BRCA2 was discovered in 
1994 by genomic linkage in families with suspected familial breast cancer but without BRCA1 
mutation. This second breast cancer susceptibility gene was mapped to the q arm of 
chromosome 13 [22]. The contribution of both these genes to inherited breast cancer was 
estimated at 52% for BRCA1 and 32% for BRCA2 with 16% of familial breast cancers not 
being linked to either of these genes [23]. Mutations in both BRCA1 and BRCA2 also increase 
the risk of ovarian cancer. In families with a history of breast and ovarian cancer 81% were 
linked to a mutation in BRCA1 and 14% to a mutation in BRCA2. Mutations in BRCA2 also 
increase the risk of male breast cancer, with 76% of families with male and female breast 
cancer being due to mutations in BRCA2 [23]. 
 
1.1.2.7   Previous breast disease 
Women who have previously had certain benign breast diseases have a higher risk of breast 
cancer. Non-proliferative lesions are not associated with an increased risk but proliferative 
lesions increase the risk. If these lesions are without atypia, there is a 2 times higher risk and 
women with previous atypical hyperplasia have a 4 times higher risk than those with no 
proliferative change [4]. 
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1.1.3   Breast cancer pathology 
 
1.1.3.1   Anatomy of the breast 
The breasts (or mammary glands) consist mainly of fat and each breast has up to 20 lobes 
each with many smaller lobules (Figure 1.2, [24]). These are connected to the nipple by ducts 
and supported by the surrounding fat and connective tissue. Breast tissue leads to the axilla 
(armpit), where a network of lymph nodes exists. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Anatomical structure of the breast. The breast consists mainly of fat and 
contains up to 20 lobes. These lobes are made of smaller lobules and are connected to the 
nipple by ducts (Image from [24]). 
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1.1.3.2   Breast cancer histopathology 
Breast tumours are mainly adenocarcinomas, which arise from epithelial cells that line the 
ducts and lobules. These cells proliferate in the absence of external stimuli and uncontrolled 
growth occurs. Normal breast tissue forms structured glands (Figure 1.3A) and this structure 
is lost in invasive carcinoma (Figure 1.3B). The development of invasive breast cancer may 
be preceded by ductal or lobular carcinoma in situ, which are confined to the site of origin 
(ducts of lobules) and do not spread beyond the basement membrane [25].  
 
 
 
 
 
 
 
 
 
Figure 1.3: Histopathology of normal breast tissue and invasive carcinoma.  
Normal tissue (A) forms structured glands and this structured appearance is lost in invasive 
cancer (B). 
 
The most common invasive breast cancer (around 70% of cases), is ductal carcinoma not 
otherwise specified and it is this group that typically carry the worst prognosis. The normal 
ductal structures form solid nests and in some cases solid sheets of cancer cells [25]. Several 
other special types of ductal carcinoma exist, such as tubular and mucinous carcinoma. These 
are much less common and have a better prognosis. Invasive lobular carcinoma, although 
more likely to occur bilaterally, has a better prognosis than invasive ductal carcinoma not 
otherwise specified and accounts for 5-15% of invasive breast cancers [26]. The cancerous 
cells form rows of cells that infiltrate the stroma [25]. Around 5% of cancers are classed as 
mixed with areas of both ductal and lobular [26]. 
 
This thesis focuses on invasive cancer and therefore does not include any patients with 
carcinoma in situ. 
A B 
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1.1.4   Pathological prognostic markers  
There are several pathological markers of breast cancer relating to the appearance of the 
tumour and how advanced the disease is. These are used diagnostically to stage tumours and 
identify tumours with different prognoses, allowing the selection of optimal treatment. 
 
1.1.4.1   Tumour Size 
Tumour size is categorised into three groups: <2, 2 - 5cm and >5cm. Tumour size is an 
independent prognostic factor for both overall survival and disease free survival [27].  
 
1.1.4.2   Histological Grade 
The grade of tumour depends on its histological appearance and differentiation. Grading of 
breast tumours is based on tubule formation (% of cancer cells composed of tubular 
structures), nuclear pleomorphism (changes in cell size and uniformity) and mitotic index 
(number of dividing cells) [28]. Each of these is scored from 1 to 3 and all are added to give a 
final score of 3-9. If there is tubule formation in more than 75% of the tumour it is scored 1 
point, if 10-64% it is scored 2 points and if less than 10% of the tumour has tubular formation 
it is scored 3 points. For nuclear pleomorphism, if nuclei show minimal variation in size and 
shape the tumour is scored 1 point, moderate variation 2 points and marked variation 3 points. 
The mitotic index is measured as the number of mitoses per 10 fields, the number used to 
assign to 1, 2 or 3 varies depending on the objective and microscope used. 
 
The final score of 3-9 defines the differentiation status of the tumour. Tumours with scores of 
3-5 are considered as Grade 1 and well differentiated. Grade 2 tumours that score a final count 
of 6-7 are considered moderately differentiated. Poorly differentiated Grade 3 tumours are 
assigned a final score of 8-9. The higher the grade, the poorer the prognosis, meaning Grade 3 
patients have the worst prognosis [28]. 
 
1.1.4.3   Nodal Status 
The locoregional lymph node status is one of the most useful prognostic factors in early stage 
breast cancer. Patients with negative lymph node have a 15-30% risk of recurrence compared 
to 70% in those with lymph node involvement [29]. The higher the number of nodes involved, 
the worse the prognosis [30-31]. Nodal status is graded from N0-3 with N0 meaning no 
involvement, N1 meaning <4 positive lymph nodes, N2 meaning 4-9 positive lymph nodes 
and N3 ≥10 [32]. 
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1.1.4.4   Metastasis 
The presence of metastases, spread to other organs, is observed in less than 10% of newly 
diagnosed breast cancers and around 30% of patients with early breast cancer will develop 
metastasis [33]. The most common distal site is bone, the second is lung, closely followed by 
brain and finally liver. After the development of metastases, treatment is palliative and aims 
to prolong survival while managing symptoms and maximising quality of life [33].  
 
1.1.5   Pathological grading systems  
 
1.1.5.1  The TNM staging system 
Breast cancer is commonly classified using the TNM system. TNM staging integrates the 
tumour size (T), whether there is lymph node involvement (N) and if metastasis has occurred 
(M). These are grouped into 4 different stages with various substages, and prognosis worsens 
the higher the stage (Table 1.2). 
 
 
 
 
Table 1.2: TNM staging of breast cancer. The stage of cancer is based on the size of the 
tumour, lymph node involvement and if any metastases are present. 5 year survival (%) 
decreases with increased stage. LN = number of lymph nodes involved (Table adapted from 
similar in [34]).  
 
 
Stage Size  Lymph Node   Metastases 
5 year 
survival 
I T1     (<2cm) N0 (no LN) M0 (no metastases) 92% 
IIa T0     (no evidence 
of tumour) 
N1 (<4 LN) M0 82% 
 T1 N1 M0 
 T2  (2-5cm) N0 M0 
IIb T2 N1 M0 65% 
 T3   (>5cm) N0 M0 
IIIa T0-T2 N2  (4-9 LN) M0 47% 
 T3 N1-2 M0 
IIIb T4   (grown into 
chest wall or skin) 
Any N M0 44% 
 Any T N3 (≥10 LN) M0 
IV Any T Any N 
 
M1 (distant metastases) 14% 
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1.1.5.2   Nottingham prognostic index (NPI) 
The Nottingham prognostic index (NPI) is used to stratify patients with primary operable 
breast cancer into prognostic groups. It uses tumour size, grade and lymph node involvement, 
calculated by: 
(Tumour size in cm x 0.2)  + tumour grade (1 = good, 2 = moderate, 3 = poor)   
+ tumour stage (based on lymph node status, 1 = no involvement, 2 = 1-3 axillary lymph node 
or 1 internal mammary lymph node involved, 3 = ≥4 axillary lymph nodes or an axillary and 
internal mammary lymph node involved). 
 
Based on the NPI there are three prognostic categories. Patients with a score of <3.4 have a 
good prognosis, a score of 3.4 - 5.4 results in a moderate prognosis and patients with a score 
of  >5.4 have a poor prognosis [35-36]. 
 
1.1.5.3   Clinical stages of breast cancer 
Breast cancer can present at several stages at diagnosis from early breast cancer to locally 
advanced breast cancer and advanced metastatic breast cancer. The clinical stage at 
presentation is an important factor in deciding treatment options. The majority of women 
diagnosed with breast cancer present with early breast cancer that is stage I-II [37]. These 
tumours are typically treated surgically. These patients also often receive radiotherapy and in 
many cases receive systemic adjuvant therapy, as discussed later.  
 
Around 6% of breast cancers are stage III at diagnosis and described as locally advanced, 
which includes tumours that are large and those that have spread to the lymph nodes or into 
other tissues around the breast [38]. Standard treatment of locally advanced breast cancer is 
typically systemic therapy and this may enable surgery when tumours were previously 
inoperable due to their size. Inflammatory breast cancer, which typically conveys a poor 
prognosis, accounts for 2.5% of breast cancers and is treated with chemotherapy followed by 
mastectomy and radiotherapy [39]. Less than 10% of women newly diagnosed breast cancer 
present with metastatic disease, stage IV. As previously mentioned, when metastases are 
present treatment is palliative with systemic treatment which aims to prolong survival and 
alleviate symptoms to maximise quality of life [33]. 
 
The tissue cohorts studied in this thesis include patients with early invasive breast cancer and 
some patients with locally advanced disease. 
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1.1.6   Molecular prognostic factors 
As well as pathological prognostic markers relating to the appearance and stage of the 
tumour, there are also molecular markers that can be employed in diagnostic laboratories. 
These molecular markers, which are based on the presence of certain proteins in the tumour, 
contribute to the patient’s prognosis and when present allows selection of appropriate targeted 
therapy. 
 
1.1.6.1   Oestrogen receptor 
The female sex hormones (oestrogen and progesterone) are important in development and 
growth of the breast and as previously described many risk factors associated with breast 
cancer are linked to oestrogen. Around 75% of breast cancers express oestrogen receptor α 
(ER), with their main growth stimulus being oestradiol [40]. ER functions as a ligand 
activated transcription factor and controls the transcription of many genes involved in cell 
proliferation and survival, which in breast cancer results in growth and progression. 
Oestrogen binds ER causing the formation of a homodimer that binds to oestrogen response 
elements (EREs) in target genes and controls their expression. The presence of co-regulators 
is important in the precise cellular response. ER also exhibits crosstalk with several growth 
factor receptor and cell signalling pathways [41]. There are 2 isoforms, ERα and ERβ, but 
only ERα is tested for and used as a prognostic biomarker for breast cancer [42].  
 
The main testing strategy for ER is immunohistochemistry (IHC) and this is scored via the 
Allred scoring method, which uses both the proportion of positive cells and staining intensity. 
Tumours are scored on a scale of 0-5 for percentage positive (0 = no positive, 1 =  < 1/100 
positive, 2 = 1/100 to 1/10, 3 = 1/10 to 1/3, 4 = 1/3 to 2/3, and 5 = ≥ 2/3 cells positive) and 0-
3 for intensity (0 = negative, 1 = weak, 2 = intermediate, 3 = strong). The two scores are 
combined and the tumour is given a score of 0 or 2-8. A score of 3 or more is considered ER 
positive. The use of immunohistochemistry for ER testing is superior to the previously used 
ligand-binding assay [43]. 
 
1.1.6.2   Progesterone receptor 
The progesterone receptor (PgR) is another steroid hormone receptor and may be a useful 
marker in breast cancer to predict how likely it is a tumour will respond to endocrine therapy. 
ER regulates expression of PgR and it is thought to represent a functional ER pathway. 
Around 55% of tumours are ER+ PgR+, 22% are ER- PgR-, 20% are ER+ but PgR- and 3% 
are PgR+ but ER- [40]. The presence of PgR makes endocrine therapy more effective [44] 
and some patients with ER- PgR+ breast cancer may respond to endocrine therapy.  
 28 
1.1.6.3   Human Epidermal Growth Receptor 2 
Around 15-20% of breast tumours overexpress Human Epidermal Growth Factor Receptor 2 
(HER2, also known as ERBB2), and are described as HER2 positive. These tumours tend to 
be faster growing with a poor prognosis; however therapies targeting HER2 signalling can be 
used [45]. IHC can be used to test for overexpression, and is scored with a semiquantitative 
method dividing expression into 4 groups: 
- 0, negative = 10% of cells or less show membrane staining 
- 1+, negative = a faint partial staining of the membrane in more than 10% of cells 
- 2+, borderline = weak to moderate staining in more than 10% of cells 
- 3+, positive = strong staining of whole cell membrane is observed in over 30%.  
 
Tumours are considered HER2 positive if 30% of cells have staining of the complete cell 
membrane. Those tumours with a 2+ score are borderline and should be tested for 
amplification of HER2 using fluorescent in situ hybridisation [46].    
 
1.1.6.4   Ki67 
The proliferation rate of a tumour is important in the prognosis of breast cancer. Ki67 is a 
nuclear antigen found when cells are proliferating (in G1, S, G2 or M phase of the cell cycle) 
but not in cells that are in G0 phase and therefore not proliferating. The development of a 
monoclonal antibody, MIB-1, which detects Ki67 has allowed immunohistochemical studies 
to use this marker to assess tumour proliferation. Expression of Ki67 correlated with clinical 
outcome in several studies [47]. 
 
For any marker to be used in routine testing, it is important guidelines and protocols are 
established to allow for reproducibility and standardisation of results, and appropriate cut off 
values must be defined. Guidelines for Ki67 have still to be established, however an expert 
panel at the St. Gallen International Breast Cancer Conference in 2011 supported the use of 
Ki67 staining to routinely split the luminal subtypes once guidelines are available [48]. 
  
1.1.7   Breast cancer subtypes 
Gene expression analyses of over 8000 genes in human breast tumours have been used to 
categorise them into subtypes based on these molecular profiles. Hierarchical clustering 
grouped expression patterns of genes correlating to proliferation, oestrogen receptor, HER2 
signalling and genes expressed in basal epithelial breast cells [49]. The breast cancer samples 
were then grouped based on the gene expression patters of the clusters of genes from each 
category into four subtypes. These are the ER+/luminal-like subtype, the basal-like subtype, 
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HER2-enriched subtype and normal breast-like subtype [49]. Since this initial study 
additional subtypes have been added with the division of the luminal subtype into luminal A 
and B, and the inclusion of the claudin-low subtype [50-51]. 
 
Both the luminal A and B subtypes show expression of ER, PgR or ER associated genes such 
as GATA3 and some genes expressed in luminal epithelial cells such as cytokeratins 8 and 18. 
Luminal A is the most common subtype, accounting for around 40% of breast cancers. 
Around 20% of tumours are luminal B and can be distinguished from luminal A due to higher 
expression of proliferation- and/or HER2-related genes and lower expression of ER-related 
genes. The HER2-enriched group accounts for 15-20% of breast cancers. These tumours 
exhibit high expression of HER2-related genes such as those involved in HER2 signalling as 
well as neighbouring genes which are overexpressed with HER2 due to gene amplification. 
The basal-like and claudin-low groups do not express ER, PgR or HER2 and are closely 
associated to triple negative breast cancers. Basal-like tumours are categorised using 
expression of basal epithelial genes such as cytokeratin 5, 14 and 17, and HER1. This subtype 
also shows high expression of genes involved in proliferation. The claudin-low subtype 
exhibits expression of genes related to cell adhesion and interaction. In the original study by 
Perou et al [49] about 5-10% of breast tumours were placed in the normal breast group, 
however many believe it is a technical artefact due to contamination with normal tissue. 
 
Gene expression profiling is continuing to evolve with genetic drivers for each subtype being 
investigated. The Cancer Genome Atlas Network has recently identified many copy number 
variations and genetic mutations associated with the different subtypes [52].  
 
The development of different subtypes highlights the variable profiles in breast cancer and the 
need to consider it as not one disease but a collection of molecularly distinct breast diseases. 
The different molecular profiles mean tumours are likely to respond differently to various 
therapies and this should be considered as much as possible when deciding on treatment.   
 
1.1.8   Tests for molecular profile of breast cancer 
The aim of translational medicine is to gain insight into mechanisms of disease in order to 
develop new therapeutics and identify which current treatments will be of most benefit to the 
patient. Understanding what drives the progression of breast cancer, and identifying a marker 
that can be tested for, may mean treatment can be tailored for each patient.  
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Several tests have been developed to generate gene expression profiles for individual patients 
to help predict which therapy they will respond to and prevent the use of chemotherapy in 
those for whom it is unnecessary. Pam50 is a real time polymerase chain reaction (PCR) 
based assay that measures expression of 50 genes to give a gene signature and classify 
tumours into the four intrinsic subtypes (luminal A, luminal B, HER2 enriched and basal-
like). Oncotype DX is a real time PCR based assay for 21 genes, which gives a recurrence 
score to ER positive, node-negative patients, to predict recurrence at 10 years. Another assay, 
MammaPrint, uses microarray technology to assess expression of 70 genes to categorise 
patients with stage I or II cancer which is node negative and <5cm into those with good and 
poor prognosis [53]. 
 
Gene expression assays provide large amounts of data on multiple genes, however, these are 
not yet routinely used and a method of classifying breast cancer into subtypes using simpler 
methods is required. Cheang et al proposed using an immunohistochemical analysis of 
ER/PgR, HER2 and Ki67 to identify the subtypes (as in Table 1.3), and an expert panel at the 
St. Gallen International Breast Cancer Conference in 2011 supported this method [48, 54]. 
This allows the classification of tumours based on markers that are already routinely tested for 
with the exception of Ki67, which is used to subdivide the luminal subtypes. The St. Gallen 
panel suggested that if Ki67 index is unavailable another measure could be used such as a 
histological grade [48]. Although several studies have included a basal marker, which is 
positive in the basal-like subtype, such as cytokeratin 5/6, staining is not sufficiently 
reproducible and the inclusion of these markers for clinical decision-making was not 
supported [48].  
 
Subtype Markers Prognosis Frequency 
Luminal A ER+ and/or PgR+, HER2-, low Ki67 Good ~40% 
Luminal B ER+ and/or PgR+, HER2+ or high Ki67 Intermediate/ 
poor 
~20% 
HER2 
enriched 
ER-, PgR-, HER2+ Poor ~20-30% 
Triple 
negative 
ER-, PgR-, HER2-  Poor ~15%  
 
Table 1.3: Subtypes of breast cancer based on routine IHC markers. For each subtype the 
IHC markers used to distinguish them, prognosis and approximate frequency of breast 
cancers are shown. (adapted from similar in [48], with addition of percentages from [55]). 
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1.2   Treatment of breast cancer 
The National Institute for Health and Clinical Excellence (NICE) and Scottish Intercollegiate 
Guidelines Network (SIGN) have both published guidelines to improve and standardise breast 
cancer treatment in the UK [56]. The treatment of breast cancer varies depending on the 
characteristics of the tumour such as size and the presence of certain markers for 
targeted/hormonal therapy. 
 
1.2.1   Surgery 
Women with invasive breast cancer may undergo breast conservation surgery or mastectomy, 
the choice of which is dependant on a number of tumour and patient specific factors. 
 
1.2.1.1   Mastectomy 
Mastectomy, surgical removal of the breast, remains the primary treatment of invasive breast 
cancer when patients present with large tumours and also in some patients who decide to 
undergo mastectomy after being fully informed of all options.  
 
1.2.1.2   Breast conserving surgery 
Many women now have the option of breast conserving surgery instead of a complete 
mastectomy. This surgery removes the tumour and some surrounding tissue [57]. 
Radiotherapy is given after surgery and patients may require further surgery if radial tumour 
margins are not clear [56]. Breast conserving surgery tends to be more cosmetically and 
psychologically preferable to patients. 
 
1.2.1.3   Axillary surgery 
If there is no evidence of axillary involvement, sentinel lymph node biopsy is the 
recommended management. Dye is injected into breast tissue and the first 1 to 4 nodes are 
removed to evaluate if any local metastasis has occured. If metastases are present, axillary 
lymph node dissection or radiotherapy of the axilla is then performed [56-57]. 
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1.2.2   Chemotherapy 
Chemotherapy is an effective adjuvant treatment for many women, reducing recurrence in 
women under 50 by 35% and 50-69 by 20%, and mortality in the under 50s by 27% and 11% 
in 50-69 year olds [58]. However, certain types of breast cancer are likely to be unresponsive 
to chemotherapy and patient selection is therefore extremely important to avoid unnecessary 
risks and side effects for patients who are unlikely to benefit from the treatment. ER positive 
tumours tend to be less responsive than ER negative tumours, however patients with luminal 
B tumours are often chemosensitive [59]. There is a great need to find a way to identify those 
patients with microscopic disease that will be sensitive to chemotherapy therefore increasing 
disease free and overall survival and reducing side effects from unnecessary treatment [60]. 
The Optimal Personalised Treatment of early Breast Cancer using Multiparameter Analysis 
(OPTIMA) trial began in the UK in 2012 with the aim of testing whether standard therapy 
(chemotherapy and endocrine therapy for all patients) or test-directed therapy (chemotherapy 
given only to patients with high risk scores, and endocrine therapy to all) is more effective. It 
also aims to identify which test, e.g. Oncotype DX, Pam50, MammaPrint, IHC4, is most cost-
effective and appropriate [60]. 
 
Chemotherapy can also be offered as neoadjuvant therapy to patients with inoperable breast 
cancer to downsize large tumours. In these patients often the only surgical option is 
mastectomy and neooadjuvant therapy may shrink the tumour meaning breast conservation 
could become an option [56]. 
 
1.2.3   Radiotherapy 
Radiotherapy is recommended after breast conserving surgery and after mastectomy in 
patients with a high or intermediate risk of recurrence [56]. The Standardisation of Breast 
Radiotherapy (START) trials began in 1999 to investigate the effectiveness of different 
radiotherapy schedules (number of doses and size of dose) following surgery. Lower overall 
doses delivered in fewer doses of a larger size (hypofractionation) were as safe and effective 
as the standard high dose previously given [61].  
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1.2.4   Targeted therapy 
Presence or over-expression of certain markers can subdivide breast cancer and guide 
treatment. ER positive tumours are treated with hormonal therapy (discussed later) and HER2 
positive patients can receive therapies that target HER2.  
 
The development of targeted therapies for HER2 positive breast cancer has greatly improved 
the outcome of patients with these tumours, which tend to be faster growing. Transtuzamab 
(branded as Herceptin) is a monocolonal antibody that is directed against the extracellular 
domain of HER2 receptor and interferes with HER2 signalling, inhibiting cell proliferation 
[62]. The first trial of this therapy showed that in metastatic breast cancer overexpressing 
HER2, the addition of trastuzumab in combination with chemotherapy resulted in longer time 
to disease progression and longer survival when compared to chemotherapy alone [62]. In the 
HERA (Herceptin Adjuvant) trial of early breast cancer patients with HER2 positive tumours, 
the use of trastuzumab after chemotherapy improved the disease free survival in comparison 
to chemotherapy alone [63].  
 
In addition to trastuzumab, additional HER targeted therapies are being developed. Lapatinib, 
a type 1 tyrosine kinase inhibitor, blocks both HER1 and HER2 and therefore disrupts 
signalling to downstream mitogen activated protein kinase (MAPK) and phosphoinositide 3-
kinase (PI3K) pathways. Advanced breast cancer following progression on trastuzumab is 
reported to respond better to lapatinib in combination with chemotherapy compared to 
chemotherapy alone [64]. Additionally, the use of lapatinib and trastuzumab together has been 
observed to be more effective than lapatinib alone [65-66]. Dual targeting allows synergistic 
effects and overcomes the primary or acquired resistance to either of the agents. Recently an 
antibody-drug conjugate, trastuzumab emtansine (T-DM1) was developed, which has HER2 
anti-tumour action of trastuzumab with the addition of cytotoxic properties of derivative of 
maytansine (DM1), a microtubule inhibitory agent. This allows more cytotoxic HER2 
targeting and reduces exposure in normal tissue [67]. The EMILIA study was designed to 
investigate the safety and efficacy of T-DM1 in HER2 positive advanced breast cancer 
patients who previously were treated with trastuzumab and chemotherapy.  Patients treated 
with T-DM1 had delayed time to progression compared with patients treated with lapatinib 
and chemotherapy [67]. 
 
Unfortunately there are no effective targeted therapies for triple negative breast cancer 
(TNBC). These tumours do not express the markers currently used for targeted therapies 
(ER/PgR and HER2) meaning endocrine therapies and HER2 targeted therapies are 
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ineffective. TNBC has relatively poor prognosis and the only adjuvant therapy available is 
chemotherapy. Several targets are being investigated, such as the PI3K pathway [68]. 
 
1.2.5   Hormonal therapy 
Many tumours depend on oestrogen for their growth, and hormonal (or endocrine) therapy is 
used to treat tumours that are ER positive, either as adjuvant therapy following surgery for 
early cancer or as neoadjuvant treatment to shrink tumours before surgery. There are three 
main categories of endocrine therapy with different mechanisms of action (shown in Figure 
1.4):  
1) Selective oestrogen receptor modulators (SERM) prevent oestrogen from binding to ER.  
2) Selective oestrogen receptor degraders (SERD) stimulate degradation of ER.  
3) Aromatase inhibitors (AI) decrease the levels of estrogen by binding to the aromatase 
enzyme. 
 
1.2.5.1  SERMs 
For several decades the anti-oestrogen tamoxifen has been the gold standard endocrine 
therapy for ER positive breast cancer patients. Tamoxifen is a selective oestrogen receptor 
modulator (SERM) that binds to the ER, altering the conformational form. This interferes 
with the interaction with nuclear transcriptional co-activators and results in altered 
downstream effects. SERMS have mixed agonist and antagonist activity which depending on 
the target organ. In the breast it has antagonistic activity and therefore acts as an anti-
oestrogen. Analysis of randomised trials of tamoxifen show that when used as an adjuvant 
therapy, it increases overall and disease free survival and reduces mortality [69]. Although 
tamoxifen is better tolerated than chemotherapy, it has several adverse effects such as an 
increase in the risk of endometrial cancer [70]. An additional challenge is that many patients 
do not respond to this therapy despite being ER positive and a high proportion of tumours, 
which initially respond, develop resistance. 
 
1.2.5.2  SERDs 
Selective oestrogen receptor degraders (SERD) are another class of anti-oestrogens that act to 
degrade the ER and therefore block ER dependent signalling. One example of a SERD is 
fulvestrant (Faslodex
TM), which enhances ubiquitination of ERα, preventing dimerisation and 
therefore inhibiting oestrogen dependent gene transcription. It is often used for patients after 
the development of tamoxifen resistance and trials have shown it to be as effective as 
tamoxifen when used as a first line treatment [71-72]. The major benefit of this treatment 
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when compared to tamoxifen is that it acts as a pure antagonist and therefore does not have 
agonistic effect in the endometrium [73]. 
 
1.2.5.3  Aromatase inhibitors 
Aromatase inhibitors (AIs) are now the first choice treatment for post-menopausal breast 
cancer patients. They bind to the aromatase enzyme and inhibit the conversion of androgens 
(testosterone and androstenedione) into oestrogens (oestradiol and oestrone). There are two 
classes, Class I (e.g. exemestane) bind irreversibly and Class II (e.g. letrozole and 
anastrozole) bind reversibly, both of which decrease circulating levels of oestrogen [74]. AIs 
are most effective in post-menopausal women as most of the circulating oestrogen is 
produced by peripheral aromatase. However in pre-menopausal women where the ovaries 
remain active, significant toxicity is observed with AIs, so tamoxifen remains the endocrine 
therapy of choice in these patients [74]. 
 36 
 
Figure 1.4: Mechanisms of action of different endocrine therapies. In normal ER 
signalling androgens are converted to oestrogens by aromatase, oestrogen binds ER, which 
dimerises and binds to oestrogen responsive elements (EREs) resulting in transcription of ER-
dependent genes. (A) Selective oestrogen receptor modulators (SERM) competitively bind to 
ER causing a conformational chance and alterations downstream. (B) Selective oestrogen 
receptor degraders (SERD) enhance ubiquitin-mediated degradation of ER and oestrogen is 
therefore unable to bind. (C) Aromatase inhibitors (AI) stop the production of oestrogen, 
preventing dimerisation of ER and ER dependent gene transcription is blocked. (Adapted 
from [74]). 
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1.2.6   Endocrine resistance 
Although endocrine therapy is highly effective and beneficial to ER positive patients, a major 
problem is endocrine resistance. Resistance can be de novo (existing before treatment) or 
acquired (developed during therapy) and several mechanisms have been proposed for 
resistance. 
 
Lack of ER expression is the primary mechanism of de novo resistance. Other causes of de 
novo resistance have been identified such as mutations in cytochrome P450 2D6 enzyme, 
which metabolises tamoxifen into its active form, endoxifen [75]. Mutations have been 
classified into three groups: silent mutations which result in a fully functioning enzyme, those 
which result in intermediate metabolism due to reduction in enzyme activity and finally those 
with poor metabolism as a result of no protein expression or expression of a protein without 
enzymatic activity. Patients with less functioning enzyme have poorer metabolism and 
therefore lower rate of conversion of tamoxifen to endoxifen [75]. 
 
There have been several mechanisms that are thought to contribute to acquired (and some 
possibly also to de novo) resistance, where patients initially respond to therapy but 
subsequently relapse. Loss of ER expression after tamoxifen treatment was found to occur in 
17% of tumours [76]. However many resistant tumours are responsive to other endocrine 
treatments after recurrence. These tumours retain ER expression and it has been hypothesised 
that the cell finds an escape pathway. Epidermal growth factor receptor (EGFR) and HER2 
expression and downstream signalling such as PI3K and MAPK pathways have been 
suggested as escape pathways by providing an alternative survival pathway. In matched tissue 
from before and after recurrence on tamoxifen, ER and HER2 initially showed inverse 
correlation but in the tamoxifen resistant tumours this was lost. Instead, a correlation between 
ER and phosphorylation of MAPK was observed [76]. An increase in phosphorylation of Akt, 
which is downstream of PI3K signaling, is observed in tamoxifen resistance breast cancer 
cells [77]. Combination treatments targeting both ER and growth factor signalling and 
therefore blocking crosstalk between the pathways and eliminating escape routes may be 
effective at reducing resistance to therapy. Everolimus has been developed as an inhibitor of 
mammalian target of rapamycin (mTOR), a downstream component of PI3K signalling 
activated by Akt. The use of everolimus and aromatase inhibitors in combination has been 
found to result in synergistic induction of apoptosis and inhibition of proliferation [78]. The 
Breast Cancer Trials of Oral Everolimus 2 (BOLERO-2) trial was designed to compare the 
use of everolimus and the aromatase inhibitor exemestane to exemestane alone in metastatic 
breast cancer. Patients who received everolimus plus exemestane exhibited improved 
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progression-free survival compared to patients treated with exemestane alone [79]. Another 
trial in post-menopausal patients with metastatic breast cancer tested the effectiveness of 
combining tamoxifen plus everolimus (TAMRAD) in resensitising tumours to endocrine 
therapy. This study found that this combination was effective in patients with acquired 
endocrine resistance resulting in a reduction in mortality risk and an overall increase in 
clinical benefit rate and time to disease progression [80]. 
 
Coregulatory proteins have also been implicated in resistance to tamoxifen. Amplified in 
breast cancer 1 (AIB1, also known as SRC3) is an ER coactivator, which can be activated by 
HER2. High expression of AIB1 reduces the antagonist effects of tamoxifen in tumours that 
also overexpress HER2, resulting in poor outcome in these patients [81]. In MCF7/HER2 
cells, which express high levels of HER2 and AIB1, tamoxifen has agonistic effects and it is 
thought that this results in de novo resistance [82]. Tamoxifen may therefore stimulate growth 
of the tumour in patients with high AIB1 and HER2. Downregulation of corepressors are also 
documented in endocrine resistance. The loss of corepressor NCoR results in loss of 
antagonist activity of tamoxifen [83]. The expression or activity of corepressors and 
coactivators appears to modulate the agonist and antagonist activity of tamoxifen and 
therefore are likely to be of importance in resistance. 
 
The complex network of ER signalling, with its crosstalk with growth factor pathways and 
interaction with coregulatory proteins, is important in mediating the progression of breast 
cancer. Further investigation is needed into these mechanisms and the possibility of 
combination therapy. Patients that will benefit most from dual targeting need to be identified. 
Although tamoxifen and other endocrine therapies are effective in ER positive tumours, 
endocrine resistance remains a clinical problem and the mechanisms behind progression are 
not yet fully understood. The Gap Analysis Working Group identified molecular mechanisms 
driving resistance to treatment as one of the top 10 gaps in research that would make the 
biggest clinical impact if filled [84]. 
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1.2.7   Summary on breast cancer treatment 
The primary treatment of breast cancer remains to be surgery, either mastectomy or 
lumpectomy. Adjuvant therapy after surgery includes chemotherapy, radiotherapy, anti-HER2 
targeted therapy in HER2 overexpressing tumours and endocrine therapies in ER positive 
tumours. These therapies may also be used in the neoadjuvant setting before surgery. 
Different subtypes of breast cancer are more responsive to certain therapies and treatment is 
tailored accordingly (as detailed in Table 1.4). Despite the development of many effective 
therapies, there remains a need for novel therapeutics for TNBC and for patients who have 
developed endocrine resistance. In order to do so, the mechanism of recurrence in different 
subtypes of patients requires further investigation to predict what patients will benefit most 
from certain treatments and to identify novel targets. 
             
 
Table 1.4: Effective therapies for the different breast cancer subtypes (adapted from 
[48]). 
 
                        
Subtype Therapy 
Luminal A (ER/PgR+, HER2-, low Ki67) Endocrine - tamoxifen, or AIs 
(postmenopausal) 
- not many require chemotherapy 
Luminal B 
(ER/PgR +) 
HER2 -, high Ki67 Endocrine ± chemotherapy 
HER2 + Chemotherapy + HER2 targeted + 
endocrine 
HER2 enriched (ER/PgR- HER2+) Chemotherapy + HER2 targeted 
Triple negative (ER-, PgR-, HER2-) Chemotherapy 
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1.3   The NF-κB pathways 
 
1.3.1    Cell growth mechanisms and signalling pathways in cancer 
There are many different pathways involved in the regulation of cellular proliferation and 
impaired signal transduction of many of these has been implicated in cancer. Targeting of 
these pathways may be an appropriate therapeutic option in many cancers, including breast 
cancer.  
 
Mutations in the PI3K pathway have been found to be frequent in cancer and dysregulation of 
MAPK signalling has also been suggested to play an important role in many cancers [85-86]. 
Aberrations in genes involved in cell cycle regulation, such as cyclins and cyclin-dependent 
kinases (CDKs), are also evident [87]. An inhibitor of CDK4/6, which form a complex with 
cyclin D1, has been demonstrated to inhibit proliferation in ER positive and HER2-amplified 
breast cancer cells and may therefore be beneficial in combination with endocrine or anti-
HER2 therapy [88].  
 
Other pathways that have an emerging role in cancer progression and development are the 
NF-κB pathways. This family of transcription factors regulates the transcription of many 
genes involved in cell growth and apoptosis and may therefore be involved in oncogenesis 
[89].  
 
The mammalian Nuclear Factor kappa B (NF-κB) was first identified in 1986 as a 
transcription factor that binds a specific DNA sequence within the immunoglobulin kappa 
light chain gene in mature B cells [90]. It has since been found to regulate transcription in 
many different cells by binding sequences known as κB sites in the promoters or enhancers of 
many genes. There have been two main NF-κB pathways identified, the canonical and non-
canonical pathways [91]. 
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1.3.2   Members of the NF-κB family  
There are five different NF-κB family members, which form homo/heterodimers to function 
as transcription factors: NF-κB1 (or p50 and its precursor p105), NF-κB2 (or p52 and its 
precursor p100), RelA (p65), RelB and c-Rel. All family members contain a conserved N-
terminal 300 amino acid Rel homology region that is responsible for homo- and hetero-
dimerisation, interaction with inhibitor proteins and contains the nuclear localisation signal 
(NLS) [92]. RelB, c-Rel and p65 also contain a transactivation domain, which is essential for 
transcriptional activity. Homo- and hetero-dimers of the NF-κB family members are present 
in most cells and normally, when in an inactive state, inhibitory proteins (IκBs) bind to NF-
κB dimers, masking the NLS and holding them in the cytoplasm. There have been 8 
inhibitory proteins identified: IκBα, IκBβ, IκBε, IκBζ, BCL-3, precursor proteins p100 and 
p105 and most recently IκBη [93]. These inhibitory proteins are characterised by a motif of 5-
7 ankyrin repeats in their C-terminal region. This motif is also present in the precursor 
proteins p100 and p105, which also inhibit nuclear localisation, and therefore transcriptional 
activity, of NF-κB. IκBα and IκBβ also contain a PEST domain, rich in proline, gutamine, 
serine and threonine, which regulates turnover [94]. Upon phosphorylation of IκB by an IκB 
kinase (IKK), the IκB protein is ubiquitinated and subsequently degraded by the proteasome. 
This releases the NF-κB dimer allowing it to translocate to the nucleus where it binds to κB 
sites, along with co-activators or co-repressors, and regulates the transcription of target genes. 
Transcriptional output differs depending on the context, with the binding of different subunits, 
co-regulators, and crosstalk with other transcription factors [89]. Target genes are involved in 
many processes including proliferation, apoptosis, inflammation and immune response.  
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1.3.3   The canonical NF-κB pathway 
The stimulus of the canonical pathway is usually pro-inflammatory cytokines such as tumor 
necrosis factor α (TNFα) and interleukin-1 β (IL-1β). Binding of the ligand to its receptor 
results in recruitment of the IKK complex, which consists of catalytic subunits IKKβ and 
IKKα and the regulatory subunit NF-κB essential modulator (NEMO) (see Figure 1.5). 
Activation of the IKK complex occurs either by trans-autophosphorylation or via an IKK 
kinase such as TAK1 [95]. Experiments with knockout mice have shown that IKKβ is the 
predominant IKK in the canonical pathway [96]. IKKβ phosphorylates the IκB, which is 
typically IκBα bound to p65/p50 dimers. The p50 subunit is encoded as a precursor of 
105kDa that is constitutively processed to form p50 [97]. Crystallographic structures of IκBα 
bound to p65/p50 demonstrate that it is only the p65 NLS that is covered and the NLS of p50 
remains unmasked [98-99]. The NLS of p50 and the nuclear export sequence (NES) of IκBα 
both being accessible means it is possible for shuttling of the IκBα/p65/p50 complex between 
the nucleus and cytoplasm to occur, but steady state localisation of the complex is in the 
cytoplasm [100-101]. Phosphorylation and subsequent ubiqitination of IκB results its 
degradation, releasing the NF-κB dimer. IKKβ, as well as other kinases, phosphorylates the 
p65 subunit at serine residue 536 (S536) in the transactivation domain (TAD). This is 
important for the transcriptional activation of the NF-κB dimer [102]. Degradation of IκBα 
means there is no longer a NES in the complex and the NLS of p65 and p50 are unmasked, 
meaning localisation is then nuclear. The NF-κB dimer, once translocated to the nucleus, 
regulates transcription of various genes. One of these genes is IκBα and there has therefore 
been a negative feedback mechanism identified. Binding of the p65/p50 dimer results in IκBα 
resynthesis and IκBα is then exported back to the cytoplasm, binding NF-κB and inactivating 
the pathway. Protein phosphatase 2A is a key regulator of this feedback loop as it 
dephosphorylates IKKβ allowing for the stabilisation of the newly synthesised IκBα in the 
cytoplasm, which is then able to bind the NF-κB dimer [103]. An amplifying loop also exists 
as cytokines such as TNFα and IL-1β are also among the genes transcribed, as well as anti-
apoptotic genes and others involved in innate immunity such as adhesion molecules 
intracellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM- 
1) [104]. 
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Figure 1.5: The canonical NF-κB pathway. In an inactive state, IκBα holds NF-κB dimers 
of p65/p50 in the cytoplasm. Upon binding of the ligand (such as TNFα) to its receptor the 
IKK complex, consisting of IKKα, IKKβ and NEMO, is activated. IKKβ phosphorylates IκBα, 
which is the ubiquitinated and degraded, unmasking the NLS of p65 and the dimer 
translocates to the nucleus. Phosphorylation of p65 also occurs in the TAD, which is 
important for transcriptional activation. In the nucleus the p65/p50 dimer binds to κB sites of 
certain genes and regulates their transcription. 
 
 Nuclear translocation 
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P 
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1.3.4   The non-canonical NF-κB pathway  
A second pathway, the non-canonical or alternate NF-κB pathway, was identified in 2001 
(Figure 1.6). This requires IKKα kinase activity and unlike the NF-κB canonical pathway is 
independent of IKKβ and NEMO [105-106]. This non-canonical NF-κB pathway is activated 
by ligands such as the B Cell-activating factor, CD40 and lymphotoxin β. Dimers of IKKα are 
activated by the upstream NF-κB-Inducing Kinase (NIK). Another difference between the 
non-canonical and canonical pathway is that the processing of p105 to p50 is constitutive, but 
processing of p100 to p52 is controlled by activation of the non-canonical pathway. In an 
inactive state, RelB is sequestered in the cytoplasm by p100, but upon activation of the 
pathway, p100 is phosphorylated and processed into p52. The processing of p100 to p52 
results in the loss of the ankyrin repeats in the C-terminus and allows translocation of the 
RelB/p52 dimers into the nucleus [107]. Similar to the canonical pathway, a negative 
feedback loop has been suggested, involving NIK phosphorylation by IKKα. This results in 
NIK stabilisation and a decrease in non-canonical signalling, therefore preventing over 
activation [108]. The non-canonical NF-κB pathway regulates genes with a role in lymphoid 
organ development and adaptive immunity [104]. 
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Figure 1.6: The non-canonical NF-κB pathway. In an inactive state, p100 holds RelB in the 
cytoplasm. Upon binding of the ligand (such as lymphotoxin β) to its receptor the pathway is 
activated and NIK phosphorylates IKKα, which is found as a homodimer in the non-canonical 
pathway. IKKα phosphorylates p100, resulting in its processing to p52. Dimers of p52/RelB 
translocate to the nucleus, bind to κB sites of certain genes and regulate their transcription. 
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1.3.5   Functions of the IKKs 
In the NF-κB pathways, the IKKs serve to induce IκB degradation and release NF-κB dimers, 
as well as being involved in post-translational modification of the NF-κB subunits. There 
have also been other functions of each IKK identified, which are independent of NF-κB 
signalling [91]. 
 
1.3.5.1   IKKβ 
IKKβ has been found to be important for normal development and IKKβ knockout mice die 
after embryonic day 12 [109]. Further investigation by histological examinations revealed 
apoptosis of the liver to be the cause of death in these mice embryos [109]. This is likely due 
to canonical NF-κB signalling as p65 knockout mice also died at a similar time in 
development [110]. It was shown that in IKKβ deficient mouse embryonic fibroblasts, IKKα 
remained expressed but IκBα was not degraded and NF-κB was not activated by TNFα [109]. 
This demonstrates that IKKβ, but not IKKα, is essential for canonical signalling. IKKβ is 
involved in regulating inflammation and cell survival through the activation of NF-κB 
dependent gene transcription. In cells expressing a dominant-negative form of IKKβ, TNFα 
failed to induce expression of inflammatory genes such as IL-8 as well as ICAM-1 and 
VCAM- 1 [111-112]. 
 
1.3.5.2   IKKα 
Despite sharing 52% identity, IKKα and IKKβ have distinct roles, both NF-κB dependent and 
independent. Like IKKβ, IKKα knockout mice are not viable however they die perinatally 
around 30 minutes - 4 hours after birth [113-114]. These mice showed various birth defects 
with shorter limbs and tails, which was thought to be due to decreased expression of the 
transcription factor Twist. They also showed skin defects with taut, shiny skin with no visible 
wrinkles [113-114]. When stained with Ki67, as a marker of proliferation, there was much 
higher expression in the basal cell layer of the epidermis of knockout mice than the wild-type. 
There was also increase in expression of Keratin K14 in the knockout mice. Fillagrin and 
involucrin (late and early markers of keratinocyte differentiation), also showed altered 
expression [113]. It has since been shown that the role of IKKα in formation of the epidermis 
is independent of NF-κB and is instead dependent on regulation of the secretion of an 
autocrine factor that induces keratinocyte differentiation [115]. 
 
IKKα, unlike IKKβ, has an NLS and is therefore able to move into the nucleus to 
phosphorylate certain proteins. IKKα has been found to have a nuclear role in regulating 
chromatin structure by inducing histone H3 phosphorylation, a process that is required for the 
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activation of NF-κB-directed gene expression [116]. The phosphorylation of histone H3 at 
Ser10 is also promoted by IKKα in an NF-κB-independent context. In EGF-stimulated cells 
IKKα is recruited to the promoter of c-fos and phosphorylates histone H3, and therefore 
regulates expression [117]. 
 
The nuclear co-repressor silencing mediator for retinoid or thyroid-hormone receptors 
(SMRT) is phosphorylated by IKKα and subsequently removed from chromatin with HDAC3 
followed by exportation from the nucleus to the cytoplasm. These events are essential for 
optimal expression of several NF-κB-dependent genes including cellular inhibitor of 
apoptosis 2 (cIAP2) and IL-8 and also for cell survival [118]. Formation of a complex of 
IKKα, AIB1 and ERα results in regulation of transcription of oestrogen genes such as cyclin 
D1 and c-Myc. IKKα enhances oestrogen-mediated expression of these genes and increases 
cell proliferation [119]. 
 
Additionally, IKKα and IKKβ both have functions in β-catenin-dependent transcriptional 
activity with IKKβ negatively regulating its activity and IKKα increasing β-catenin-dependent 
transcriptional activation. IKKα therefore also induces cyclin D1 transcription through β 
catenin [120]. Cyclin D1 levels were decreased in IKKα deficient mouse embryonic 
fibroblasts. IKKα is also required in the mammary gland during pregnancy for lactation, and 
mice with an IKKα mutant that is unable to perform its kinase activity have a reduction in 
proliferation and are therefore unable to lactate [121]. A different study however found that 
cyclin D1 was phosphorylated by IKKα, resulting in its degradation [122]. A complex 
crosstalk is therefore evident between the IKKs and pathways involving cyclin D1. 
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1.3.6   NF-κB/IKKs and cancer 
The NF-κB pathways regulate the transcription of a wide range of genes involved in the 
immune response, inflammation, proliferation and apoptosis. Many of these processes are 
hallmarks of cancer [123] and NF-κB has been hypothesised to be a link between 
inflammation and tumourigenesis.  
 
Aberrant NF-κB signalling has been detected in some leukaemias and lymphoma. This results 
in dysregulation of expression of genes involved in the regulation of growth and proliferation 
of lymphocytes such as the cytokines interleukin-2 and interleukin-6. Constitutively active 
NF-κB signaling, due to loss or mutation of IκBα, has been observed in Hodgkin’s lymphoma 
[124-125]. Constitutive activity of IKKα has also been reported in Hodgkin’s lymphoma 
[126]. Chronic lymphocytic leukaemia patients have been observed to have constitutively 
high NF-κB activity [127] and constitutive activation of the non-canonical NF-κB pathway 
has been linked to pathogenesis of multiple myeloma [128]. 
 
High levels of NF-κB activity have also been observed in gastrointestinal cancers. NF-κB and 
IKK are constitutively active in pancreatic adenocarcinoma cells. Inhibition decreases 
expression of NF-κB regulated genes, which have been implicated in pancreatic cancer such 
as cyclooxygenase-2 [129]. Colorectal cancer tumours have increased activity of the p65 
subunit compared to normal colorectal tissue. This was reported to be associated with higher 
stage and in colon cancer cells NF-κB activation correlated with an increase in proliferation 
[130]. 
 
NF-κB pathways are implicated in prostate cancer, which is also hormonally controlled and 
develops resistance to anti-hormone therapy.  An increase in NF-κB activity and higher levels 
of phosphorylated IκBα were observed in highly invasive PC3 cells compared to PC3 cells 
with lower invasive potential [131]. A faster turnover of IκBα has been reported in androgen-
independent prostate cancer cells and kinase assays show constitutive activation of IKK in 
these cells [132]. Tissue studies with prostate cancer patients have demonstrated that 
activation of the canonical NF-κB pathway is associated with poor outcome [133], metastasis 
to the lymph nodes [134] and progression to castrate resistant disease [135]. Additionally, 
nuclear localisation of RelB is associated with higher-grade tumours [136]. 
 49 
1.3.7   NF-κB/IKKs and breast cancer  
Expression and activity of NF-κB has been reported to change in the mammary epithelium 
during pregnancy, lactation and involution [137] and IKKα has an essential role in the 
proliferation of mammary epithelium during post-natal development [121]. Considering 
this, along with its role in the regulation of proliferation and apoptosis, it is not surprising 
that aberrant NF-κB signalling has been reported in breast cancer. 
 
Elevated expression of NF-κB and increased DNA binding activity have been reported in 
breast cancer cell lines, in rat mammary tumours when compared to normal tissue, and in 
human primary breast tumours [138]. Nuclear expression of the p65 subunit (and therefore 
activation of the canonical pathway) was found to correlate with higher proliferation index, 
higher tumour grade and ER negativity in breast tumours [138]. DNA binding activity of 
p65 and p50 strongly correlated in breast cancer tumour samples, although p50 was more 
abundant [139]. Kaplan-Meier curves for disease free survival showed that patients with 
tumours displaying higher p50 DNA binding activity had poorer disease free survival than 
those with lower activity [139]. 
 
Subunits involved in both the NF-κB pathways have been investigated. Both the p50 
subunit from the canonical NF-κB pathway and the p52 subunit from the non-canonical 
NF-κB pathway are expressed in the nucleus of breast cancer tumours. When 
immunohistochemistry was employed on breast cancer tissue and adjacent normal tissue, 
expression of the p50 and p52 subunits were significantly higher in the cancer tissue. 
Western blots of nuclear fractions extracted from cancerous and adjacent normal breast 
tissue also showed an increase in p52 in breast cancer [140]. This was accompanied by an 
increase in mRNA levels of κB dependent genes including p50, p52, inhibitory proteins 
IκBα and Bcl-3 and cyclin D1, which likely represents an increase in transcription of genes 
regulated by NF-κB [140]. In mice that transgenically overexpress p100/52, a delay in 
mammary gland development is observed as well as an increase in cyclin D1, MMP2, 
MMP9 and COX-2 expression. These mice developed multiple tumours and although 
during mammary gland development p100/52 levels were low, during tumourigenesis 
expression of p100/52 was elevated [141]. 
 
Several studies have shown a correlation of NF-κB activity with oestrogen independence. 
In breast cells lines, elevated levels of NF-κB DNA binding activity were observed in ER 
negative cells in comparison to ER positive cells [142]. Additionally, rat mammary 
adenocarcinoma cells with a hormone-independent phenotype had a two-fold increase in 
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DNA binding activity compared to those who had not progressed to hormone-
independence [142]. The absence of ER also correlated with increased NF-κB DNA 
binding in a series of primary breast tumours [142]. This is consistent with other evidence 
showing an inverse relationship between ER and NF-κB with tumours with lower ER 
content displaying higher NF-κB DNA binding activity [139]. 
 
Increased NF-κB activity has also been reported in cells that display endocrine resistance. 
Expression of NF-κB was compared between MCF7 cells and MCF7/LCC9 cells, which 
are tamoxifen and fulvestrant resistant. The p65 subunit displayed increased expression in 
MCF7/LCC9 cells and the addition of parthenolide, an inhibitor of NF-κB activation, 
inhibited proliferation in these cells. This restored fulvestrant sensitivity and combination 
of parthenolide and fulvestrant acted synergistically, further reducing cell growth and 
increasing apoptosis [143]. Subsequent studies using these cells have shown that inhibition 
of NF-κB also restores sensitivity to tamoxifen. A decrease in BCL2 expression was 
observed, which has anti-apoptotic activity, and induction of apoptosis via caspase-8 [144]. 
 
Crosstalk between other pathways and NF-κB has been reported in breast cancer and there 
is evidence to suggest that this contributes to endocrine resistance. HER2 has been 
reported to activate NF-κB [145-146] and overexpression of HER2 potentiates the 
apoptotic response to TNFα via NF-κB [147]. In breast cancer cell lines with different ER 
and HER2 expression, ER negative cells (both HER2 positive and negative) showed higher 
p50 DNA binding activity than ER positive, HER2 negative cells (MCF7 and T47D) and 
ER positive, HER2 positive cells showed intermediate activity (BT474 and MCF7/HER2). 
Higher p65 activity was observed in ER negative, HER2 negative cells (MDA-MB-231) 
compared to ER positive cells (HER2 positive and negative) and also ER negative, HER2 
positive SkBr3 cells [139]. Treatment with parthenolide was found to restore tamoxifen 
sensitivity in MCF7/HER2 cells and BT474 cells, both of which are ER and HER2 
positive, supporting the hypothesis that HER2 induces activation of NF-κB and this 
contributes to resistance to tamoxifen [139].  
 
NF-κB p65/p50 dimers have been found to display higher DNA-binding activity in ER 
negative tumours, especially those that also express HER2. NF-κB activation was 
stimulated by heregulin (which stimulates HER2) in SkBr3 cells, which are ER negative 
with HER2 amplification. The addition of herceptin then inhibited NF-κB activity, as did 
the NEMO-binding domain peptide, resulting in blocked cell cycle progression and 
proliferation and induction of apoptosis [146]. 
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ER positive MCF7 cells transfected with a plasmid conferring constitutive activation of 
Akt (myrAkt1 MCF7 cells) displayed tamoxifen resistance and addition of 
eicosapentaenoic acid, which inhibits Akt, sensitised the cells to tamoxifen treatment 
[148]. Further investigation using these tamoxifen-resistant myrAkt1 MCF7 cells, in 
comparison to normal MCF7 cells, showed they had elevated levels of phosphorylated 
IκBα and NF-κB DNA binding and increased transcriptional activity [149]. Addition of the 
NF-κB inhibitor parthenolide or a non-degradable IκB, to inhibit NF-κB activity in these 
cells, restored sensitivity to tamoxifen [149].  
 
Furthermore, urokinase-type plasminogen activator (uPA) (which regulates cell migration) 
is activated by interaction between NF-κB and activator protein 1 (AP-1), a transcription 
complex which is also involved in regulation of genes involved in many processes 
including proliferation and apoptosis [150-151]. DNA binding activity of the NF-κB 
canonical pathway was found to correlate with levels of HER2 in ER positive breast 
tumours [139]. Activation of the p50 subunit correlated with the activity of AP-1 and 
expression of uPA [139]. High expression of uPA has been demonstrated to result in 
decreased disease free survival in early breast cancers [152] and NF-κB may therefore be 
involved in invasive potential and recurrence of breast cancer. 
 
A relationship between NF-κB and ER is evident and the NF-κB pathways have been 
demonstrated to play a role in the progression of breast cancer. It is therefore likely that 
they make attractive therapeutic targets and inhibitors may be beneficial in ER positive 
cancers following development of endocrine resistance. One strategy is to target the IKKs 
in order to inhibit their function and downstream NF-κB signalling as well as NF-κB 
independent functions. At present there are no IKKα selective inhibitors available and 
IKKβ inhibitors that have been developed have exhibited adverse effects such as cellular 
toxicity and immunosuppression [91]. Selective IKKα inhibitors and effective IKKβ 
inhibitors are therefore required. 
 
A current collaboration between the University of Glasgow and the University of 
Strathclyde with the aim of developing IKKα and IKKβ selective inhibitors is ongoing and 
several compounds have shown promising preclinical results in various cancer 
backgrounds. This may represent a future targeted approach in breast and other cancers. 
There is also a need to further explore the role of the NF-κB pathways in different 
subtypes, due to evidence presented above, as crosstalk with other pathways and 
expression of ER and HER2 appear to impact on NF-κB activity. 
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1.4   Research aims and hypothesis 
This thesis investigated the role of the canonical and non-canonical NF-κB pathways in the 
progression of breast cancer. Using archival tissue from breast cancer patients, as well as 
breast cancer cell lines, the expression of key components of each pathway were assessed. 
Additionally, we observed the effect of knock down of the upstream kinases from the 
canonical and non-canonical NF-κB pathways, the IKKs, in breast cancer cell lines in 
order to investigate their potential as novel targets in breast cancer.  
 
This tested the hypothesis that high expression of the NF-κB pathways would result in 
poorer outcome in breast cancer patients and also due to evidence from the literature that 
these pathways may be involved in the development of endocrine resistance. It was also 
speculated that inhibition of the IKKs would reduce the viability of breast cancer cells. 
Therefore, the aim of this study was to establish if members of the NF-κB pathway were 
associated with clinical outcome in patients with invasive breast cancer and whether these 
pathways were attractive therapeutic targets. In order to address this and test the 
hypotheses, the main objectives were to: 
 
● Further develop a clinical database with linked tissue by assessing levels of apoptosis 
and proliferation within the tumours and establishing tumour subtype as classified by the 
St. Gallen guidelines. 
● Establish if expression of NF-κB family members could be employed as prognostic or 
predictive breast cancer markers.   
● Validate markers identified as prognostic/predictive in an independent cohort of breast 
cancer patients. 
● Establish markers of downstream signalling associated with IKKα or IKKβ in breast 
cancer. 
● Assess the phenotypic impact of modification/manipulation of IKK signalling in breast 
cancer cell lines to establish if further investigation was warranted into the IKKs as 
therapeutic targets in breast cancer. 
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Chapter 2: 
 
Materials and methods 
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2.1   Tissue studies 
To test whether the NF-κB pathways were associated with clinical outcome and other 
clinical parameters, expression of members of the pathways were assessed using IHC on a 
tissue microarray (TMA) of breast cancer patients. All antibodies were validated before 
use in the patient cohort to ensure the antibody was specific to the antigen of interest. 
 
2.1.1   Antibody validation 
This was demonstrated by a single band of the correct size on a western blot, followed by 
blocking peptide experiments and/or appropriate expression in stimulated or silenced cell 
pellets (see Table 2.1). Antibodies for p65 and phospho-p65 S536 were validated as part of 
this thesis. The remaining antibodies had previously used in the laboratory and had already 
been validated: IKKα, IKKβ, RelB and NIK antibodies by Mr Lewis McKenzie and Dr 
Antonia Roseweir and p65 NLS by Dr Pamela McCall. 
 
Protein Antibody Validation method 
p65 Santa Cruz 
sc-8008 
● Validated in breast and prostate cancer cell lines 
● Single band on western blot ~65kDa 
●  Expression in TNFα stimulated cell pellets 
phospho-
p65 S536 
Abcam  
ab28856 
● Validated in breast and prostate cancer cell lines 
●  Single band on western blot ~65kDa 
●  Expression in TNFα stimulated cell pellets 
p65 NLS 
Millipore 
MAB3026 
● Validated in prostate cancer cell lines 
●  Single band on western blot ~65kDa 
●  Expression in TNFα stimulated cell pellets 
IKKβ 
 
Abcam 
ab32135 
● Validated in prostate cancer tissue/cell lines 
●  Single band on western blot ~87kDa 
●  IHC on IKKβ and IKKα silenced cell pellets 
●  Specific loss of staining when mixed with IKKβ  
    protein (but not IKKα or p65 protein) in IHC 
IKKα 
 
Genway 
GWB-662250 
● Validated in prostate cancer cell lines 
●  Single band on western blot ~85kDa 
●  Western blot of IKKα and IKKβ silenced lysates 
●  IHC on IKKα and IKKβ silenced cell pellets 
NIK 
Epitomics  
S2922 
● Validated in prostate cancer cell lines 
●  Single band on western blot ~125kDa 
●  IHC on cell pellets transfected with NIK virus 
RelB 
 
 
Cell Signaling 
4954 
● Validated in prostate cancer cell lines 
●  Single band on western blot ~70kDa 
●  Cellular location in cell pellets  after  
    lymphotoxin treatment 
 
Table 2.1: Antibody validation. Protein of interest, antibody used and validation method 
are detailed, as well as the tumour types that antibodies were validated in.  
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2.1.2   Patient TMA 
Formalin-fixed paraffin-embedded tissue (FFPE) blocks were retrieved from Pathology 
archives and used to construct a TMA, which was available for use in this thesis. 
Haematoxylin and eosin stained sections were used to identify tumour rich areas from each 
block, which were marked by Dr Elizabeth Mallon (Consultant Pathologist at the 
Department of Pathology, Southern General Hospital). Marked slides were matched to the 
FFPE blocks and three different 0.6mm
2
 cores were lifted from each donor block and 
placed into three separate recipient paraffin blocks.  
 
The use of TMAs has several benefits. Firstly, only 3 small cores from each paraffin block 
are used and the remaining block can be returned to the patient archives. All tissue can be 
stained in one run as 544 patients could be analysed in triplicate on just 9 slides. This 
means the internal consistency of the staining is greater and it also saves on reagents and 
time. There are however some issues when considering intra-tumour heterogeneity. The 
analysis of a single core might not be representative of the whole tumour and may not 
allow for the detection of varied levels of protein in different areas. To overcome this, 
three cores were used to allow a more representative result. Ethical approval for the use of 
this tissue was granted by the Research Ethics Committee of the North Glasgow University 
Hospitals NHS Trust (West of Scotland REC 4, Molecular profiling and clinical validation 
of Breast Cancer biological subtypes, REC reference: 07/S0704/61). 
 
This study was conducted and is reported in accordance with REMARK criteria, with the 
exception of point 9 [153]. There was no power calculation used to determine the number 
of patients included in this study, as patients were included based on availability of tissue 
from retrospective cohorts. However, as detailed in the following sections, the events for 
each end point were around 100 and therefore this should allow enough events for 
statistical significance to compare high/low expression and also for analysis after 
stratification of the cohorts. 
 
2.1.2.1   Cohort 1: 1800-Bre-TMA 
This retrospective TMA of breast cancer patients was constructed by Clare Orange (TMA 
and Image Analysis Unit Manager, University Department of Pathology, Southern General 
Hospital). The cohort included 544 breast cancer patients (identified by Ms Julie Doughty, 
consultant breast surgeon, Western Infirmary) presenting with invasive breast cancer in the 
West of Scotland (at Glasgow Royal Infirmary, Glasgow Western Infirmary and Stobhill 
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Hospital), between 1995 and 1998. From an initial list of 1800 patients, the first block was 
constructed using ER positive patients from this list, followed by an ER negative TMA and 
a further ER positive TMA. These were constructed in this manner to allow for ER positive 
and ER negative specific studies and this selection accounts for the slightly skewed 
proportion of ER negative cases included in the cohort. A database was available with 
clinico-pathological data including age, tumour grade, tumour size, lymph node status, and 
any therapy the patient received.  
 
Dr Zahra Mohammed performed staining for ER, PgR, HER2 and Ki67. Additionally, 
microvessel density was available due to the study by Dr Zahra Mohammed. Large vessels 
and single stained endothelial cells that were separate from adjacent microvessels and 
tumour cells as well as any other elements of connective tissue were counted as a single 
microvessel and branching structures were also considered. This was completed both on 
full sections by visually counting the number of vessels in three fields per section and 
using an average score and in TMAs by counting the number of vessels in each core. There 
was good correlation between scores obtained using whole sections and TMAs, with an 
ICCC of 0.87 [154]. 
 
Updated clinical follow up was available thanks to Dr Jennifer Campbell. Patients were 
excluded if there was incomplete follow up or had insufficient tumour tissue (as 
determined by the pathologist). Clinical end points used were the recurrence free interval 
[155] (which included locoregional and distant recurrences), and breast cancer specific 
survival (which included deaths due to breast cancer and deaths from other causes were 
censored).  
 
Median follow up time for breast cancer specific survival was 12.4 years, with an 
interquartile range (IQR) of 5.9 to 13.9 years. For recurrence free interval the median 
follow up was 5.7 years (IQR = 4.9 to 6.7 years). At the last follow up 101 patients had 
died of their disease and 102 had died of other causes. Follow up of recurrence status 
found 120 patients had relapsed. 
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2.1.2.2   Cohort 2: ST-Bre-TMA (validation) 
In order to confirm results from the first cohort, a second cohort of patients was stained for 
IKKα and phospho-p65 S536. This TMA and clinical database was retrospectively 
constructed by Dr Sian Tovey and included 456 patients presenting with operable breast 
cancer between 1980 and 1999. Patients were included in this cohort based on ER positive 
pathology reports. However when this was verified using current technologies it was found 
although the majority of cases were ER positive (392), 20 were found to be ER negative 
and 44 were of unknown ER status.  All patients selected for inclusion in this cohort were 
treated with adjuvant tamoxifen and time on tamoxifen was available in the database, as 
well as recurrence and survival follow up.  
 
Clinical end points used were again recurrences or deaths due to breast cancer. The 
recurrence free interval was defined as the time from surgery to recurrence at any site. 
Breast cancer specific survival was defined as the time from surgery to death due to breast 
cancer and deaths from other causes were censored. Additionally, recurrence on tamoxifen 
was used with recurrence at any site whilst receiving tamoxifen as events.  
 
The follow up for breast cancer specific survival was 7.3 years (IQR = 5.1 to 10.0 years). 
For recurrence free interval average follow up was 6.2 years (IQR = 4.3 - 9.0 years) and for 
recurrence on tamoxifen was 5.0 (IQR = 4.0 - 5.0 years). At the last follow up 97 patients 
had died of their disease and 78 had died of other causes. Recurrence follow up found 111 
patients had relapsed, 85 of which were during tamoxifen treatment. 
 
There was no overlap in patients included in this cohort and the previous cohort. A 
comparison of both cohorts is detailed in Table 2.2. Both cohorts were similar in terms of 
percentage in each group for age, size, invasive grade, nodal status and NPI. However the 
ST-Bre-TMA, which is mainly ER positive, differed in terms of treatment with less 
patients receiving chemotherapy and radiotherapy but all patients were treated with 
tamoxifen. This cohort also had a higher proportion of PgR positive and less HER2 
positive than the 1800-Bre-TMA. 
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 1800-Bre-TMA 
(N=544) 
ST-Bre-TMA  
(N=456) 
Age  ≤50 years 29% 18.5% 
>50 years 71% 81.5% 
missing - 13 
Size  ≤20 mm 60.1% 52.5% 
21-50 mm 36.7% 42% 
>50 mm 3.1% 5.5% 
missing 2 37 
Invasive grade I 20.1% 24.7% 
II 43.5% 48.9% 
III 36.3% 26.4% 
missing 2 43 
Nodal status Negative 57.4% 53.5% 
Positive 42.6% 46.5% 
missing 6 52 
NPI <3.4 31.1% 37.5% 
3.4 - 5.4 51.7% 45.5% 
>5.4 17.3% 17.1% 
missing - 93 
ER ER- 35.9% 4.9% 
ER+ 64.1% 95.1% 
missing 4 44 
PgR PgR- 54.5% 41.5% 
PgR+ 45.5% 58.5% 
missing 6 49 
HER2 HER2- 85.3% 91.4% 
HER2+ 14.7% 8.6% 
missing 21 24 
Chemotherapy No 59% 76.3% 
Yes 41% 23.7% 
missing 3 13 
Radiotherapy No 55.3% 69.5% 
Yes 44.7% 30.5% 
mising 3 - 
Endocrine 
therapy 
No 25.6% 0% 
Yes 74.4% 100%  
All received tamoxifen 
missing 9 - 
 
Table 2.2: Comparison of the two cohorts used. The percentage of patients in each 
group for each factor of the cohort is detailed for both the 1800-Bre-TMA and the ST-Bre-
TMA. Missing indicates the number of patients for which this was unknown. 
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2.1.2.3   Control tissue 
TMAs of breast cancer patients without linked clinical data were available for optimisation 
of antibodies. These were included as positive and negative controls in IHC experiments. 
Positive controls were included in every step of the IHC process and incubated in identical 
solutions as to the patient TMAs. Negative controls were included in every step with the 
exception of primary antibody where antibody was omitted and slides were instead 
incubated in antibody diluent for the duration of primary antibody incubation. 
  
 
2.1.3   Immunohistochemistry 
IHC was performed on the tissue to assess protein levels of members of the NF-κB 
pathways. This uses a primary antibody that recognises the specific antigenic site and is 
recognised by EnVision™ (K5007, Dako, Glostrup, Denmark). The EnVision™ reagent 
has a polymer backbone to which a large number of horseradish peroxidase (HRP) 
molecules and secondary antibody molecules have been coupled. The secondary antibody 
reacts with both rabbit and mouse immunoglobulins. Following incubation with secondary 
antibody the tissue is incubated with a substrate solution, which consists of 3,3’-
diaminobenzidine (DAB) chromogen and hydrogen peroxide. The HRP molecules on the 
EnVision™ interact with the substrate solution to produce a brown end product, 
representing the antigen of interest, which can be viewed using a light microscope. 
 
2.1.3.1   Preparation of slides 
Once antibodies were validated as specific and had been fully optimised, sections from 
patient TMAs were requested from Clare Orange (TMA and Image Analysis Unit 
Manager, University Department of Pathology, Southern General Hospital) and stored at 
4ºC for up to 1 month before use. TMAs were cut into 2.5μm thick paraffin wax sections 
and mounted onto slides.  Slides were then incubated at 56ºC overnight and stored at 4ºC. 
Immediately before use in IHC the slides were baked again for 15 minutes at 56ºC to 
minimise risk of lost cores. 
 
2.1.3.2   Dewaxing and rehydration of tissue 
Tissue was dewaxed by immersing in xylene twice for 5 minutes, and rehydrated through a 
series of graded alcohols (2x 100% for 3 minutes; 1x 90% for 3 minutes, 1x 70% for 3 
minutes) before being washed in running water. 
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2.1.3.3   Antigen retrieval 
In FFPE tissue the fixation process can often mask antigenic sites meaning it is necessary 
to perform antigen retrieval to break the protein crosslinks and uncover these sites to allow 
antibody binding.  This was performed by heat induced antigen retrieval in a solution of 
either Citrate Buffer pH6 or TE Buffer pH9, depending on what was optimal for each 
antibody (see Table 2.2). TE Buffer pH9 contained 1mM Ethylenediaminetetraacetic acid 
(EDTA) (27285, Sigma-Aldrich, St Louis, USA) and 5mM Tris Base (BP152-1, Fisher 
Scientific, Loughborough, UK) in 1L distilled water. Citrate Buffer pH6 was prepared 
using 2mM Sodium Citrate (S/3320/53, Fisher Scientific, Loughborough, UK) and 8mM 
Citric Acid (27109, Sigma-Aldrich, St Louis, USA) in 1L distilled water. 
 
Buffer solutions were preheated in the microwave in a pressure cooker for 13.5 minutes 
before slides were placed into the solution and the lid secured. This was heated for around 
1.5 minutes until under pressure, then heated for a further 5 minutes once under pressure, 
before being cooled for 20 minutes. 
 
2.1.3.4   Blocking endogenous peroxidase 
Due to the presence of endogenous peroxidase activity in some tissue, it is necessary to 
block peroxidase activity to prevent background staining.  This was achieved by incubating 
the tissue in 3% hydrogen peroxide for 10 minutes. 
 
2.1.3.5   Blocking non-specific binding 
Non-specific background staining can occur if hydrophobic bonds are formed between the 
antibody and other tissue proteins. This is blocked by incubation at 25°C in either 5% 
horse serum (S-2000, Vector Laboratories, Burlingame, CA, USA) for 30 minutes (diluted 
in Tris Buffer Saline (TBS)) or 1x Caesin (SP-5030, Vector Laboratories, Burlingame, CA, 
USA) for 1 hour (diluted in distilled water). Sections were circled with the Dako delimiting 
pen (S2002, Dako, Copenhagen, Denmark) to create a hydrophobic barrier around the 
tissue and ensure solutions remained covering the tissue, helping to achieve more uniform 
staining and reducing the amount of reagent required. Each antibody was used with 
whichever blocking solution was found to be optimal (see Table 2.3). 
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Protein of 
interest 
Buffer 
solution 
Blocking 
conditions 
Antibody dilution & incubation 
conditions 
p65 
Citrate  
pH6 
5% Horse serum  
30 mins     
1:25 dilution, 2 hours 25°C 
(Santa Cruz, sc-8008) 
phospho-
p65 S536 
Tris-EDTA 
pH9 
1x Caesin  
1 hour 
1:25 dilution, overnight 4°C 
(Abcam, ab28856) 
p65 NLS 
Tris-EDTA 
pH9 
5% Horse serum  
30 mins     
1:200 dilution, overnight 4°C 
(Millipore, MAB3026) 
IKKβ 
Citrate  
pH6   
5% Horse serum 
30 mins     
1:500 dilution, overnight 4°C 
(Abcam, ab32135) 
IKKα 
Citrate  
pH6 
5% Horse serum 
30 mins     
1:1000 dilution, overnight 4°C 
(Genway, GWB-662250) 
NIK 
Citrate  
pH6   
1x Caesin  
1 hour                      
1:250 dilution, overnight 4°C 
(Epitomics, S2922) 
RelB 
Citrate  
pH6   
5% Horse serum 
30 mins     
1:75 dilution, overnight 4°C 
(Cell Signaling, 4954) 
Ki67 
Tris-EDTA 
pH9 
5% Horse serum 
30 mins     
1:150 dilution, overnight 4°C 
(Dako, M7240) 
 
Table 2.3: Antibody optimal conditions. The antigen retrieval buffer, blocking solution 
and antibody conditions for each protein of interest are listed. 
 
2.1.3.6   Incubation with primary antibody 
Immediately after incubation in the blocking solution, tissue was then incubated in primary 
antibody. Antibodies were diluted in antibody diluent (Dako, Copenhagen, Denmark) and 
the mixture added to slides. This was either incubated at 25°C for either 1 or 2 hours or 
overnight at 4°C. Optimal dilution and incubation conditions were assessed on practice 
tissue before being applied to the cohort.  
 
2.1.3.7   Incubation with secondary antibody 
Following incubation with the primary antibody, slides were washed twice in TBS for 5 
minutes.  Slides were then incubated for 30 minutes at 25°C in Dako EnVision™ (K5007, 
Dako, Copenhagen, Denmark), which detects both mouse and rabbit primary antibodies 
before being washed twice with TBS Buffer for 5 minutes.  
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2.1.3.8   Detection and visualisation 
The chromagen used to visualise the presence of the protein of interest was 3,3’-
diaminobenzidine (DAB). A DAB peroxidase substrate kit was used (SK-4100, Vector 
Laboratories, Burlingame, CA, USA). To make the solution, 5ml of distilled water was 
mixed with 2 drops of DAB Buffer solution, 2 drops of DAB Substrate solution, and 1 
drop of Hydrogen Peroxidase solution. This was added to the tissue and left for 5 minutes 
until brown staining developed, and slides were then washed in running water. 
 
2.1.3.9   Counterstaining of the slides 
Counterstaining was performed by immersing slides in Harris Haematoxylin (HHS128, 
Sigma, UK) for 1 minute until tissue appeared red, then quickly dipping in 1% Acid 
Alcohol to remove excess Haematoxylin.  Tissue was then blued in Scott‘s Tap Water 
Substitute (STWS) for 45 seconds.  Acid Alcohol (1%) was prepared using 396ml 70% 
Ethanol + 4ml Hydrochloric acid.  STWS contained 80mM Magnesium sulphate 
(25165.260, VWR, Poole, UK) and 40mM Sodium hydrogen carbonate (102475W, BDH, 
Poole, UK) in 2L dH2O. 
 
2.1.3.10   Dehyrating and mounting of the slide 
After counterstaining, tissue was dehydrated in a series of alcohol washes with increasing 
percentage: 1x 70% for 1 minute, 1x 90% for 1 minute, 2x 100% for 1 minute and 2x 
Xylene for 1 minute.  Slides were then mounted with coverslips using DPX mountant 
(06522, Sigma-Aldrich, St Louis, USA). 
 
2.1.4   TUNEL assay 
The amount of apoptotic cells in each core was assessed using the ApopTag® Peroxidase 
In Situ Apoptosis Detection Kit (S7100, Millipore, Billerica, MA, USA). This uses the 
terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay method. 
One hallmark of apoptosis is DNA fragmentation, which causes nicks in DNA. The 
enzyme TdT catalyses the addition of dUTPs to the 3’hydroxyl DNA ends to form a 
heteropolymer which anti-digoxigenin antibody binds to. As in the previously described, 
this antibody has been labelled with peroxidase and on the addition of DAB created a 
brown end product which allows visualisation. The kit was used following manufacturers 
guidelines. Tissue was dewaxed and rehydrated as normal but antigen retrieval was 
achieved by incubation in 20μg/ml Proteinase K Solution (539480, Millipore, Billerica, 
MA, USA). Slides were washed in distilled water twice for 2 minutes then endogenous 
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peroxidase was quenched in 3% hydrogen peroxide for 5 minutes before slides were 
washed twice for 5 minutes. Equilibration buffer was then applied to the tissue for 10 
minutes.  Positive slides were then incubated in a 70:30 ratio of Reaction buffer and TdT 
Enzyme for 1 hour at 37°C. Negative slides remained in equilibration buffer during this 
time. Slides were then washed in stop/wash buffer, first agitating the solution for 15 
seconds then washing for 10 minutes. Slides were then washed 3x for 1 minute in TBS and 
anti-digoxignenin conjugate was applied for 30 minutes. After washing slides 4 times in 
TBS for 2 minutes, working strength peroxidase substrate (1:50 DAB substrate:DAB 
dilution buffer) was then added to the slides and the brown colour allowed to develop for 
10 minutes. Slides were then washed for 10 minutes in running water before being 
counterstained with Harris haematoxylin, blued in STWS then dehydrated and mounted 
with coverslips and DPX mountant. 
 
2.1.5   Scoring of IHC 
 
2.1.5.1   Histoscore 
Protein expression of each core was assessed with the scorers blinded to clinical end point 
or any information on stage or hormone receptor status and other markers. This was scored 
using the weighted histoscore method as described in Kirkegaard et al [156]. This grades 
staining intensity as negative (0) weak (1), moderate (2) and strong (3), multiplied by the 
percentage of tumour cells in each category giving a histoscore ranging from a minimum 
of 0 to a maximum of 300.  One observer blindly scored all cores present, having 
previously found to correlate with an experienced scorer. A second observer then 
independently scored 10% of cores, blinded to the previous observers score as well as 
outcome and clinico-pathological factors, and statistical analysis was performed to 
measure consistency between scores using the interclass correlation coefficient (ICCC). An 
ICCC of >0.7 was classed as having good correlation. Patients were then split into low and 
high expressors. Those with a score above the median were classed as having high 
expression and under as low. 
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2.1.5.2   Ki67 and TUNEL scoring 
Ki67 and TUNEL expression was scored using the percentage of positive nuclei.  
The total number of nuclei and the number of positive nuclei were counted and the 
percentage was calculated using: 
 
Number of positive nuclei 
 
   X 100 
Total number of nuclei 
 
For the 1800-Bre-TMA cohort Ki67 was already available, both manual and automated 
scoring. Scores obtained by manual scoring were used for analysis in this thesis. TUNEL 
was scored using the Slidepath Tissue IA system to automatically count the positive and 
negative nuclei. Similar to the histoscore, 10% was manually scored and ICCC calculated 
to assess correlation between automated and manual scoring. For the ST-Bre-TMA cohort, 
Ki67 and TUNEL were both manually counted due to discordance with automated 
counting. Ki67 expression was categorised as high if the value was ≥15% [157] and 
TUNEL was split using the median score, as no cut off value has previously been 
established. 
 
2.1.6   Statistical Analysis 
Analysis was performed using SPSS version 18 (IBM, New York, USA). Kaplan-Meier 
curves were plotted to assess breast cancer specific survival, recurrence free interval and 
recurrence on tamoxifen. Chi squared tests were conducted to test the associations between 
markers of the pathway and clinico-pathological factors. Hazard ratios were calculated 
using Cox regression with 95% confidence intervals. Cox’s multivariate analysis (Cox 
regression) was also performed with the inclusion of known predictive factors, such as 
size, grade and nodal status. Values of P<0.05 were reported as statistically significant, and 
a more stringent significance value of P<0.01 was also considered. Where multiple 
comparisons were made with more than two groups in a Kaplan Meier curve, a more 
stringent P value is required using Bonferroni’s correction. This was the case with the 
1800-Bre-TMA subtype breast cancer specific survival analysis. In this analysis there were 
6 possible comparisons: (1) luminal A versus luminal B, (2) luminal A versus triple 
negative, (3) luminal A versus HER2 enriched, (4) luminal B versus triple negative, (5) 
luminal B versus HER2 enriched and (6) triple negative versus HER2 enriched. As there 
were 6 possible comparisons a P value of 0.008 is required to consider the result 
statistically significant (as 0.05 divided by 6 is 0.00833). All statistical analysis was 
performed by myself and repeated by a second (and senior) investigator (Joanne Edwards) 
in order to validate methods used and results obtained. 
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2.2   In vitro studies 
 
2.2.1   Culturing of breast cancer cell lines 
MCF7 (ER positive) and MDA-MB-231 (ER negative) breast cancer cells were routinely 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) (10313-021, Life Technologies, 
Paisley, UK) with 10% Fetal Bovine Serum (FBS) (F9665, Sigma-Aldrich, St Louis, 
USA), 10 Units/ml Penicillin/Streptomycin (15070-063, Life Technologies, Paisley, UK) 
and 1x GlutaMAX™ (35050-038, Life Technologies, Paisley, UK). Cells were grown in 
T-75 flasks and maintained in 5% CO2 at 37°C, with media changed twice per week and 
cells passaged once a confluency of around 70% was reached. To passage cells, flasks 
were washed once with 1.5 ml of trypsin to remove traces of serum. This was removed and 
1ml trypsin was added to detach cells from the flask and then incubated at 37°C in 5% CO2 
until cells detached. Once cells had detached, DMEM was added to inactivate the trypsin. 
Cells were gently pipetted on the side of the flask to break any clusters, before being split 
1:6 into new T-75 flasks with fresh DMEM. Cells were routinely tested for mycoplasma 
twice a year. 
 
Stocks of cells were stored in liquid nitrogen at -196°C. To freeze cells the procedure was 
as follows: after trypsinisation cells were centrifuged at 1200 rpm for 5 minutes and media 
removed before resuspension in 1ml of culture media with 10% DMSO, which is used as a 
cryoprotectant. Cells were then immediately placed in a Mr Frosty™ freezing container 
(5100-0001, Thermo Scientific Nalgene) and stored in -80°C overnight before being 
transferred to liquid nitrogen (-196°C) for storage. When new cells were required, aliquots 
were retrieved from liquid nitrogen, cells were defrosted by warming in a 37°C water bath 
and added to a T-75 flask with 10ml DMEM immediately due to the toxicity of DMSO. 
Cells were passaged twice before use in experiments. Stocks of MCF7 cells were P11-14 
and passages used in experiments were P13-20. MDA-MB-231 cell stocks were P9-11 and 
experiments used P11-20. 
 
2.2.2   Stimulation of the NF-ĸB pathways in breast cancer cells 
In order to activate the pathways and stimulate expression of certain pathway members, 
various ligands were applied to the cells. Protein was then extracted to observe expression 
of the pathway members, or a functional assay was performed to observe the effect of 
stimulation on cell growth/survival.  
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Ligands: 
● Tumour necrosis factor alpha (TNFα):  
The canonical pathway was stimulated in MCF7 and MDA-MD-231 cells using 20ng/ml 
TNFα (SRP3177, Sigma-Aldrich, St Louis, USA) at a range of time points (5 minutes, 15 
minutes, 30 minutes, 60 minutes and 120 minutes). 
● Interleukin-1 beta (IL-1β):  
20ng/ml IL-1β (10-1012-C, Insight Biotechnology, Wembley, UK) was also used to 
stimulate the canonical pathway at a range of time points (5 minutes, 15 minutes, 30 
minutes, 60 minutes and 120 minutes). 
● Lymphotoxin α1β2: 
For stimulation of the non-canonical pathway, 20ng/ml Lymphotoxin α1β2 (LTx) (L5162, 
Sigma-Aldrich, St Louis, USA) was used for 4 hours, 8 hours and 24 hours. 
 
For use in western blot, cells were seeded in 12 well plates at 1x10
5 
cells/well, grown to 
70% confluency before being serum starved in DMEM media with no FBS for 24 hours 
followed by stimulation with the ligand at the appropriate concentration and time point 
before protein was lysed (section 2.6.1).  
 
For use in functional assays, cells were seeded in 96 well plates (as described in section 
2.3), then serum starved for 24 hours and stimulated with TNFα or LTx (both at 20ng/ml) 
then the functional assay of interest performed. 
 
2.2.3   siRNA knockdown of IKKα and IKKβ in breast cancer cells 
In order to observe the effect the loss of the IKKs has on the cells, MCF7 and  
MDA-MB-231 cells were transfected with siRNA for IKKα and IKKβ. Expression of 
mRNA was knocked down using ON-TARGETplus siRNA (Thermo Scientific, Waltham, 
MA, USA) specific to CHUK (IKKα) and IKBKB (IKKβ). Target sequences are shown in 
Table 2.4. 
 
Each siRNA was made to a stock concentration of 20uM by resuspension in 1ml of siRNA 
buffer (B-002000-UB-100, Thermo Scientific, Waltham, MA, USA; diluted to from 5x to 
1x in RNase free water) and placed in an orbital mixer for 30 minutes 
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Gene ON-TARGET PLUS siRNA Target Sequence 
CHUK (IKKα) CHUK (1147) 
Cat#: J-003473-09 
GCGUGAAACUGGAAUAAAU 
IKBKB (IKKβ) IKBKB (3551) 
Cat#: J-003503-13 
GAGCUGUACAGGAGACUAA 
Non-targeting 
(negative control) 
Non-targeting #1 
Cat#: D-001810-01-20 
UGGUUUACAUGUCGACUAA 
 
Table 2.4: siRNA information. The gene, siRNA used and target sequence are shown. 
 
Lipofectamine® RNAiMAX (13778150, Life Technologies, Paisley, UK) was used as the 
transfection reagent to deliver the siRNA to the cells. Lipofectamine® and siRNA were 
both diluted in Opti-MEM® (11058-021, Life Technologies, Paisley, UK), then both 
mixed together at a 1:1 ratio and left to incubate at room temperature for 20 minutes to 
allow the formation of complexes. Cells were meanwhile incubated in Opti-MEM® for 20 
mins before the siRNA mixture was added drop by drop to the cells. Volumes for each 
component for 6 well, 12 well and 96 well plates are shown in Table 2.5. After 6 hours 
media was replaced with the usual 10% DMEM. 
 
● 6 well plates were seeded at 2x105 cells/well and used to make protein lysates. These 
were used to establish the optimal concentration (100nM, 200nM and 300nM) and time (48 
or 72 hours) for each siRNA in both MCF7 and MDA-MB-231. Once optimal 
concentration/time point established, 12 well plates were seeded at 1x10
5
 cells/well and 
used to make lysates for each functional assay to observe siRNA knockdown efficiency for 
each assay. 
 
● 96 well plates were seeded at 5x103 cells/well (as described in section 2.6.1/2) and once 
the correct confluency was reached, cells were silenced using 200nM siRNA for 48 hours 
before the functional assay was performed. 
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Well/flask 
format 
OptiMEM
® 
volume 
siRNA mixture 
volumes 
Lipofectamine® 
mixture volumes 
Total 
volume 
6 well 1.5ml 
(2ml in 
control) 
100nM 
 
5μl + 245μl 
OptiMEM® 
10μl + 240μl 
OptiMEM® 
2ml 
 
200nM 10μl + 240μl 
OptiMEM® 
300nM 15μl + 235μl 
OptiMEM® 
12 well 750μl 
(1ml in 
control) 
5μl siRNA + 125μl 
OptiMEM® (200mM) 
5μl + 125μl 
OptiMEM® 
1ml 
96 well 150μl 
(200μl in 
control) 
1μl siRNA + 24μl 
OptiMEM® (200mM) 
1μl + 24μl 
OptiMEM® 
200μl 
 
Table 2.5: siRNA/Lipofectamine® dilution volumes for each size of plate. 
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2.2.4   DN-IKKβ adenovirus infection in breast cancer cells 
Breast cancer cells were infected with dominant negative IKKβ adenovirus in order to 
overexpress dominant negative (DN) IKKβ, which is catalytically inactive. This is an 
alternative approach to silencing to inhibit activation of the pathways, allowing the protein 
to perform it’s scaffolding role but preventing it acting as a kinase. 
The adenoviral construct used was supplied by Dr Andrew Paul, University of Strathclyde. 
Cells were seeded in 6 well plates at 2x10
5
 cells/well and once around 50% confluence was 
reached one well was trypsinised and counted using a haemocytometer. Adenovirus (of 
known titre) was then added to cells (in normal growth medium) using the appropriate 
volume calculated using the formula: 
Number of cells x concentration (pfu) 
        Titre of the adenovirus 
 
A range of concentrations of adenovirus, measured by plaque forming units per cell 
(pfu/cell), was applied to establish which was most appropriate including 25, 50, 100 and 
200 pfu/cell. Cells were also infected with 200 pfu/cell of adenovirus containing  
β-galactosidase (β-gal) as a negative control to ensure changes in expression were not due 
to the infection procedure. After 40 hours incubation, protein was lysed (described in 
2.3.1) and western blotting performed to assess protein levels (described in 2.3.2 - 2.3.4). 
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2.3   Western blotting 
 
2.3.1   Lysis of protein 
Cells were exposed to appropriate agonist/vehicle or siRNA for the relevant period of time 
and they were then placed on ice to stop the reaction and prevent protein degradation or 
dephosphorylation. Cells were then washed twice with 750μl ice cold PBS before adding 
250μl (for a 12 well plate) or 500μl (for a 6 well plate) of pre-heated laemmli’s sample 
buffer (63mM Tris-HCl pH6.8, 2mM Na4P2O7, 5mM EDTA, 10% glycerol, 2% SDS, 
50mM DTT, 0.007% bromophenol blue). Cells were then scraped and pushed through a 21 
gauge needle to shear the chromosomal DNA. Samples were then transferred to Eppendorf 
tubes and boiled for 5 minutes to denature the proteins and stored at -20°C until use. 
 
2.3.2   SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Resolving gels were prepared containing 0.1% SDS, 0.375M Tris base (pH8.8), 3% 
glycerol, 10% Ammonium persulfate (APS), the appropriate amount of 30% 
acrylamide/bisacrylamide stock depending on the size of the protein of interest, and 
distilled water to 12mls. Most proteins were suitable to be separated on 10% gels (4mls of 
30% acrylamide/bisacrylamide in 12ml total volume), but due to the size and lack of 
specificity of the phospho-p100 antibody, a 7.5% (3mls of 30% acrylamide/bisacrylamide 
in 12ml total volume) gel was required to allow separation of the fragments. The addition 
of 0.05% tetramethylethylenediamine (TEMED) then began the polymerisation process. 
Glass plates were set up on a Mini-PROTEAN casting chamber and the solution was 
poured between the 2 plates with 200μl of 0.1% SDS added on top. Following gel 
polymerisation the SDS solution was removed and a stacking gel containing 10% 
acrylamide, 0.1% SDS, 10% APS and 0.05% TEMED was poured on top of the resolving 
gel, and a comb was inserted. After polymerisation, the comb was carefully removed and 
gels were assembled in a Bio-Rad Mini-PROTEAN electrophoresis tank filled with 
electrophoresis buffer (25mM Tris, 129mM glycine, 0.1% SDS). 15μl of sample was 
loaded per well using a Hamilton microsyringe. A prestained marker of known molecular 
weights was run on the same gel in order to identify the protein of interest by size and 
ensure transfer to membrane was successful. Samples were electrophoresed at a constant 
voltage of 120V, until the bromophenol blue dye had reached the bottom of the gel 
(usually around 1.5 hours). 
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2.3.3   Protein transfer 
Proteins were transferred from the gel to nitrocellulose membranes by electrophoretic 
blotting in wet conditions.  A sandwich of sponge, filter paper, gel, membrane, filter paper 
and sponge was immersed in transferred buffer (25M Tris, 19mM glycine, 20% methanol) 
and stacked on the Bio-Rad cassette as in Figure 2.1. This was slotted into a Bio-Rad Mini-
PROTEAN electrophoresis tank and a constant current of 300mA was applied for 1h and 
45min with an ice pack included to cool the tank. The presence of SDS gives the protein a 
negative charge, so the cassette was oriented with the membrane towards the anode 
meaning protein would move towards this positive electrode and bind to the membrane. 
 
 
 
 
 
 
 
Figure 2.1: Assembly of the sandwich for western blot transfer. Diagram showing how 
the sandwich of sponge, filter paper, membrane and gel were stacked for transfer. 
 
2.3.4   Blocking, staining and visualisation 
Following transfer, the membrane was removed and non-specific binding blocked by 
incubation in a solution of 3% or 4% BSA in NaTT buffer for 90 minutes on an orbital 
shaker. Membranes were then incubated overnight, either at room temperature or 4°C, in 
primary antibody specific to the target protein diluted to optimal concentration in NaTT 
buffer containing 0.3% BSA. Conditions for each antibody are listed in Table 2.6. The next 
day membranes were washed 6 times in NaTT at 15 minute intervals, shaking gently. 
Secondary (either rabbit or mouse, depending on primary antibody used) HRP-conjugated 
antibody was diluted 1:10000 in NaTT with 0.3% BSA, and the membranes were then 
incubated in dilute secondary antibody for 90 minutes at room temperature. After another 6 
washes in NaTT at 15 minute intervals, presence of the protein of interest was detected by 
chemiluminescence. Membranes were incubated in 6mls of enhanced chemiluminescence 
(ECL) reagent (1:1 mixture of solution 1 [1M Tris ph8.5, 250mM luminol, 250mM  
p-cymuric acid and water] and solution 2 [1M Tris pH8.5, 0.19% H2O2 and water]) for 3 
minutes on a shaker. Membranes were then placed into a cassette, covered with cling film 
and in the dark room exposed to X-ray film for the required time and developed using an 
X-OMAT machine. 
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Protein of 
interest 
Antibody Species Blocking 
conditions 
Antibody 
conditions 
IKKα OP133 
Calbiochem 
Mouse 4% BSA in 
NaTT 
1:3500 @ 4°C 
IKKβ Ab32135 
Abcam 
Rabbit 4% BSA in 
NaTT 
1:2500 @ 4°C 
phospho-p65 
S536 
3031 
Cell signalling 
Rabbit 3% BSA in 
NaTT 
1:1000 @ 4°C 
p65 sc-8008 
Santa Cruz 
Rabbit 3% BSA in 
NaTT 
1:10000 @ room 
temperature 
IκBα 9242 
Cell signalling 
Rabbit 3% BSA in 
NaTT 
1:7500 @ room 
temperature 
p100/52 05-361 
Millipore 
Mouse 3% BSA in 
NaTT 
1:3000 @ 4°C 
phosho-p100 4810 
Cell signalling 
Rabbit 3% BSA in 
NaTT 
1:2000 @ 4°C 
 
Table 2.6: Antibodies used for western blot and optimal conditions. Table showing the 
company, catalogue number and species raised in for each antibody and the optimal 
conditions for western blotting. 
 
 
2.3.5   Stripping membrane 
Nitrocellulose membranes were reprobed for the subsequent detection of other proteins. 
Before reprobing, membranes were stripped using a stripping buffer containing 0.05M 
Tris-HCl and 2% SDS. The membrane was incubated at 60°C in 15ml of stripping buffer 
with 0.1M (105μl) β-mercaptoethanol for 60 minutes on a shaker. The membrane was 
washed in NaTT buffer 3 times for 15 minutes to remove all stripping buffer. Membranes 
were then ready for reprobing, following the protocol previously described (section 2.3.4). 
Lysates were assessed for levels of β tubulin as a loading control (1:10000, ab21058, 
Abcam). 
 
2.3.6   Quantification of expression levels 
Expression levels of proteins observed via western blots were calculated using ImageJ 
(NIH). Levels were normalised to β tubulin and fold change to control calculated using a 
one-way ANOVA with Bonferroni correction and Dunnets test used to compare to control. 
Changes were considered significant if P<0.05 and highly significant if P<0.001. 
  
 73 
2.4   Cell pellets 
 
2.4.1   Preparation of cell pellets 
Cells were seeded in a T-75 flask, grown to the correct confluency then quiesced for 24 
hours then exposed to TNFα at 20ng/ml for 15 minutes. After the appropriate treatment, 
flasks were washed with PBS and trypsinised then span down in 15ml corning tubes. The 
supernatant was discarded and cells were resuspended in 1ml PBS and transferred to 1.5ml 
eppendorfs before spinning down again, PBS discarded and cells resuspended in 4% 
formalin and incubated at room temperature for 15 minutes to fix the cells. Pellets were 
then formed by centrifugation for 5 minutes, supernatant discarded and all traces of 
formalin removed by PBS. Heated 1% agarose was then pipetted to the bottom of the tube 
to lift the pellet, before refrigeration for 30 minutes or until agarose solidified. Pellets in 
agarose were carefully removed from eppendorfs and placed into a cassette and dehydrated 
through a series of graded alcohols, before being submersed in xylene twice for 15 minutes 
and then placed in melted wax for an hour. Pellets were then removed from cassettes and 
placed into a mould, which was then filled with wax and cooled on cool plate. 
 
2.4.2   Cutting cell pellets 
4μM thick sections were cut from cooled FFPE blocks using a Leica microtome and placed 
into a waterbath to smooth out sections which were then attached onto slides and baked 
overnight at 56°C.  
 
2.4.3   IHC of cell pellets 
After cutting onto slides, pellets were used in IHC to assess expression level of the protein 
of interest. This follows the same protocol as IHC on the TMAs (see section 2.1.3) with the 
following exceptions: 
- Antigen retrieval time was halved to 2 minutes and 30 seconds. 
- Antibody concentrations were halved. 
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2.5   Gene expression profiling 
 
2.5.1   RNA extraction 
After treatment, MCF7 cells were trypsinised, media added to neutralise trypsin and two 
wells of a 6 well plate (of the same treatment) were combined. After centrifugation, Ice 
cold PBS was used to wash cells and transfer them to RNase free eppendorfs before 
centrifugation to remove PBS. Cells were then resuspended in 1ml Trizol (15596026, Life 
Technologies, Paisley, UK) and mixed gently for 10 minutes. 1/5 volume (200μl) of 
Chloroform (C2432, Sigma) was then added, the mixture vortexed and centrifuged at 
12500rpm for 15 minutes. The aqueous top layer was removed (400μl) and added to a 
fresh RNase free eppendorf with equal volume of Phenol:Chloroform:IAA (AM9732, 
Ambion) and again vortexed and centrifuged at 12500rpm for 15 minutes. The top layer 
(300μl) was added to a fresh RNase free eppendorf with equal volume of isopropanol 
(19576, Sigma), the tube inverted to gently mix and placed in the -80°C freezer for 1 hour. 
Tubes were then centrifuged for 15 minutes at 12500rpm, the supernatant disposed of and 
the pellet washed with 75% ethanol in nuclease free water. After centrifugation, all ethanol 
was removed and tubes left to dry for around 5 minutes before the pellet was resuspended 
in 15μl of nuclease free water. Concentration and 260/280 ratio of samples were measured 
using the Nanodrop, and samples stored at -80°C until use.  
 
2.5.2   cDNA synthesis 
Before cDNA synthesis, RNA samples were treated with DNase to eliminate any DNA. 
2μg of RNA was added with 2μl 10x DNase I buffer (M198A, Promega), 1μl RQ DNase I 
(M610A, Promega) and 1μl RNase OUT (10777-019, Life Technologies, Paisley, UK), 
and nuclease free water to a volume of 20μl. After incubation at room temperature for 15 
minutes, 1μl of stop solution was added (M199A, Promega) and the mixture heated for 10 
minutes at 65°C.  Samples were again measured for concentration and 260/280 ratio using 
the Nanodrop. 
 
For a 100μl cDNA synthesis reaction, 5μl random primers (48190-011, Life Technologies, 
Paisley, UK), 1μg RNA and nuclease free water was added to a volume of 62μl. This was 
heated to 65°C for 10 minutes and then 20μl 5x FS buffer, 2.5μl Superscript II reverse 
transcriptase (18064-014, Life Technologies, Paisley, UK), 10μl dNTPs (N04475, NEB), 
3.5μl DMSO and 2.5μl RNase OUT were added to make a final volume of 100μl. This was 
incubated at 25°C for 10 minutes followed by 50°C for 30 minutes then the transcriptor 
was inactivated at 85°C for 5 minutes. cDNA was then stored at -20°C until use. 
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2.5.3   Quantitative Real Time-PCR 
In order to compare gene expression between control samples and samples with silenced 
IKKα or IKKβ and to find selective downstream targets, quantitative real time PCR 
(qPCR) was used. To each well of a 96 well optical fast PCR plate, 40ng cDNA, 10μl 
master mix (4304437, Life Technologies, Paisley ,UK), 5μl nuclease free water and 1μl of 
Gene expression assay (Primers for specific genes, see Table 2.7), were added. Blank wells 
with only the mixture and no cDNA were included to ensure amplification was of the 
sample cDNA and not contaminants. Plates were then sealed and centrifuged for 3 minutes 
at 1200rpm and the plate was read on an ABI 7500 real time PCR machine.  The 
programme was as follows: 50°C for 2 minutes, 95°C for 10 minutes then 40 cycles of 
95°C for 15 seconds and 60°C for 1 minute.  Gene expression was normalised to the 18S 
gene and the comparative Ct (cycle threshold) ΔΔCt method used to quantify relative gene 
expression using the formula: Fold Change = 2
-Δ(ΔCt), where ΔCt = Ct, target - Ct, 18S and 
Δ(ΔCt) = ΔCt, stimulated - ΔCt, control. 
 
Gene Assay ID  Amplicon length 
18S Hs03928990_g1    61  
CHUK Hs00989507_m1 149  
IKBKB HS00233287_m1 61  
CCND1 Hs00765553_m1 57  
NCOR2 Hs00196955_m1 75  
CXCL10 Hs01124251_g1 135  
CRLF1 Hs00191064_m1 74  
 
Table 2.7: Information on Gene expression assays. The gene, assay ID and amplicon 
length are detailed. 
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2.6   Phenotypic assays 
 
2.6.1   Cell death assay 
Cells were assessed for apoptosis level using a Cell Death Detection enzyme-linked 
immunosorbent assay (ELISA) kit (11544675001, Roche, USA), both after stimulation and 
siRNA knockdown. This one step sandwich ELISA quantifies the amount of histone-
complexed DNA fragments (mono- and oligonucleosomes) from the cytoplasm of cells, 
which are enriched in apoptotic cells. Cells were seeded in a 96 well plate at a density of 
5x10
3
 cells/well in 100μL of standard culture medium. Once a confluency of 60-70% was 
reached siRNA knockdown was performed or cells were quiesced in serum free media for 
24 hours followed by stimulation. After treatment cells were pelleted by centrifugation at 
200xg for 10 minutes and the supernatant was discarded. The cells were resuspended with 
100μl of lysis buffer and incubated at room temperature for 30 minutes. The cells were 
collected by centrifugation at 200x g after lysis, and 20μl of the supernatant was 
transferred to the streptavadin coated microtiter plate. 100μl of immunoreagent (containing 
two monoclonal antibodies: biotin-labelled anti-histone and peroxidase conjugated anti-
DNA) was added to the wells and incubated for 2 hours at room remperature. Plates were 
washed 3x with incubation buffer before 100μl of ABTS solution was added to each well 
and incubated on a shaker at room temperature for 2 hours befire 100μl of ABTS stop 
solution was then added. The optical absorbance level was measured using a 96 well 
microplate reader at 405nm with reference 490nm. 
 
2.6.2   WST-1 viability assay 
Cell viability was assessed using the water-soluble tetrazolium salt (WST-1) reagent 
(05015944001, Roche, Switzerland). This colorimetric assay is based on cleavage of WST-
1 to formazan by cellular enzymes. More activity of these mitochondrial dehydrogenases 
results in an increase in formation of formazan dye, which corresponds to the number of 
viable cells. The amount of dye can then be measured using a multiwell 
spectrophotometer. Cells were seeded in 96 well plates at a density 5x10
3
 cells/well with 
100μL of media. Once 60% confluence was reached, cells were silenced for 48 hours or 
quiesced in serum free media for 24 hours followed by stimulation. The assay was 
performed by adding 10μL of WST-1 reagent to each well and after 2 hours incubation at 
37°C, the optical absorbance level was measured using a 96 well microplate reader at 
450nm. Each treatment was repeated at least in triplicate on the plate, and experiments 
repeated to an N=3. 
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2.6.6   Statistical analysis of WST-1/apoptosis assays 
Analysis was performed using SPSS version 18 (IBM, New York, USA). Fold change 
compared to control was assessed for significance based on p values from a one-way 
ANOVA. Bonferroni posthoc test was used for multiple comparisons and Dunnets was 
used to compare to control. P values were considered significant if P<0.05 and highly 
significant if P<0.001. 
 
2.6.3   Cell viability via the xCELLigence  
The xCELLigence machine (ACEA Biosciences Inc, San Diego, CA, USA) was used to 
display cell growth/viability in real time. This uses special plates with microelectrodes on 
the bottom allowing the impedance of each well to be measured. These measurements are 
continuously sent to the computer, allowing for real time growth curves to be plotted. 
Measurements are given as “Cell Index” which represents the number and viability of the 
cells. Cells were seeded in a 96 well E-plate™ (012738, ACEA Biosciences, San Diego, 
CA) at 3x10
3
 cells/well with 200μl of media in each well and grown for two days to ensure 
in log phase of growth. Cells were then quiesced in serum free media for 24 hours before 
appropriate treatment (stimulation or silencing) was applied. After 72 hours graphs 
showing cell index over time were drawn. 
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Chapter 3: 
Assessment of proliferation, apoptosis and 
molecular subtypes in breast cancer 
clinical specimens by 
immunohistochemistry
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3.1   Introduction 
Patient tissue is an extremely valuable tool in translational research that allows novel 
markers to be tested for association with clinico-pathological characteristics such as the 
size and stage of the tumour, as well as clinical outcomes including breast cancer specific 
survival and recurrence free interval.  Two different cohorts of patients presenting with 
invasive breast cancer were utilised in this study. The first, the 1800-Bre-TMA was used as 
a training cohort to identify markers and cut off values, and the ST-Bre-TMA was used as 
a validation cohort to investigate clinically significant markers in a separate cohort with 
information available for recurrence on tamoxifen. 
 
Increased proliferation and loss of apoptosis are both hallmarks of cancer [123]. Using 
MIB1, the monoclonal antibody to detect expression of Ki67 and therefore proliferation, 
an association between Ki67 and clinical outcome has been reported. Several studies have 
implicated a poorer disease free and overall survival in patients with tumours that display 
high Ki67 [158-159]. Lower levels of apoptosis are also likely to result in poorer outcome. 
Several markers have been employed in tissue studies to determine levels of apoptosis 
including DNA fragmentation (TUNEL), Bcl2, Bax and caspase-3 [160-161]. In order to 
further develop the information available in both cohorts, levels of apoptosis and 
proliferation within the tumours were assessed and tumour subtype established as 
recommended by the expert panel at the St. Gallen International Breast Cancer Conference 
[48]. 
 
3.2   Clinico-pathological characteristics of the patient cohorts 
 
3.2.1   1800-Bre-TMA 
This cohort included 544 breast cancer patients presenting with invasive breast cancer 
between 1995 and 1998. A database was available with full clinical follow up as well as 
clinico-pathological data including invasive grade, ER status, HER2 status, necrosis, 
angiogenesis (measured in a previous study by microvessel density using an anti-CD34 
antibody in IHC), lymph node status and any therapy the patient received. The number of 
patients in each group is detailed in Table 3.1. 
 
The majority of patients (71%) were over 50 years of age, had Grade II (43.5%) or Grade 
III (36.3%) tumours of 20mm or less (60.1%) with 36.7% having tumours between 21 and 
50mm in size. 64.1% of tumours were ER positive and 14.7% were HER2 positive. There 
was a fairly even split in groups for nodal status (57.4% negative and 42.6% positive), PgR 
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(54.5% negative and 45.5% positive), necrosis (47.6% absent and 52.4% present) and 
chemotherapy (59% did not receive and 41% did). The majority of patients (74.4%) 
received endocrine therapy. 
 
Size, invasive grade, nodal status, ER status, PgR status, HER2 status, levels of 
angiogenesis and whether the patient received chemotherapy were all significantly 
associated with clinical outcome, both breast cancer specific survival and recurrence free 
interval.  Age was not significant when either outcome was considered and endocrine 
therapy did not reach significance with breast cancer specific survival but was significantly 
associated with recurrence free interval. 
 
Clinico-pathological 
characteristic 
Patient numbers (and %) 
(Total N = 544) 
Clinical outcome 
significance  
Age  
(≤50/>50 years) 
158 (29%) / 386 (71%) S: P=0.385 
R: P=0.094 
Size  
(≤20/21-50/>50 mm) 
326 (60.1%) / 199 (36.7%) / 17 (3.1%) 
m2 
S: P<0.001 
R: P<0.001 
Invasive grade 
(I/II/III) 
109 (20.1%) / 236 (43.5%) / 197 (36.3%) 
m2 
S: P<0.001 
R: P<0.001 
Nodal status 
(negative/positive) 
309 (57.4%) / 229 (42.6%)  
m6 
S: P<0.001 
R: P<0.001 
NPI 
(<3.4/3.4-5.4/>5.4) 
169 (31.1%) / 281 (51.7%) / 94 (17.3%) 
 
S: P<0.001 
R: P<0.001 
ER 
(ER-/ER+) 
194 (35.9%) / 346 (64.1%)  
m4 
S: P=0.002 
R: P<0.001 
PgR 
(PgR-/PgR+) 
293 (54.5%) / 245 (45.5%)  
m6 
S: P<0.001 
R: P<0.001 
HER2 
(HER2-/HER2+) 
446 (85.3%) / 77 (14.7%)  
m21 
S: P<0.001 
R: P<0.001 
Necrosis  
(absent/present) 
253 (47.6%) / 278 (52.4%)  
m13 
S: P<0.001 
R: P<0.001 
Angiogenesis (CD34) 
(≤15/16-23/>23 H score) 
175 (35.9%) / 161 (33%) / 152 (31.1%) 
m56 
S: P=0.007 
R: P=0.001 
Chemotherapy 
(no/yes) 
319 (59%) / 222 (41%)  
m3 
S: P=0.001 
R: P<0.001 
Radiotherapy 
(no/yes) 
299 (55.3%) / 242 (44.7%) 
m3 
S: P=0.293 
R: P=0.742 
Endocrine therapy 
(no/yes) 
137 (25.6%) / 398 (74.4%)  
m9 
S: P=0.061 
R: P=0.036 
 
Table 3.1: Clinico-pathological characteristics of the 1800-Bre-TMA cohort of breast 
cancer patients. The number of patients in each group is detailed as well as significance 
on clinical outcome. S = breast cancer specific survival, R = recurrence free interval, m = 
missing. 
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3.2.2   ST-Bre-TMA  
This cohort included 456 patients presenting with operable breast cancer between 1980 and 
1999. The strength of this cohort is that patients were treated with adjuvant tamoxifen and 
time on tamoxifen was available in this database. Clinico-pathological data including size, 
invasive grade, PgR status, HER2 status, lymph node status and NPI was also available. 
The number of patients in each group is detailed in Table 3.2. 
 
Again most patients were over 50 years old with tumours under 50mm in size. 52.5% of 
tumours were 20mm or less and 42% were 21-50mm. The majority of patients had grade II 
tumours (48.9%) and were mainly HER2 negative (91.4%).  An even division is observed 
between groups of PgR and nodal status and only 23.7% of patients received adjuvant 
chemotherapy. 
 
Size, invasive grade, NPI, nodal status and PgR were all significant on both breast cancer 
specific survival and recurrence free interval, while chemotherapy was only significant on 
breast cancer specific survival. Age was not associated with clinical outcome, neither was 
HER2 although very few patients were HER2 positive.  
 
Clinico-pathological 
characteristic 
Patient numbers (and %) 
(Total N = 456) 
Clinical outcome 
significance  
Age  
(≤50/>50 years) 
82 (18.5%) / 361 (81.5%) 
m13 
S: P=0.127 
R: P=0.801 
Size  
(≤20/21-50/>50 mm) 
220 (52.5%) / 176 (42%) / 23 (5.5%)  
m37 
S: P<0.001 
R: P<0.001 
Invasive grade 
(I/II/III) 
102 (24.7%) / 202 (48.9%) / 109 (26.4%) 
m43 
S: P<0.001 
R: P<0.001 
Nodal status 
(negative/positive) 
216 (53.5%) / 188 (46.5%)  
m52 
S: P<0.001 
R: P<0.001 
NPI 
(<3.4/3.4-5.4/>5.4) 
136 (37.5%) / 165 (45.5%) / 62 (17.1%) 
m93 
S: P<0.001 
R: P<0.001 
PgR 
(PgR-/PgR+) 
169 (41.5%) / 238 (58.5%)  
m49 
S: P=0.015 
R: P=0.002 
HER2 
(HER2-/HER2+) 
395 (91.4%) / 37 (8.6%)  
m24 
S: P=0.126 
R: P=0.078 
Chemotherapy 
(no/yes) 
338 (76.3%) / 105 (23.7%)  
m13 
S: P=0.002 
R: P=0.084 
Radiotherapy 
(no/yes) 
317 (69.5%) / 139 (30.5%) S: P=0.732 
R: P=0.378 
 
Table 3.2: Clinico-pathological characteristics of the ST-Bre-TMA cohort of breast 
cancer patients. The number of patients in each group is detailed as well as significance 
on clinical outcome. S = breast cancer specific survival, R = recurrence free interval, m = 
missing. 
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3.3   Ki67 as a marker of proliferation 
 
3.3.1   Ki67 in the 1800-Bre-TMA cohort 
Ki67 status was already available in the 1800-Bre-TMA from a previous study by Dr 
Zahra Mohammed. The percentage of positive cells was calculated and the range of scores 
is shown in the histogram in Figure 3.1A. When survival analysis was performed using 
tertiles, and the highest tertile, with values of 15% or more, was associated with a poor 
clinical outcome and the lower and middle tertiles displayed more favourable outcomes 
[157].  
 
Studies assessing the prognostic value of Ki67 have used various cut offs, usually ranging 
from 10-20%. The 15% cut off applied to our cohort, based on tertiles, is reassuringly in 
the middle of these values and was found to be associated with clinical outcome. Using 
this 15% cut off Ki67 was associated with breast cancer specific survival (P=3.3x10
-5
, 
Figure 3.1B). Those with a low Ki67 index had a longer average breast cancer specific 
survival of 13.1 years compared to 11.2 in those with high Ki67. Similar results were 
observed with recurrence free interval (P=0.003, Figure 3.1C). The 15% cut off was 
therefore used in this and future studies. 
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Figure 3.1: Ki67 and outcome in the 1800-Bre-TMA. The range of % positive cells for 
Ki67, as a marker of proliferation, is shown in the histogram (A). Ki67 was significantly 
associated with breast cancer specific survival (B) and recurrence free interval (C). 
Censor lines in B indicate loss to follow up or death due to other cause i.e. not a breast 
cancer related death. Censor lines in C indicate loss to follow up. 
 
 
A 
B 
P=3.3x10-5 
Low Ki67 (<15%) 
N=398, 13.1 years 
High Ki67 (≥15%) 
N=118, 11.2 years 
C 
Low Ki67 (<15%) 
N=378, 7.6 years 
High Ki67 (≥15%) 
N=110, 6.9 years 
P=0.003 
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3.3.2   Ki67 in the ST-Bre-TMA cohort 
IHC was employed using the MIB1 antibody to assess the levels of Ki67, as a marker of 
proliferation, in the ST-Bre-TMA cohort. Due to discordance with the results using the 
automated system and the manually counted level of Ki67, cores were assessed for Ki67 
by manually counting the number of positive and negative nuclei and calculating the 
percentage of positive cells. The 15% cut off established in the previous cohort was 
applied to the cohort, with those tumours with a Ki67 index of 15% or more being classed 
as highly proliferative and those with a value of less than 15% being classed as low. 
Expression of Ki67 is pictured in Figure 3.2. The percentage of positive cells ranged from 
0 to 94.7 and of the 375 tumours scored, 264 (70.4%) had a low Ki67 index of less than 
15% and 111 (29.6%) displayed high Ki67 with an index of 15% or more. Across the cores 
from the same patient the average standard deviation of percentage positive cells was 5.7 
and the median was 3.2 (IQR = 1.1 – 7.8). 
 
 
 
 
 
 
 
 
 
Figure 3.2: Expression of Ki67 in the ST-Bre-TMA cohort. (A) an example of a tumour 
with no positive nuclei and (B) a tumour displaying high levels of Ki67. Images were taken 
at 400x magnification, scale bar represents 100μm. 
 
 
Using the log rank test, high Ki67 was found to be associated with poorer breast cancer 
specific survival (P=0.002, Figure 3.3A), decreased recurrence free interval (P=1.1x10
-5
, 
Figure 3.3B) and increased recurrence on tamoxifen (P=1.5x10
-8
, Figure 3.3C). Patients 
with highly proliferative tumours had an average breast cancer specific survival of 12.7 
years, 5.2 years less than those with tumours that displayed low Ki67.  
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Figure 3.3: Ki67 and clinical outcome in the ST-Bre-TMA cohort. The range of % 
positive cells for Ki67, as a marker of proliferation, is shown in the histogram (A). High 
Ki67 was associated with poor breast cancer specific survival (B), decreased recurrence 
free interval (C) and an increase in recurrence on tamoxifen (D). Censor lines in panel B 
indicate loss to follow up or death due to other cause and in panel C and D indicate loss to 
follow up.  
 
 
 
Low Ki67 
N=258, 17.9 yrs 
High Ki67 
N=85, 12.7 yrs 
P=0.002 
B 
Low Ki67 
N=259, 13.9 yrs 
High Ki67 
N=84, 8.6 yrs 
P=1.1x10-5 
C 
Low Ki67 
N=258, 13.4 yrs 
High Ki67 
N=85, 6.0 yrs 
P=1.5x10-8 
D 
A
=
A 
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3.4   Categorising tumours into subtypes using IHC markers  
As previously discussed, there are several subtypes of breast cancer, each with distinct 
characteristics and response to different therapies. Due to lack of fresh tissue, the breast 
tumours were subtyped based on 4 IHC markers (ER, PgR, HER2 and Ki67) in accordance 
with the definitions proposed by Cheang et al and recommended by the expert panel at St. 
Gallen [48, 54] 
 
3.4.1   Subtypes in the 1800-Bre-TMA cohort 
As the 1800-Bre-TMA cohort includes both ER positive and ER negative patients, and 
PgR status, HER2 status and Ki67 index were available, it was possible to split the cohort 
into 4 distinct subtypes as detailed in Table 3.3: 
 
1: Luminal A - ER or PgR positive, HER2 negative and low Ki67. 
2: Luminal B -  ER or PgR positive, and HER2 positive and/or high Ki67. 
3: Triple negative - ER negative, PgR negative and HER2 negative 
4: HER2 enriched - ER and PgR negative but HER2 positive. 
 
 
Table 3.3: Subtyping of the 1800-Bre-TMA cohort using 4 IHC markers. Four IHC 
markers (ER, PR, HER2 and Ki67) were used to subtype the cohort into four groups. The 
number of patients in each group is detailed as well as duration of breast cancer specific 
survival.  
 
Subtype 
 
IHC markers 
 
Number of 
patients (%) 
N=505 
 
Average breast 
cancer specific 
survival 
 
Luminal A 
ER or PgR positive, 
HER2 negative,  
low Ki67 (<15%) 
 
237 (46.9%) 
 
 
14.0 years 
 
 
Luminal B 
 
ER or PgR positive,  
HER2 positive and/or  
high Ki67 (≥15%) 
 
100 (19.8%) 
 
  
11.7 years 
 
Triple 
negative 
ER, PgR and  
HER2 negative 
 
122 (24.2%) 
 
11.7 years 
HER2 
enriched 
ER, and PgR 
negative, HER2 
positive 
 
46 (9.1%) 
 
10.3 years 
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Several patients (39/544) were missing HER2 or Ki67 status and were therefore excluded 
from analysis. The majority of the 505 breast cancer patients analysed were luminal A 
(46.9%), 19.8% were luminal B, 24.2% were triple negative and the remaining 9.1% were 
HER2 enriched. Kaplan-Meier survival graphs were plotted (Figure 3.4) and the log rank 
test was used to compare low and high Ki67.  Patients with luminal A tumours had a 
significantly longer breast cancer specific survival (14 years, P=7.2x10
-9
) compared to all 
other subtypes. As multiple comparisons were used in this analysis, using Bonferroni’s 
method a more stringent P value of 0.008 is required since there are 6 possible 
comparisons. This result remains significant at this more stringent P value. Luminal B 
patients and triple negative patients both had an average breast cancer specific survival of 
11.7 years. The group with the poorest prognosis was the HER2 enriched tumours, in 
which patients were found to have an average breast cancer specific survival of 10.3 years.  
This is in line with previous reports examining breast cancer subtypes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Breast cancer subtypes and clinical outcome in the 1800-Bre-TMA cohort.  
Breast cancer specific survival showed luminal A patients had the longest average survival 
of 14 years, then luminal B and triple negative (11.7 years), and the worst prognosis was 
in the HER2 enriched group (10.3 years). Censor lines indicate loss to follow up or death 
due to other cause. 
 
 
 
Luminal A 
N=237 
Triple negative 
N=122 
P=7.2x10-9 
Luminal B 
N=100 
HER2 enriched 
N=46 
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3.4.2   Subtypes in the ST-Bre-TMA cohort 
As this cohort was an ER positive cohort (with the exception of 44 of unknown ER status 
and 20 ER negative, which were excluded from analysis of subtypes), there were no 
tumours that fell into the catergories of triple negative or HER2 enriched. The cohort was 
subdivided into luminal A and luminal B using HER2 status and Ki67 index. 79 of the 392 
patients were excluded from analysis due to lack of HER2 status or Ki67 index. Of the 
remaining 313 patients, 223 were categorised as luminal A (71.2%) and 90 as luminal B 
(35.5%), as detailed in Table 3.4. Luminal A patients had significantly longer average 
breast cancer specific survival of 16.6 years compared to 14.2 years survival in the luminal 
B group (P=0.002, Figure 3.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Breast cancer subtypes and clinical outcome in the ST-Bre-TMA cohort.  
Breast cancer specific survival analysis showed luminal A patients had a longer average 
survival of 16.6 years compared to luminal B patients which had an average survival of 
14.2 years (P=0.002), Censor lines indicate loss of follow up. 
 
 
 
 
 
 
Luminal B 
N=90, 14.2 yrs 
Luminal A 
N=223, 16.6 yrs 
P=0.002 
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Table 3.4: Subtyping of the ST-Bre-TMA cohort into different luminal subtypes using 
Ki67 and HER2. The cohort was split into luminal A and luminal B tumours using HER2 
status and Ki67 index. The number of patients in each group is detailed as well as duration 
of breast cancer specific survival.  
 
 
3.5   TUNEL as a marker of apoptosis 
 
3.5.1   Apoptosis in the 1800-Bre-TMA cohort 
An IHC based approach was also employed to the cohort to detect apoptosis using a 
commercially available kit to detect DNA fragmentation. Levels of apoptosis were 
assessed using the number of percentage positive cells, similar to Ki67. Scoring was 
assessed using the Tissue Image Analysis software on the Slidepath Digital Image Hub.  
TMAs were dearrayed and matched to the correct position on a map of each TMA 
allowing separate analysis of each core. The thresholds of a range of size and shape of 
nuclei and staining colour and intensity were adjusted in the nuclear algorithm. Optimal 
conditions were established using several cores before the algorithm was applied to the 
whole cohort. Figure 3.6 shows an example of accepted nuclei and the differentiation 
between positive and negative nuclei. 10% of cores were scored manually to compare 
results with the automated system to manual scoring and the ICCC was calculated. The 
ICCC was 0.83 indicating good correlation between automated and manual scoring. All 
cores were checked to ensure the automated score seemed appropriate and no artefacts had 
been counted and included in analysis. 
 
 
Subtype 
 
IHC markers 
 
Number of 
patients (%) 
N = 313 
 
Average breast 
cancer specific 
survival 
 
Luminal A 
ER or PgR positive, 
HER2 negative,  
low Ki67 (<15%) 
 
223 (71.2%) 
 
16.6 years 
 
 
Luminal B 
 
ER or PgR positive,  
HER2 positive and/or  
high Ki67 (≥15%) 
 
90 (28.8%) 
  
14.2 years 
 
 90 
 
Figure 3.6: Automated scoring of TUNEL using the Slidepath Tissue Image Analysis 
nuclear algorithm. The algorithm was optimised for this breast cohort and stain, with 
thresholds adjusted to include correct size and shaped nuclei and identify positive and 
negative staning. (A) an example of an area with positive (one is indicated by the arrow) 
and negative nuclei. (B) Green areas represent accepted nuclei and (C) blue areas 
indicate the nuclei have been identified as negative and orange as positive. 
 
Several cores were missing or did not contain tumour, leaving 444 cores available for 
analysis. The percentage positive values ranged from 0 to 90%, with a median of 0.33%. 
Average standard deviation of percentage of cells exhibiting staining across the cores from 
the same patient was 1.25 and median was 0.58 (IQR= 0.0 - 1.0). Figure 3.7 shows an 
example of staining observed for negative cores and for those with high levels of 
apoptosis. Using the median as a cut off, tumours were split into those with low levels of 
apoptosis (≤ 0.33%) and those with high levels of apoptosis (>0.33%).  Of the 444 cores 
available for analysis, 246 (55.4%) were classed as low and 198 (44.6%) as high. Figure 
3.8A shows a histogram with the distribution of percentage positive scores for TUNEL. 
 
 
 
 
 
 
 
 
 
Figure 3.7: Expression of TUNEL in the 1800-Bre-TMA. (A) an example of a tumour 
with no positive nuclei and (B) a tumour displaying high levels of apoptosis. Images taken 
at 400x magnification, scale bar represents 100μm. 
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Kaplan-Meier survival curves were drawn for both breast cancer specific and recurrence 
free interval and high and low expression was compared using the log rank test. Apoptosis 
was not associated with breast cancer specific survival (Figure 3.8A, P=0.304) but was 
significantly associated with recurrence free interval (Figure 3.8B, P=0.033). Patients 
whose tumours displayed low levels of apoptosis had a shorter recurrence free interval of 7 
years compared to 7.8 years in those with high apoptosis. However, using a more stringent 
P value of 0.01 this is not regarded as significant. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: Apoptosis and clinical outcome in the 1800-Bre-TMA cohort. (A) 
Histogram showing distribution of % positive cells for TUNEL. (B) Apoptosis was not 
associated with breast cancer specific survival (P=0.304). (C) Those with high TUNEL 
had a longer recurrence free interval of 7.8 years compared to 7 years in those with low 
TUNEL (P=0.033). Censor lines in panel A indicate loss to follow up or death due to other 
cause and in panel B indicate loss to follow up. 
A 
B 
P=0.304 
High TUNEL 
N=198, 12.9 years 
Low TUNEL 
N=246, 12.4 years 
C 
Low TUNEL 
N=230, 7.0 years 
High TUNEL 
N=188, 7.8 years 
P=0.033 
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3.5.2   Apoptosis in the ST-Bre-TMA cohort 
Apoptosis was also assessed in the ST-Bre-TMA by TUNEL. Cores were scored manually 
due to incorrect percentages reported by the automated Tissue Image Analysis system. The 
average standard deviation of percentage positive cells in the three cores from one tumour 
was 16.6 and the median was 11.4 (IQR= 1.2 - 26.5).  Examples of tumours with different 
levels of TUNEL are shown in Figure 3.9. Using the cut off established in the previous 
cohort, tumours were categorised as having high (>0.33%) and low (≤0.33%) levels of 
apoptosis. Figure 3.10A shows a histogram of percentage positive cells for TUNEL. Many 
more tumours in this cohort displayed higher levels of tumours, in comparison to the 1800-
Bre-TMA where (as shown in the histogram in Figure 3.8A) most tumours displayed no or 
low levels of apoptosis. 
 
 
 
 
 
 
 
 
 
Figure 3.9: Expression of TUNEL in the ST-Bre-TMA. (A) an example of a tumour 
with no positive nuclei and (B) a tumour displaying high levels of apoptosis. Images taken 
at 400x magnification, scale bar represents 100μm. 
 
 
Higher levels of apoptosis were associated with a more favourable clinical outcome. Those 
with high levels of apoptosis had a longer average breast cancer specific survival of 16.1 
years compared to 11.8 years for those with low apoptosis (P=0.034, Figure 3.10B). 
Higher apoptosis also resulted in a longer recurrence free interval (9.1 years for low versus 
12.8 years for high, P=0.025, Figure 3.10C). When recurrence on tamoxifen was 
considered, those with high levels of apoptosis had a longer time to recurrence of 12.4 
years compared to 7.6 years on average for patients with low apoptosis (P=0.038, Figure 
3.10D). Again, however, the use of a more stringent P value of 0.01 means this association 
would not be considered significant. It is therefore debatable whether TUNEL, as a marker 
of apoptosis, is associated with clinical outcome. 
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Figure 3.10: Apoptosis and clinical outcome in the ST-Bre-TMA cohort.  (A) 
Histogram of percentage positive cells stained using the TUNEL assay to measure 
apoptosis. Low apoptosis was associated with poor breast cancer specific survival (B), 
decreased recurrence free interval (C) and an increase in recurrence on tamoxifen (D). In 
Figure B censor lines indicate loss of follow up or death due to other cause and in Figures 
C and D indicate loss to follow up. 
 
Levels of Bcl2 were already available in this cohort as part of a study by Dr Elizabeth 
Cannings [162]. Chi squared analysis showed expression of TUNEL was significantly 
associated with expression of Bcl2 (P=0.034).  TUNEL was found to be a stronger 
prognostic apoptosis marker, as there was no significant difference between low and high 
Bcl2 expression on breast cancer specific survival (P=0.729), recurrence free interval 
(P=0.515) or recurrence on tamoxifen (P=0.193). 
C D 
P=0.036 
Low TUNEL 
N=86, 11.8 yrs 
High TUNEL 
N=249, 16.4 yrs 
B 
Low TUNEL 
N=87, 8.3 yrs 
High TUNEL 
N=249, 12.8 yrs 
P=0.011 
Low TUNEL 
N=86, 7.4 yrs 
High TUNEL 
N=250, 12.2 yrs 
P=0.025 
A 
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3.6   Discussion 
IHC is a valuable tool in translational research and also in diagnostic use to assist in the 
selection of appropriate targeted therapies. There are however many pitfalls as it can be 
variable due to the quality of the tissue and for routine use in diagnostic laboratories there 
needs to be standardised protocols for technique and analysis and extensively validated cut 
offs.   
 
The proliferation rate of a tumour is important in the prognosis of breast cancer and the 
development of MIB-1, a monoclonal antibody that detects Ki67, has allowed 
immunohistochemical studies to use this marker in the assessment of tumour proliferation. 
This antibody was recommended to be considered as the ‘gold standard’ for Ki67 detection 
by the International Ki67 in Breast Cancer Working Group [163]. It was also 
recommended that Ki67 was scored using the percentage of positive cells [163] and it was 
this method that was applied in this thesis. Several cut offs for Ki67 have been used in 
studies, usually ranging from 10-20% [159]. A cut off of 15% was previously established 
in the 1800-Bre-TMA cohort using tertiles and was found to be associated with clinical 
outcome in both this cohort and the ER positive ST-Bre-TMA cohort. In order to establish 
a cut off for routine diagnostic use, guidelines on the standardisation of fixation, staining, 
scoring and analysis are required. This was recognised by the International Ki67 in Breast 
Cancer Working Group and a consensus on the most appropriate cut off value was not 
reached as it was recommended further independent studies were required for validation 
[163]. The tissue available for this thesis used TMAs, which allows for simultaneous 
assessment of hundreds of patients in a single experiment. Although this is useful for high 
throughput, variable levels of Ki67 have been reported in whole sections with hotspots 
occurring at certain areas of tumour [163]. In order to account for tumour heterogeneity, 
three separate TMAs were constructed to allow analysis of three separate areas of tumour, 
as identified by a pathologist. The use of TMAs to stain Ki67 is controversial due to 
heterogeneity observed with certain tumour areas. A validation study was conducted in 
colorectal cancer comparing TMAs and whole sections for Ki67 and several other markers 
[164]. Comparing the % positive cells (using a 20% cut off) in TMAs and whole sections, 
the authors found that there was a 0.79 kappa value between both methods for Ki67 [164]. 
In a previous study in our laboratory, using a small set of patients with available whole 
sections, it was found that scores obtained using TMAs and whole sections were 
comparable (Oral communication, Dr Joanne Edwards). In another study in breast cancer, 
however, it has been reported that in a cohort of 213 patients whole sections are superior to 
TMAs for prognostication and correlation with clinic-pathological correlation [165]. This 
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study also reported poor correlation between each method with a Pearson’s correlation 
coefficient of 0.13417 [165]. It appears the TMAs tended to underestimate the scores, 
which may be due to missing “hot spots” (areas where Ki67 is particularly high) that are 
present on the section. Guidelines on the recommended scoring method when hotspots are 
present yet to be established, with some using hot spots as a focus for scoring, others using 
them in the general assessment of the section as a whole and others recommending 
ignoring hot spots. However the International Ki67 in Breast Cancer Working Group have 
recommended that until proper guidelines are established, that is hot spots are present the 
assessment of Ki67 should include these and give an overall average score for the whole 
section [163]. The use of whole sections therefore may be more appropriate for assessment 
of Ki67, however unfortunately only TMAs were available for this study. Further 
investigations are needed with much larger datasets to assess the level of correlation 
between each method. In both cohorts Ki67 was demonstrated to be a useful marker, which 
correlated with breast cancer specific survival, recurrence free interval and recurrence on 
tamoxifen and allows stratification of patients. However for use clinically strict adherence 
to guidelines on fixation, staining and scoring would have to be followed in order to make 
it reproducible across diagnostic laboratories. Additional assesment is also needed to 
compare the use of TMAs for Ki67. 
 
Apoptosis, the loss of which is another hallmark of cancer, was also investigated in both 
patient cohorts. Various markers have been used in studies such as caspases, Bax, Bcl2 and 
DNA fragmentation using the TUNEL method. This study used a commercially available 
kit to measure apoptosis levels via the TUNEL method. It was hypothesised that a higher 
level of apoptosis in breast tumours would result in a better clinical outcome in patients. 
TUNEL was associated with recurrence free interval in the first cohort with those patients 
with lower TUNEL expression having a quicker time to recurrence. However levels of 
TUNEL were not associated with disease specific survival, although a similar trend is 
observed. The association with clinical outcome was validated in the second cohort, using 
the previously established cut off, with low levels of TUNEL associating with decreased 
breast cancer specific and recurrence free interval and a quicker time to recurrence on 
tamoxifen. To compare different markers of apoptosis and their significance on clinical 
outcome, expression of TUNEL was assessed as well as Bcl2, which was available from a 
previous study in the ST-Bre-TMA cohort. Bcl2 is anti-apoptotic, blocking pro-caspases, 
and therefore may be expected to correlate with low levels of TUNEL. Levels of Bcl2 
were significantly associated with TUNEL when chi squared test was performed. 
Apoptosis detection via the TUNEL assay was found to be a stronger prognostic marker 
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than Bcl2, which was not found to be significantly associated with breast cancer specific 
survival, recurrence free interval or endocrine resistance.  
 
As this study used TMAs with three representative cores from each tumour and scores 
were calculated as the average across the three cores, the standard deviation was also 
calculated across these cores as a measure of heterogeneity and the median and 
interquartile range have also been calculated. This is particularly important for Ki67 and 
apoptosis, where the markers may exhibit variable expression due to the tumour 
microenvironment. Cores were generally taken from the centre of the tumour and although 
some heterogeneity was observed, overall there was fairly good agreement in the 
expression of markers examined in this study, shown by the standard deviation values. 
There was heterogeneity observed with Ki67 with the maximum standard deviation of 
38.4, this may be due to the hotspots observed with Ki67 staining. The use of three cores in 
the TMAs is designed to account for heterogeneity and result in a representative score for 
the whole tumour. A much larger deviation is likely to have been observed had the TMA 
included cores from the invasive age as well as the centre of the tumous and this would 
also allow comparinson of expression of various markers at different areas. 
 
Although an association with disease recurrence was observed, TUNEL is not warranted 
for inclusion in routine analysis at present until the most appropriate marker is established 
and guidelines on its use developed. Additionally, the findings of this study contradict 
others, which have found that a high apoptotic index is associated with poorer survival, 
although these used different methods of apoptosis detection [163, 166-168]. Another 
study of clinical outcome and apoptosis used DNA fragmentation as a marker of apoptosis 
and also investigated Bcl2 expression on clinical outcome [169]. High Bcl2 was associated 
with a favourable outcome but was not associated with apoptosis. Apoptosis was not 
significantly associated with clinical outcome in this study [169]. There is therefore 
controversy surrounding apoptosis and clinical outcome in breast cancer, however these 
results support the hypothesis that low levels of apoptosis are associated with poorer 
outcome. The use of markers to quantify levels of apoptosis are however useful in the 
research setting when investigating other markers as it allows markers to be correlated with 
different processes involved in the development and progression of breast cancer. 
Furthermore, detection of apoptosis may be a useful marker to show response to therapy 
[168]. Consensus and extensive validation is required on the use of markers and cut offs 
before assessment of apoptosis can be considered for adoption clinically. 
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In order for assessment of markers of proliferation and apoptosis to be implemented in 
routine diagnostic laboratories, as well as the development of standard protocols and 
guidelines on assessment being required, a method of automatically assessing expression is 
necessary. Analysis can be very tedious as it is not possible to accurately estimate the 
percentage of cells that are positive and manual counting is a very arduous task. The 
introduction of image analysis software offers the possibility of automated assessment of 
IHC slides, reducing the workload of the pathologist. However use of such software 
remains to be demonstrated to be reproducible and highly accurate. As part of a previous 
study Ki67 was counted both visually and automatically using the Slidepath Image 
Analysis system and an excellent correlation was observed between the two methods 
[157]. A stronger association was observed, however, with Ki67 levels and clinical 
outcome when counting was performed visually rather than with the automated system 
[157]. Other studies investigating the use of automated assessment of Ki67 index in breast 
cancer have also reported good correlation between manual and automated scoring [170-
171]. Although good correlation is observed between the two scoring methods, more 
investigation and optimisation is required to ensure automation is able to generate reliable 
clinical measurements before it is adopted in the routine clinical pathology laboratory.  
 
In this study apoptosis, measured using a TUNEL assay, was scored in the 1800-Bre-TMA 
cohort using the automated system and although several artefacts had to be corrected, there 
was generally good correlation between manual and automated counting. There was 
however discordance with percentages obtained for apoptosis and Ki67 percentages in the 
ST-Bre-TMA cohort, meaning all cores had to be scored visually. This again highlights 
that further work is required before the use of automated systems is appropriate. The time 
to fixation has been reported to have little effect on visual analysis but is important when 
using automated image analysis as it impacts on the integrity of the nucleus [163]. Antigen 
retrieval is required and the use of a standard protocol for this is recommended [163]. The 
counterstain is another aspect that can affect the results obtained from automated scoring. 
If the stain is too weak the software does not detect all the nuclei, and it is important all 
nuclei are counted as it can drastically alter the percentage obtained if the number of 
negative nuclei are underestimated [163]. Equally, when counterstaining is too strong, it is 
often difficult for the software to differentiate between negative dark blue nuclei and 
brown positive nuclei. Every step of the process of IHC and scoring therefore needs to be 
standardised to improve reliability of automated scoring. Additionally, the problems with 
the automatic scoring highlights a limitation of this part of the study due to the use of two 
different analysis methods, visual and automatic, for each cohort in the assessment of 
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apoptosis, making comparison of results from each cohort for apoptosis problematic and 
therefore caution should be applied in interpretation of these results. In order to be used for 
validation and to apply the same cut offs the same method of analysis is required and 
ideally the 1800-Bre-TMA cohort should be scored visually due to the problems in 
optimisation of the automated scoring system in the ST-Bre-TMA. These problems may be 
due to slightly different fixation methods or strength of counterstaining which, as 
previously discussed, can affect the results of automatic scoring. The use of Ki67 is 
arguably of greater importance in this study due to the inclusion of Ki67 in stratification by 
molecular subtype. For this reason Ki67 values used in each cohort for Kaplan-Meier 
graphs and log-rank tests used visual scoring for both cohorts and these are therefore 
comparable.  
 
The use of proliferation requires additional validation and guidelines on its use, but an 
expert panel at the St. Gallen International Breast Cancer Conference supported the use of 
Ki67 staining to routinely split the luminal subtypes once guidelines are available [48]. 
Using the 15% cut off for Ki67, the clinical cohorts were stratified into four subgroups: 
luminal A (ER+ and/or PgR+, HER2-, low Ki67), luminal B (ER+ and/or PgR+ and 
HER2+ and/or high Ki67), HER2 enriched (ER-, PgR-, HER2+) and triple negative (ER-, 
PgR-, HER2-). Percentages were in line with those reported elsewhere, with luminal A 
tumours being the most frequent in both cohorts. Additionally, as expected patients with 
luminal A tumours displayed a more favourable outcome compared with other subtypes. 
Levels of Ki67 and HER2 therefore appropriately stratified luminal tumours into luminal 
A and B. As discussed in Chapter 1, the different subtypes of breast cancer have been 
reported to respond differently to various therapies, which should be considered when 
deciding on the most appropriate treatment and therefore the availability of this 
information is beneficial to clinicians.  Ki67 therefore has been demonstrated to be an 
extremely useful marker overall, which once proper guidelines are in place to standardise 
would provide valuable clinical information.   Performing Ki67 assessment in both cohorts 
in this chapter allowed the division of both cohorts into molecular subtypes, allowing 
stratification of patients in future chapters. 
 
 
 
 
 
 99 
In conclusion, this chapter has shown that Ki67, as a marker of proliferation, is able to split 
the cohorts into groups with different prognosis and in combination with ER, PgR and 
HER2 appeared to be able to stratify tumours into the four main breast cancer subtypes. 
Apoptosis, in this case measured using a TUNEL assay, appears to be prognostic, but this 
does not appear to be as useful as proliferation. Additionaly a standardised marker is 
required before any guidelines on protocol and cut offs could be produced. This study also 
demonstrated that extensive optimisation of image analysis is needed and at present 
manually scoring these markers is a superior method than using computer software. 
Furthermore, Ki67 along with HER2 status appears to appropriately subdivide the ER 
positive tumours into luminal A and B and markers that allow stratification may become 
increasingly important as more is learned about the different subtypes. 
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Chapter 4: 
Expression of members of the NF-κB 
pathways in breast cancer  
clinical specimens
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4.1   Introduction 
The NF-κB pathways have been implicated in the progression of breast cancer. Studies with 
large numbers of patients exploring the role of different members are however lacking. We 
aimed to investigate the expression of key family members of both the canonical and non-
canonical NF-κB pathways in breast cancer patient tissue and assess the clinical significance 
of each member. Before use in valuable patient tissue, each antibody was validated to confirm 
it specifically targeted the protein of interest. Antibodies were then optimised for IHC in 
breast tissue before protein expression of each marker was assessed in the 1800-Bre-TMA 
cohort. 
 
4.2   Antibody validation of members of the canonical pathway 
Antibodies are one of the most commonly used tools in research, particularly in translational 
tissue based research. In order to produce reliable results, antibodies must be demonstrated to 
be specific and immunostaining reproducible. Selection of appropriate antibodies and 
verification of specificity are extremely important steps before use in patient tissue. All 
antibodies used in this study were confirmed as specific. 
 
4.2.1   Validation of anti-IKKβ antibody 
The antibody against IKKβ was previously validated in our laboratory by Mr L MacKenzie to 
ensure specificity using several methods. First, a single band of the predicted size of 87 kDa 
was observed by western blotting (Figure 4.1A). In paraffin embedded cell pellets of LNCaP 
prostate cancer cells, a decrease in expression of IKKβ was shown in IKKβ silenced cells 
compared to control, but expression was retained in cells treated with IKKα or non-targeting 
siRNA (Figure 4.1B). Blocking peptide experiments using IHC on archival prostate tissue 
showed loss of expression when the antibody was pre-incubated with excess IKKβ protein 
before use on tissue, but not when pre-incubated with IKKα or p65 protein (Figure 4.1C). 
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Figure 4.1: Validation of the anti-IKKβ antibody. (A) Western blotting showed a clear 
band of appropriate size (87 kDa) in extracts from LNCaP prostate cancer cells. (B) Silenced 
LNCaP cell pellets showed a decrease in expression of IKKβ in cells where IKKβ was 
silenced, but expression was retained in IKKα silenced cells and non-targeting (NT) control 
cells. (C) Blocking peptide experiments in prostate cancer tissue showed an excess of IKKβ, 
but not IKKα or p65, reduced expression of IKKβ. 
 
 
4.2.2   Validation of antibodies detecting the p65 subunit 
Antibodies for p65, phosphorylated p65 were confirmed as specific as part of this study. Dr 
Pamela McCall demonstrated the p65 NLS antibody to be specific as part of a previous study. 
A single band of correct size (65 kDa) was shown on a western blot of MCF7 cell lysates for 
p65 (Figure 4.2A) and phospho-p65 (Figure 4.2C). In IHC of cell pellets of MCF7 breast 
cancer cells, nuclear translocation was observed when exposed to 20ng/ml of TNFα. Blue 
(negative) nuclei are observed in the untreated control cells and translocation to the nucleus 
after TNFα treatment resulted in brown nuclei due to p65 (Figure 4.2B) and phospho-p65 
(Figure 4.2D) expression. Western blotting of LNCaP cell extracts showed a single band of 
around 65 kDa (Figure 4.2E), and nuclear translocation and an increase in expression of p65 
NLS was observed when IHC was performed on cell pellets of LNCaP cells treated with 
TNFα compared to untreated cells (Figure 4.2D). 
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Figure 4.2: Validation of the anti-p65, anti-phospho-p65 and anti-p65-NLS antibodies. 
(A) Western blot for anti-p65 showing a single band of appropriate size (65 kDa) in lysates of 
MCF7 breast cancer cells. (B) IHC was employed to show nuclear translocation of p65 in 
TNFα stimulated MCF7 cell pellets. Blue nuclei are observed in the untreated cells and 
brown are observed in the stimulated cells due to nuclear expression of p65. (C) Western blot 
using the phosho-p65 antibody showed a single band of appropriate size (65 kDa) in MCF7 
cells. (D) IHC on TNFα treated MCF7 cell pellets showed nuclear translocation of phospho-
p65. (E) Western blot for anti-p65-NLS showing a single band of 65 kDa. (F) Cell pellets 
showing increase in p65 NLS and nuclear translocation in TNFα treated LNCaP cells. 
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4.3   Expression and clinical outcome of members of the canonical pathway 
 
4.3.1   Expression of IKKβ and clinical outcome  
IKKβ expression was analysed in the 1800-Bre-TMA cohort. 144 patients had cores which 
were missing or contained no tumour leaving 400 patients available for analysis. The 
histoscores for cytoplasmic expression of IKKβ ranged from 0 to 275 with a median of 120 
(with an interquartile range (IQR) of 95.4 - 150), and for the nuclear compartment ranged 
from 0 to 230 with a median of 96.7 (IQR = 65 - 135).  An example of high and low 
expression of IKKβ is displayed in Figure 4.3A. The cohort was subdivided into those with 
low and high expression using the median as a cut off. Tumours with a cytoplasmic histoscore 
over 120 were classed as having high cytoplasmic IKKβ and tumours with a nuclear 
histoscore of more than 96.7 assigned to the high nuclear expression group. The average 
standard deviation in histoscore across the cores from the same patient for cytoplasmic 
expression was 32.2 and the median was 26.5 (IQR = 14.1 - 45.5). For nuclear expression the 
average standard deviation was 38.4 with a median of 32.1 (IQR = 20.8 - 50.8). An example 
of immunostaining of IKKβ is displayed in Figure 4.3, with low expression shown in 4.3A 
and high in 4.3B. Also included in Figure 4.3 are histograms displaying distribution of 
cytoplasmic (Figure 4.3C) and nuclear (Figure 4.3D) histoscores. Bland altman plots 
demonstrated no bias between observers and the ICCC was 0.89 for cytoplasmic expression 
and 0.81 for nuclear expression showing good correlation between observers.   
 
To determine whether IKKβ expression was significantly associated with clinical outcome, 
Kaplan-Meier survival curves for cytoplasmic and nuclear expression of IKKβ were plotted 
and low and high expression was compared using the log rank test. No association was 
observed with recurrence free interval for cytoplasmic (P=0.213, hazard ratio (HR) = 1.3 (0.8 
- 2.1), Figure 4.3E) or nuclear (P=0.769, HR = 0.9 (0.6 - 1.5), Figure 4.3F) expression. Chi 
squared analysis was performed to assess the association with clinic-pathological factors of 
the cohort including age, size, grade, nodal status, NPI, ER status, PgR status, HER2 status, 
Ki67 index, apoptosis, necrosis, angiogenesis and necrosis. Expression of IKKβ, in the 
cytoplasm or nucleus, was not associated with any clinico-pathological factors of the cohort. 
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Figure 4.3: Expression of IKKβ and clinical outcome in the 1800-Bre-TMA.  An example 
of low (A) expression and of high (B) expression of IKKβ in breast cancer tissue is shown 
(images taken at 400x magnification, scale bar represents 100μm) as well as histograms with 
normal distribution of cytoplasmic (C) and nuclear (D) histoscores. Expression of IKKβ in the 
cytoplasm (E) or nucleus (F) was not associated with recurrence free interval. Censor lines 
indicate loss to follow up. 
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4.3.2   Expression of p65 and clinical outcome 
Expression of p65, both cytoplasmic and nuclear, was assessed in 438 patients (80.5%) in the 
1800-Bre-TMA cohort, with 19.5% (N=106) missing or containing no tumour. Of those 
tumours assessed, 94.1% (412) showed cytoplasmic expression with a histoscore range of 0 to 
170. The median histoscore was 60 (IQR = 30  - 86.7). Only 13.7% (N=60) showed nuclear 
expression with a range of 0 to 66.7 and a median histoscore of 0 (IQR = 0 - 0). Across the 
cores from the same patient the average standard deviation in histoscore for cytoplasmic 
expression was 23.8 and the median was 20.8 (IQR = 10.0 - 35.5), and for nuclear expression 
the average was 1.5 with a median of 0.0 (IQR = 0 - 0). An example of immunostaining 
showing low and high p65 expression is shown in Figure 4.4. This figure also displays 
histograms of cytoplasmic (Figure 4.4C) and nuclear (Figure 4.4D) histoscores. Bland altman 
plots again demonstrated no bias between observers. Correlation between observers scoring 
was excellent for cytoplasmic expression with an ICCC of 0.91. Good correlation was also 
evident for nuclear expression with an ICCC of 0.8. 
 
To determine whether p65 expression was significantly associated with clinical outcome, 
Kaplan-Meier survival curves for cytoplasmic and nuclear expression of p65 were plotted and 
low and high expression were compared using the log rank test. No association was observed 
with recurrence free interval for cytoplasmic (P=0.904, HR = 0.9 (0.7 - 1.6), Figure 4.4C) or 
nuclear (P=0.464, HR = 1.3 (0.7 - 2.3), Figure 4.4D) expression of p65. When chi squared 
analysis was performed to assess the association with clinic-pathological factors of the cohort 
expression of p65, in the cytoplasm was associated with tumour size (P=0.020) and also 
moderately with Ki67 (P=0.047) and in the nucleus was associated with nodal status 
(P=0.013) and necrosis (P=0.017). 
  
Correlation between members of the pathway was measured using Pearson correlation 
coefficient. Expression levels of p65 and IKKβ in the cytoplasm were found to weakly 
correlate (Figure 4.5). The correlation coefficient between cytoplasmic expression of p65 and 
IKKβ was 0.299 (P=2.84x10-9). Although this P value is highly significant, the correlation 
coefficient (which in this analysis is of greater importance) is low showing only weak 
correlation between cytoplasmic expression of p65 and IKKβ. 
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Figure 4.4: Expression of p65 and clinical outcome in the 1800-Bre-TMA. An example of 
low (A) expression and of high (B) expression of p65 in breast cancer tissue is shown (images 
taken at 400x magnification, scale bar represents 100μm) as well as histograms with normal 
distribution of cytoplasmic (C) and nuclear (D) histoscores. Expression of p65 in the 
cytoplasm (E) or nucleus (F) was not associated with recurrence free interval. Censor lines 
indicate loss to follow up. 
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Figure 4.5: Correlation in expression between members of the canonical pathway. 
Cytoplasmic expression of p65 and IKKβ were found to weakly correlate. Although a highly 
significant P value was obtained, the correlation coefficient was only 0.299 and therefore 
only a weak correlation was observed. C.c = Pearson correlation coefficient. 
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4.3.3   Phosphorylation of p65 and clinical outcome 
Expression of p65 phosphorylated at Serine residue 536 (phospho-p65) was assessed in 
76.1% of patients (N=414). Of these, 98.3% (N=405) showed cytoplasmic expression with a 
range in expression of 0 to 220 and a median histoscore of 80 (IQR = 46.7 - 110). 81.6% 
(N=338) showed nuclear expression of phospho-p65 S536 ranging from 0 to 160 histoscore 
units, with a median histoscore of 14.2 (IQR = 5 - 30). The canonical NF-κB pathway is 
therefore found to be active in the majority of breast cancers. The average standard deviation 
in cytoplasmic histoscore across the cores from the same patient was 38.4 and the median was 
35.4 (IQR = 15.3 - 56.6). Across the cores the average standard deviation in nuclear 
histoscore was 14.8 with a median of 7.1 (IQR = 2.9 - 21.2). Figure 4.6A shows 
immunostaining of a tumour with low phospho-p65 expression and Figure 4.6B shows an 
example of high expression. Histograms in Figure 4.6 show distribution of histoscores for p65 
expression in the cytoplasm (Figure 4.6C) and nucleus (Figure 4.6D). Scoring of cytoplasmic 
expression showed excellent correlation between the two observers with an ICCC of 0.91 for 
cytoplasmic expression and nuclear scores had good correlation with an ICCC of 0.84. 
Additionally, bland altman plots showed no bias between observers. 
 
Kaplan-Meier survival curves for cytoplasmic and nuclear expression of p65 were plotted and 
low and high expression compared using the log rank test. Cytoplasmic expression of 
phospho-p65 was not associated with recurrence free interval (P=0.904, HR = 1.0 (0.7 - 1.7), 
Figure 4.6C). Nuclear expression of phospho-p65 was however associated with decreased 
recurrence free interval (P=0.005, HR = 2.0 (1.2 - 3.1), Figure 4.6D). Patients with tumours 
with high levels of phospho-p65 in the nuclear compartment had a shorter recurrence free 
interval of 7 years on average compared to 7.9 years for those with low expression. This was 
independent in cox regression multivariate analysis when combined with tumour size, 
invasive grade, nodal status, NPI, ER status, PgR status, HER2 status, Ki67, Necrosis and 
angiogenesis (P=0.01, HR = 1.9 (1.2 - 3.2)). When chi squared analysis was performed to 
explore the association of phosphorylation of p65 in the cytoplasm with factors of the cohort, 
it was found to associate with tumour size (P=0.010) and weakly with Klintrup (P=0.044). 
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Figure 4.6: Expression of phospho-65 and clinical outcome in the 1800-Bre-TMA.  
(A) Example of low expression and (B) of high expression of p65 phosphorylated at S536 in 
breast cancer tissue. Images were taken at 400x magnification, scale bar represents 100μm. 
(C) Histogram showing normal distribution of cytoplasmic and (D) nuclear histoscores (E) 
Expression of phospho-p65 in the cytoplasm was not associated with recurrence free interval. 
(F) High nuclear phospho-p65 was associated with quicker recurrence. Censor lines indicate 
loss to follow up. 
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Chi-squared analysis was performed to establish whether expression of nuclear phospho-p65 
was associated with any clinico-pathological characteristics of the cohort. These factors and 
their association with nuclear phospho-p65 are detailed in Table 4.1.  As part of a previous 
study by Dr Zahra Mohammed, microvessel density was assessed using IHC with an anti-
CD34 antibody. Expression of phospho-p65 in the nuclear compartment was found only to 
associate with angiogenesis, as measured by this microvessel density (P=0.041).  
 
 
 
Table 4.1: Association of nuclear phospho-p65 with clinico-pathological characteristics 
of the 1800-Bre-TMA cohort. Chi-squared analysis explored the relationship of nuclear 
expression of phospho-p65 with various characteristics of the cohort. Nuclear expression of 
phospho-p65 was found to associate with angiogenesis measured by CD34. 
 
 
 
 
Clinico-pathological characteristic Association with nuclear phospho-p65  
Age P=0.663 
Size P=0.478 
Grade P=0.377 
Nodal Status P=0.741 
NPI P=0.304 
ER status P=0.269 
PgR status  P=0.764 
HER2 P=0.798 
Ki67 P=0.169 
Apoptosis (TUNEL) P=0.342 
Necrosis P=0.219 
Klintrup P=0.215 
Angiogenesis (CD34) P=0.041 
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4.3.4   Expression of phosphorylated p65 versus p65 NLS and clinical outcome 
Due to problems with antibodies targeting phosphorylated protein, we explored the prognostic 
significance of p65 NLS as an alternative marker of the canonical pathway. Figure 4.7A and 
4.7B show an example of immunostaining of breast tumours with low and high expression 
and Figure 4.7C shows the distribution of nuclear histoscores. Nuclear expression of p65 NLS 
ranged from 0 to 300 with a median histoscore of 163.3 (IQR = 106.7 - 215). Interobserver 
correlation between the two scorers was good with an ICCC of 0.86 and bland altman plots 
showed there was no bias evident between observers. Kaplan-Meier survival analysis shows 
that nuclear expression of p65 NLS was not associated with recurrence free interval (P=0.379, 
HR = 1.2 (0.8 - 2.0), Figure 4.7D), and phospho-p65 was therefore found to be a stronger 
prognostic marker of recurrence in breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Comparison of p65 NLS and phospho-p65 nuclear expression on clinical 
outcome in the 1800-Bre-TMA. (A) Example of low expression and (B) of high expression of 
p65 NLS in breast cancer tissue (images taken at 400x magnification, scale bar represents 
100μm). (C) Histogram showing distribution of histoscores. Nuclear expression of p65 NLS 
was not associated with recurrence free interval. Censor lines indicate loss of follow up. 
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4.3.5   Expression of phospho-p65 in different subgroups of breast cancer and 
clinical outcome 
In order to determine whether nuclear expression of phospho-p65 was associated with 
recurrence in a particular subgroup, the cohort was divided using ER status. The observation 
of higher nuclear phospho-p65 associating with quicker recurrence was accentuated in ER 
positive tumours (P=0.002, HR = 3.1 (1.5 - 6.4), 7.10 years vs. 8.34 years, Figure 4.8B), and 
negated in ER negative tumours (P=0.670, HR = 1.1 (0.6 - 2.2), Figure 4.8A).  In patients 
who were ER positive and received endocrine therapy this was even more significant  
(P=2.67x10
-4
, HR = 4.2 (1.8 - 9.9), Figure 4.8C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Nuclear expression of phospho-p65 is associated with recurrence free 
interval in ER positive patients. The relationship between nuclear p-p65 S536 and 
recurrence free interval is negated in ER negative tumours (A), but accentuated in ER 
positive (B) and even further in ER positive patients who received endocrine therapy (C). 
 114 
In patients on endocrine therapy, when split further into subtype this was negated in luminal 
A tumours (P=0.083, HR = 3.1 (0.8 - 11.6), Figure 4.9A) but significance increased in luminal 
B tumours (P=2.54x10
-5
, HR = 7.2 (2.4 - 22.0), 5.5 years vs. 8.2 years, Figure 4.9B). There 
was no association between phospho-p65 nuclear expression and recurrence free interval in 
the triple negative (P=0.926, HR = 1.0 (0.4 - 2.5), Figure 4.9C) or HER2 enriched subtypes 
(P=0.708, HR = 1.2 (0.5 - 3.1), Figure 4.9D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Nuclear expression of phospho-p65 and recurrence free interval in different 
subtypes of breast cancer. In patients on endocrine therapy, luminal A tumours were not 
associated with recurrence (A), but in luminal B tumours (B) high expression of phospho-p65 
in the nucleus was significantly associated with increased recurrence. The relationship 
between nuclear phospho-p65 S536 and recurrence free interval is negated in triple negative 
(C) and HER2 enriched (D) subtypes. 
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These patients were further divided into the different types of luminal B tumours (HER2+ or 
high Ki67), this relationship was only significant in highly proliferative tumours  
(P=2.74x10
-4
, HR = 7.6 (2.1 - 27.1), Figure 4.10A), and not in those with HER2 positive 
tumours (P=0.073, HR = 5.9 (0.6 - 53.5), Figure 4.10B), although very small numbers were 
available for analysis in this group and a similar trend is observed. 
 
 
 
 
Figure 4.10: Nuclear expression of phospho-p65 and recurrence free interval in luminal 
B patients. Patients on endocrine therapy with luminal B tumours were further subdivided 
into those with HER2- high Ki67 tumours and HER2+ tumours. Nuclear expression of 
phospho-p65 was significantly associated with recurrence free interval in patients with 
luminal B HER2- high Ki67 tumours (A) but not in those with HER2 amplification (B), 
although only small numbers were available for analysis. 
 
 
P=0.073 
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When recurrence was considered only in the first five years in patients receiving endocrine 
therapy (tamoxifen), and therefore likely to be recurrence on tamoxifen, there was a 
significant difference between high and low expression (P=0.015, HR = 5.3 (1.2 to 24.1), 
Figure 4.11).  However, using a more stringent P value of 0.01 this is not regarded as 
significant, however there are only a low number of patients in each group and in a larger 
cohort this may reach significance using this P value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: Nuclear expression of phospho-p65 and recurrence free interval in the first 
5 years of tamoxifen treatment. In patients on endocrine therapy with luminal B tumours, 
when recurrence was considered in the first five years and therefore likely to be recurrence 
on tamoxifen, a significant relationship was observed between phospho-p65 nuclear 
expression and recurrence free interval. 
 
 
In conclusion, phosphorylation of p65, a marker of activation of the canonical NF-κB 
pathway, was associated with shorter recurrence free interval in ER positive breast cancer 
patients, particularly those with luminal B tumours.  Of the family members tested in this 
study, phosphorylation of p65 appears to be the best biomarker of the canonical pathway in 
breast cancer clinical specimens. 
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4.4   Antibody validation of members of the non-canonical pathway 
 
4.4.1   Validation of anti-NIK antibody  
Western blotting and IHC on cell pellets were carried out using the anti-NIK antibody to 
confirm specificity as part of a previous study in our laboratory. A single band of correct size 
(125 kDa) was observed on a western blot (Figure 4.12A). In cell pellets of HUVEC cells 
infected with β-galactosidase (β-gal) or NIK adenoviruses, IHC using the anti-NIK antibody 
showed an increase in cells infected with NIK adenovirus (Figure 4.12B).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Validation of the anti-NIK antibody. (A) Western blot showing a single band 
of appropriate size (125 kDa). (B) IHC was employed to cell pellets of HUVEC cells infected 
with β-galactosidase (β-gal) or NIK adenoviruses and showed an increase in staining in the 
NIK adenovirus infected cells. 
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4.4.2   Validation of anti-RelB antibody 
A previous study in our laboratory confirmed specificity of the anti-RelB antibody. Western 
blotting showed a single band of appropriate size observed (70 kDa, Figure 4.13A). 
Additionally, IHC on cell pellets treated with 20ng/ml lymphotoxin for 24 hours showed a 
marked increase in nuclear localisation of RelB compared with untreated controls (Figure 
4.13B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Validation of the anti-RelB antibody. (A) Western blot showing a single band 
of appropriate size (70 kDa). (B) Paraffin embedded cell pellets of LNCaP cells treated with 
lymphotoxin showed an increase in RelB nuclear expression compared with control cells. 
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4.4.3   Validation of anti-IKKα antibody 
Western blotting using the anti-IKKα antibody showed a single band of the predicted 
molecular weight (85 kDa). LNCaP cells were pre-treated with 200nM siRNA against either 
IKKα or IKKβ to check specificity for IKKα. A reduction in expression was observed in 
IKKα-silenced but not IKKβ-silenced cells (Figure 4.14A). Additionally, IKKα-silenced and 
IKKβ-
reduction in IKKα-silenced cells, but not in IKKβ-silenced or control cells (Figure 4.14B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14: Validation of the anti-IKKα antibody. (A) Western blot showing a single band 
of appropriate size (85 kDa). A reduction in expression was observed in lysates from IKKα-
silenced but not IKKβ-silenced LNCaP cells (B) Paraffin embedded cell pellets of LNCaP 
cells treated with siRNA showed a decrease in expression in IKKα-silenced but not IKKβ-
silenced, compared to control cells. 
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4.5  Expression and clinical outcome of members of the non-canonical pathway 
 
4.5.1   Expression of NIK and clinical outcome  
Expression of NIK, the kinase upstream of IKKα in the non-canonical pathway, was analysed 
in the 1800-Bre-TMA cohort. 119 patients had cores that were missing or contained no 
tumour leaving 429 patients available for analysis. The histoscores for cytoplasmic expression 
of NIK ranged from 0 to 240 with a median of 95 (IQR = 70 - 113.3), and for the nuclear 
compartment ranged from 0 to 300 with a median of 191.7 (IQR = 159.2 - 226.7). The cohort 
was subdivided into those with low and high expression using the median as a cut off. Across 
the cores from the same patient the average standard deviation in cytoplasmic histoscore was 
29.1 and the median was 26.5 (IQR = 14.1 - 42.4). For nuclear expression the average 
standard deviation was 32.8 with a median of 28.2 (IQR = 15.3 - 43.6). An example of 
immunostaining of NIK is displayed in Figure 4.3, with low expression shown in 4.15A and 
high in 4.15B. Bland altman plots demonstrated no bias between observers and an ICCC of 
0.86 for cytoplasmic expression and 0.81 for nuclear expression showed good correlation 
between observers. 
 
To determine whether NIK expression was significantly associated with clinical outcome, 
Kaplan-Meier survival curves for cytoplasmic and nuclear expression were plotted and low 
and high expression was compared using the log rank test. No association was observed with 
recurrence free interval for cytoplasmic (P=0.287, HR = 0.8 (0.5 -1.2), Figure 4.15C) or 
nuclear expression of NIK (P=0.914, HR = 1.0 (0.6 - 1.5), Figure 4.15D). When chi squared 
analysis was performed to test the association of expression of NIK and clinic-pathological 
factors of the cohort, expression in the cytoplasm was found to be associated with Ki67 
(P=0.012) and apoptosis (P=0.006) and in the nucleus showed a weak association with nodal 
status (P=0.047). 
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Figure 4.15: Expression of NIK and clinical outcome in the 1800-Bre-TMA. (A) Example 
of low expression and (B) of high expression of NIK in breast cancer tissue (images taken at 
400x magnification, scale bar represents 100μm). Histograms show distribution of 
histoscores for cytoplasmic (C) and nuclear NIK (D). Expression of NIK in the cytoplasm (E) 
or nucleus (F) was not associated with recurrence free interval. Censor lines indicate loss of 
follow up. 
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4.5.2   Expression of RelB and clinical outcome 
In order to investigate activation of the non-canonical pathway, RelB expression was assessed 
in the 1800-Bre-TMA cohort. 20.4% (N=111) of patients had cores that were missing or 
containing no tumour leaving 433 (79.6%) available for analysis. Of those tumours assessed, 
99.3% (430) showed cytoplasmic expression with a range of 0 to 290 and a median histoscore 
of 110 (IQR = 86.7 - 145). Only 32.7% (N=146) showed nuclear expression with range of 0 to 
226.7 and a median histoscore of 0 (IQR = 0 - 6.7). A low amount and very low intensity of 
nuclear staining observed for RelB suggested lack of activation of the non-canonical pathway 
in the majority of breast tumours. The average standard deviation in histoscore across the 
cores from the same patient for cytoplasmic expression was 31.5 and the median was 26.5 
(IQR= 14.1 - 43.6). For nuclear expression the average standard deviation was 9.7 and the 
median was 0 (IQR = 0 - 11.5). 
 
An example of immunostaining showing low and high RelB expression is shown in Figure 
4.16A and 4.16B and histograms in Figure 4.16 display distribution of histoscores for 
cytoplasmic (Figure 4.16C) and nuclear (Figure 4.16D) expression of RelB. Excellent 
correlation was seen between observers scoring with an ICCC of 0.9 for cytoplasmic 
expression. An ICCC of 0.82 for nuclear expression showed good correlation and bland 
altman plots also showed no bias between observers. RelB was not associated with recurrence 
free interval for cytoplasmic (P=0.139, HR = 0.7 (0.5 - 1.1), Figure 4.16E) or nuclear 
(P=0.418, HR = 0.8 (0.5 - 1.3), Figure 4.16F) expression. When chi squared analysis was 
performed, expression of RelB in the cytoplasm was found to show a weak association with 
both size (P=0.039) and angiogenesis (P=0.038), but no associations were observed with 
expression in the nucleus. 
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Figure 4.16: Expression of RelB and clinical outcome in the 1800-Bre-TMA. (A) Example 
of low expression and (B) of high expression of RelB in breast cancer tissue (images taken at 
400x magnification, scale bar represents 100μm). Histograms show distribution of 
histoscores for cytoplasmic (C) and nuclear RelB (D). Expression of RelB in the cytoplasm 
(E) or nucleus (F) was not associated with recurrence free interval. Censor lines indicate loss 
to follow up. 
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4.5.3   Expression of IKKα and clinical outcome 
Expression of IKKα was assessed in 73.3% of patients (N=399). Of these, 97.2% (N=388) 
showed cytoplasmic expression with a range of 0 to 260 and a median histoscore of 100  
(IQR = 66.7 - 140). 94% (N=375) showed nuclear expression of IKKα with a range of 0 to 
280 and a median histoscore of 130 (IQR = 75 - 180). Across the cores from the same patient 
the average standard deviation in cytoplasmic histoscore was 47.5 and the median was 43.6 
(IQR = 21.2 - 68.1). For nuclear expression the average standard deviation was 58.3 and the 
median was 52.4 (IQR = 28.3 - 81.5). 
 
Figure 4.17A shows immunostaining of a tumour with low IKKα expression and Figure 
4.17B shows an example of high expression. Histograms in Figure 4.17 show distribution of 
histoscores for cytoplasmic (Figure 4.17C) and nuclear (Figure 4.17D) expression of RelB. 
Scoring between the two observers was found to have excellent correlation for both 
cytoplasmic and nuclear expression both with ICCC values of 0.95. 
 
Kaplan-Meier survival curves for cytoplasmic and nuclear expression of IKKα were plotted, 
and low and high expression was compared using the log rank test. Nuclear expression of 
IKKα was not associated with recurrence free interval (P=0.502, HR = 0.9 (0.5 - 1.4), Figure 
4.17F). Cytoplasmic expression of IKKα was however associated with decreased recurrence 
free interval (P=0.014, HR = 1.8 (1.1 - 2.9), Figure 4.17E). However, using a more stringent  
P value of 0.01 this is not regarded as significant and on multivariate analysis when combined 
with with tumour size, invasive grade, nodal status, NPI, ER status, PgR status, HER2 status, 
Ki67, Necrosis and angiogenesis this was not independently prognostic (P=0.524 HR = 1.2 
(0.7 - 2.0)). Chi squared analysis showed nuclear expression of IKKα was associated with 
necrosis (P=0.020) and Klintrup (P=0.014). 
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Figure 4.17: Expression of IKKα and clinical outcome in the 1800-Bre-TMA.  
(A) Example of low expression and (B) of high expression of IKKα in breast cancer tissue 
(images taken at 400x magnification, scale bar represents 100μm). Histograms show 
distribution of histoscores for (C) cytoplasmic (D) and nuclear IKKα. (E) High cytoplasmic 
IKKα was associated with quicker recurrence. (F) Expression of IKKα in the nucleus was not 
associated with recurrence free interval. Censor lines indicate loss to follow up.  
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Chi-squared analysis was performed to determine whether expression of IKKα was associated 
with any clinico-pathological characteristics of the cohort. These factors and their association 
with nuclear IKKα are detailed in Table 4.2.  Expression of IKKα in the cytoplasm was 
associated with size (P=0.028), grade (P=0.018), hormone status (ER P=0.002 and PgR 
P<0.001), HER2 status (P=0.019), Klintrup (P=0.029), apoptosis measured by TUNEL 
(P=0.024) and necrosis (P=0.019).  
 
 
 
Table 4.2: Association of cytoplasmic IKKα with clinico-pathological characteristics of 
the 1800-Bre-TMA cohort. Chi-squared analysis explored the relationship of nuclear 
expression of IKKα with various characteristics of the cohort. Cytoplasmic expression of 
IKKα was associated with size, grade, NPI, hormone receptor status, HER2 status, apoptosis 
measured by TUNEL and necrosis. 
 
Clinico-pathological characteristic Association with cytoplasmic IKKα 
Age P=0.642 
Size P=0.028 
Grade P=0.018 
Nodal Status P=0.914 
NPI P=0.019 
ER status P=0.002 
PgR status  P<0.001 
HER2 P=0.019 
Ki67 P=0.614 
Apoptosis (TUNEL) P=0.024 
Necrosis P=0.019 
Klintrup P=0.029 
Angiogenesis (CD34) P=0.131 
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Correlation between members of the pathway was measured using Pearson correlation 
coefficient. Correlations in expression of NIK, RelB and IKKα in the cytoplasm are shown in 
Figure 4.18. Although highly significant P values were obtained, the correlation coefficient is 
of much greater importance and more consideration should be placed on this and therefore 
none of these markers show a strong association. The correlation coefficient between NIK and 
IKKα cytoplasmic expression was very weak with a value of 0.161 (P=0.002) and there was a 
weak correlation between IKKα and RelB with a correlation coefficient of 0.228 (P=1.12x10-
5
). Histoscores of NIK and RelB cytoplasmic expression also showed a weak association with 
a correlation coefficient of 0.316 (P=6.13x10
-11
). Additionally, the correlation coefficient 
between cytoplasmic expression of IKKα and IKKβ, which form heterodimers in the 
canonical pathway, was moderate with a value of 0.392 (P=1.4x10
-15
).  
Figure 4.18: Correlation in expression between members of the non-canonical pathway. 
Correlation between cytoplasmic expression of NIK, RelB and IKKα is shown, these family 
members showed weak correlation in expression. C.c = Pearson correlation coefficient. 
 128 
The association between shorter recurrence free interval and high cytoplasmic expression of 
IKKα was negated in ER negative tumours (P=0.998, HR = 1.0 (0.5 - 1.9), Figure 4.19A) and 
accentuated in ER positive tumours (P=0.008, HR = 2.5 (1.3 - 5.1), 7.6 years vs. 8.0 years, 
Figure 4.19B). When this was considered in ER positive patients on endocrine therapy, the 
relationship between higher cytoplasmic IKKα and quicker time to recurrence remained 
significant (P=0.043, HR = 2.1 (1.0 - 4.2), Figure 4.19C). However, using a more stringent 
significance value of 1% (P<0.01), this is not regarded as significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Cytoplasmic expression of IKKα is associated with recurrence free interval 
in ER positive patients. The relationship between cytoplasmic IKKα and recurrence free 
interval was negated in ER negative tumours (A), but accentuated in ER positive (B). 
Significance was retained in ER patients on endocrine therapy (C). 
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When split into subtype this association was negated in all subtypes except luminal A. In 
patients on endocrine therapy with luminal A tumours, those with high cytoplasmic 
expression of IKKα was associated with a quicker recurrence than those with low cytoplasmic 
IKKα (P=0.028, HR = 3.9 (1.1 - 14.6), 7.9 years vs. 8.3 years, Figure 4.20A). Using a more 
stringent significance value of  P<0.01, this would not be regarded as significant. The use of a 
larger cohort would be useful to investigate this further. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20: Cytoplasmic expression of IKKα and recurrence free interval in different 
breast cancer subtypes.  When split into the different subtypes, the relationship between 
cytoplasmic IKKα and recurrence free interval in patients who received endocrine therapy 
was retained in luminal A tumours (A) but was negated in the luminal B tumours (B). IKKα 
was not associated with recurrence in triple negative breast cancer (C) or the HER2 enriched 
subtype (D). 
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Patients on endocrine therapy with luminal B tumours did not have a significant difference in 
recurrence free interval between low and high cytoplasmic IKKα (P=0.441, HR = 1.5 (0.6 - 
3.4), Figure 4.20B). IKKα was not associated with recurrence in triple negative breast cancer 
(P=0.893, HR = 0.9 (0.4 - 2.4), Figure 4.20C) or the HER2 enriched subtype (P=0.481, HR = 
0.7 (0.3 - 1.9), Figure 4.20D). 
 
This relationship between high cytoplasmic IKKα and recurrence in patients with luminal A 
tumours was also observed when recurrence was considered in the first 5 years (and therefore 
likely recurrence on tamoxifen). Those with higher cytoplasmic IKKα had a shorter time to 
recurrence on tamoxifen than those with low cytoplasmic IKKα (P=4.4x10-5, HR = 22.0 (2.7 - 
180.7), 3.2 years vs. 5.0 years, Figure 4.21). This was independent in cox regression 
multivariate analysis when combined with tumour size, invasive grade, nodal status, NPI, ER 
status, PgR status, HER2 status, Ki67, necrosis and angiogenesis (P=0.003, HR = 24.9 (2.9 - 
212.7)). There are however very small numbers available for analysis and caution is therefore 
required when interpreting these results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Cytoplasmic expression of IKKα is associated with recurrence on tamoxifen 
in luminal A patients. Patients with luminal A tumours that have higher expression of 
cytoplasmic IKKα have a quicker time to recurrence on tamoxifen than those with low 
expression. Censor lines indicate loss to follow up. 
 
In conclusion, IKKα, a kinase involved in activation of the non-canonical NF-κB pathway, 
was associated with shorter recurrence free interval in ER positive breast cancer patients. 
IKKα appears to be the best biomarker of the non-canonical pathway in breast cancer clinical 
specimens. 
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4.6   Discussion 
For many years an association between inflammation and cancer has been suspected and 
evidence has emerged in the last decade demonstrating the importance of this link. NF-ĸB 
regulates genes involved in many processes including inflammation, proliferation and 
apoptosis and has a critical role in both innate and adaptive immunity. In many cancers  
NF-ĸB is constitutively active and the central regulators of this pathway, the kinases IKKs, 
are likely candidates for the link between the two processes [172].  
Tissue biomarkers have the potential to improve the diagnosis and prognostication of cancer, 
including breast cancer where many are already used routinely including ER and HER2. It 
may also benefit the selection of therapy using stratified medicine, allowing maximum benefit 
to the patient and avoiding unnecessary use of therapies that will have little effect for many 
patients.  Before use in patient tissue all antibodies were optimised and validated. Although 
antibodies detecting p65 and phosphorylation of p65 were validated in both breast and 
prostate cancer cells, all other antibodies were validated in only prostate cancer cells. This 
possibly could lead to problems with further use in other tissue types as certain antibodies 
may have tissue specific immune-reactivity and therefore ideally all antibodies should be 
confirmed as specific in each tumour type. In order to validate results obtained in the breast 
cancer patient cohort, antibodies used to detect expression of members of the NF-ĸB 
pathways should be confirmed as specific in breast cancer cells and tissue, particularly IKKα. 
IHC was employed to breast cancer tissue to detect phosphorylated status of the p65 subunit 
at serine residue 536, which is important for transcriptional activation of the NF-ĸB dimer 
[102], and therefore signifies activation of the canonical pathway. In a cohort of 544 breast 
cancer patients it was found that higher levels of phospho-p65 in the nucleus was associated 
with a shorter recurrence free interval. However, there are often difficulties with 
phosphorylated antibodies, limiting their possibility for use in diagnostic laboratories where a 
high sensitivity and reproducibility is required. One study compared the phosphorylation 
status of Akt and Erk1/2 in tissue taken immediately after surgery and fixed, tissue taken after 
X-ray of the tumour then fixed, and in tissue from specimens fixed in the histopathology 
department using routine fixation procedures [173]. No difference was observed between 
tissue that was taken immediately after surgery and fixed and tissue that was taken and fixed 
after X-ray of the tumour. There was however a significant discordance in results obtained in 
specimens subject to routine fixation, with many tumours now displaying lack of 
phosphorylation when many had shown high phosphorylation [173]. Fixation procedures are 
therefore important in the use of phospho-specific antibodies and limit their use as larger 
tumours take longer to formalin fix and therefore reduction in phospho-staining is likely. The 
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NLS of p65 has been used in prostate cancer tissue and high expression was demonstrated to 
be associated with shorter time to disease recurrence and shorter cancer specific survival 
[135]. The use of p65 NLS as an alternative marker of activated p65 in breast cancer tissue 
was therefore explored. No significant association with recurrence free interval and p65 NLS 
nuclear expression was observed however, and phospho-p65 nuclear expression was therefore 
found to be of more prognostic significance. A different marker of activation of the canonical 
pathway is therefore required. Other studies have utilised degradation, as well as 
phosphorylation, of IĸBα. Levels of IĸBα were higher in prostate cancer tissue compared to 
adjacent normal tissue and in prostate cancer cells the addition of an IKK inhibitor diminished 
the ability of TNFα to degrade IĸBα [174]. Further investigation into selective markers of the 
canonical NF-ĸB pathway in breast cancer is required and downstream markers will be 
explored. 
 
Expression of NF-ĸB has been reported to be elevated in breast cancer cell lines and in rat 
mammary tumours when compared to normal tissue [138]. A difference has been observed 
between ER negative and ER positive cells. Furthermore, NF-ĸB expression has been 
demonstrated to correlate with oestrogen independence, with high levels reported in ER-
negative tumours [142]. It may therefore be expected that it would be beneficial to block NF-
ĸB activity in ER negative patients, however the results from the current study suggest a role 
in ER positive disease and that these patients would benefit most from inhibitors of the 
pathway. This is in agreement with a study in ER positive tumours that found higher DNA 
binding activity of p50 was associated with shorter disease free survival [139]. 
 
The non-canonical NF-ĸB pathway has also been implicated in breast cancer development 
and progression. In mice that transgenically overexpress p100/52, a delay in mammary gland 
development is observed and these mice developed multiple tumours [141]. Additionally, 
although during mammary gland development p100/52 levels were low, during 
tumourigenesis expression of p100/52 was elevated [141]. There are few studies exploring the 
non-canonical NF-ĸB pathway in breast cancer patients. Comparison between breast cancer 
tissue and adjacent normal tissue has shown expression of the p50 and p52 subunits is 
significantly higher in cancer tissue with an increase in p52 in the nucleus [140]. IHC was 
employed to assess levels of NIK, RelB and IKKα to investigate the impact of their 
expression on clinical outcome in breast cancer patients. Patients with tumours that expressed 
high levels of IKKα in the cytoplasm had shorter recurrence free interval. However 
expression of NIK or RelB, in the nucleus or cytoplasm, was not associated with recurrence. 
Unfortunately effective markers of activation of the non-canonical NF-ĸB pathway for use in 
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tissue studies are lacking. In our cohort only around a third of tumours displayed RelB 
expression even at low levels in the nuclear compartment. The median histoscore was 0 with 
an interquartile range of just 0 - 6.7. This low amount and very low intensity of nuclear 
staining observed for RelB suggested lack of activation of the non-canonical pathway. A 
possible alternative explanation is that the protein is present in the nucleus in many tumours 
however a confirmation change upon nuclear translocation may have resulted in the antigen 
that the antibody binds to is masked resulting in a lack of detection by the antibody. 
Expression of p100/52 has also been reported as a marker of the non-canonical pathway in 
clinical tissue [140, 175], however although nuclear expression suggests activation, antibodies 
are unable to differentiate between p100 and p52 and therefore a more appropriate and 
specific marker is required. Induction of the non-canonical NF-ĸB pathway results in 
phosphorylation of p100, however disappointingly the only commercially available phospho-
p100 antibody shows many non-specific bands rendering it inadequate for use in patient 
tissue.  Phosphorylation of the IKKs has also been used as a marker of NF-ĸB activation, 
however available antibodies do not distinguish between IKKα or IKKβ phosphorylation 
[174]. Additionally, any phospho-p100 or phospho-IKK antibody again would be subject to 
the variability observed for phospho-specific antibodies. Establishment of an appropriate 
marker is therefore required and will be explored as part of this study.  
 
There are several subtypes of cancer, all with different molecular profiles and varied 
responses to chemotherapy and other therapies [176]. This is reflected in the results from this 
study, as there appears to be diverging roles for NF-κB in the different luminal subtypes. High 
activation of the canonical NF-ĸB pathway, measured by nuclear expression of p65 
phosphorylated at S536, was found to associate with angiogenesis and the luminal B subtype. 
The non-canonical NF-ĸB pathway, more specifically cytoplasmic IKKα, was associated with 
cell death (apoptosis and necrosis) and hormone receptor status. High expression of IKKα was 
found to associate with shorter recurrence free interval. As phospho-p65 and IKKα were 
associated with recurrence in different subtypes, luminal B and A respectively, this suggests 
that the increased recurrence observed with IKKα expression is a result of its role in the non-
canonical NF-ĸB pathway. Another study recently investigated which signalling pathways are 
dominant in each subtype and defined additional protein subgroups [52].  The number of 
different subgroups of breast cancer continue to grow and a better understanding of the 
signalling pathways involved in each is likely be important when considering treatment 
options for patients. 
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In this study, where there was a range in expression the median was used as the cut off for 
high and low expression and if a high proportion of tumours were negative (as was the case 
with RelB and p65 nuclear expression) groups were split using presence and absence of 
staining into positive and negative. Software has been developed that allows users to enter 
their range of scores and this selects the optimal cut off based on this distribution, such as X-
Tile [177] and Cutoff Finder [178]. The use of such software may have been more appropriate 
for selection of optimal cut off values and should be considered in future work. 
 
The results from this chapter suggest that the NF-κB pathways may be involved in promoting 
recurrence in patients with ER positive tumours and may be involved with development of 
endocrine resistance.  However, each pathway seems to be involved in different subtypes with 
the canonical pathway associating with recurrence in the luminal B subtype and the non-
canonical with the luminal A subtype. Further studies in an independent cohort combined 
with mechanistic studies are required to further investigate the role of the pathways in the 
progression of breast cancer. These results do however highlight ER positive tumours may 
have different signalling pathways driving disease progression and therefore patients may 
benefit from different therapeutic strategies 
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Chapter 5: 
Expression of phospho-p65 and IKKα 
in an independent cohort of 
ER positive breast cancers 
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5.1   Introduction 
It was previously demonstrated that high expression of phosphorylated p65 in the nuclear 
compartment and high cytoplasmic IKKα were associated with reduced recurrence free 
interval. These findings require validation in an independent cohort, and due to the 
observation that both were associated with recurrence in ER positive breast cancer a cohort 
consisting of ER positive patients was selected. Luminal subtypes had been established using 
HER2 and Ki67 to subdivide luminal A and luminal B tumours, as described in chapter 3. An 
additional strength of this cohort, other than providing a platform to validate previous 
findings, is that information was available on how long each individual patient received 
tamoxifen therapy, therefore allowing the markers to be tested for recurrence on tamoxifen.  
 
5.2   Expression of phosphorylated p65 in the ST-Bre-TMA 
This cohort included 456 patients, 20 of which were found to have ER negative tumours and 
44 were of unknown ER status. These patients were therefore excluded from analysis in this 
chapter, leaving 392 patients available for investigation. Immunohistochemistry was 
employed to TMAs using an antibody to detect phosphorylation of the p65 subunit at serine 
residue 536. As with the previous cohort, three representative cores were available for each 
tumour in order to account for tumour heterogeneity. Expression was scored using the 
weighted histoscore method to quantify intensity and percentage positive staining [156]. 
 
5.2.1   Nuclear expression of phospho-p65 in the ST-Bre-TMA 
Expression of phospho-p65 was assessed in 78% of patients (322/392). Of these patients, 98% 
(316/322), had tumours that displayed expression of phospho-p65 in the nucleus. The median 
histoscore in these tumours was 110 with an interquartile range of 80 to 140. The median 
from the previous cohort was 15, however only 12 patients had a histoscore of 15 or less 
meaning the previously established cut off could not be applied for analysis due to insufficient 
numbers. The median histoscore of 110 observed in this cohort was therefore used to 
subdivide patients into those with low and high expression of nuclear phospho-p65. 186 
patients were found to have low expression of phosphorylated p65 in the nuclear 
compartment and 173 patients were classified as having high expression. An example of 
immunostaining showing low and high phospho-p65 expression is shown in Figure 5.1A and 
5.1B. Across the cores from the same patient the average standard deviation of the histoscores 
was 34.2 and the median was 30.6 (IQR= 17.3 - 46.5). 
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Figure 5.1: Nuclear expression of phospho-p65 in the ST-Bre-TMA.  (A) An example of 
low nuclear expression and (B) of high nuclear expression of phospho-p65 in breast cancer 
tissue is shown (images taken at 400x magnification, scale bar represents 100μm). (C) 
Histogram displaying frequency of nuclear phospho-p65 histoscores.  
 
5.2.2   Nuclear expression of phospho-p65 in the ST-Bre-TMA and clinical 
outcome 
To examine whether nuclear expression of phospho-p65 was significantly associated clinical 
outcome in the ST-Bre-TMA cohort, Kaplan-Meier survival curves were plotted and low and 
high expression compared using the log rank test. No association was observed with 
recurrence free interval (P=0.177, HR = 1.3 (0.9 - 2.0), 11.5 years vs. 12.6 years, Figure 5.2A) 
or recurrence on tamoxifen (P=0.137, HR = 1.4 (0.9 - 2.3), 8.9 years vs. 11.2 years, Figure 
5.2B), although this trended towards high expression having slightly poorer outcome. Nuclear 
expression of phospho-p65 was, however, associated with poorer breast cancer specific 
survival (P=0.041, HR = 1.6 (1.0 - 2.5), 14.1 vs. 15 years, Figure 5.2C). 
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Figure 5.2: Nuclear expression of phospho-p65 and clinical outcome in the ST-Bre-
TMA.  (A) Expression of phospho-p65 in the nucleus was not associated with recurrence free 
interval or (B) recurrence on tamoxifen. (C) High nuclear phospho-p65 was associated with 
poorer breast cancer specific survival. Censor lines in (A) and (B) indicate loss to follow up 
and in (C) indicate loss to follow up or death due to other cause. 
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5.2.3   Association of phospho-p65 nuclear expression with clinico-
pathological characteristics of the ST-Bre-TMA 
Chi-squared analysis was performed to establish whether expression of nuclear phospho-p65 
was associated with any clinico-pathological characteristics of the cohort. These factors and 
their association with nuclear phospho-p65 are detailed in Table 5.1.  Unlike the previous 
cohort a measure of angiogenesis, klintrup and necrosis was not available to correlate with. 
From the available parameters expression of phospho-p65 in the nuclear compartment was not 
found to associate with any of the clinico-pathological factors.  This is consistent with the 
previous study, in which only CD34 as a marker of angiogenesis was found to correlate with 
expression of phospho-p65. 
 
 
Table 5.1: Association of nuclear phospho-p65 with clinico-pathological characteristics 
of the ST-Bre-TMA cohort. Chi-squared analysis explored the relationship of nuclear 
expression of phospho-p65 with various characteristics of the cohort. 
 
Clinico-pathological characteristic Association with nuclear phospho-p65  
Age P=0.482 
Size P=0.494 
Grade P=0.056 
Nodal Status P=0.206 
NPI P=0.756 
PgR status  P=0.873 
HER2 P=0.430 
Ki67 P=0.414 
Apoptosis (TUNEL) P=0.532 
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5.2.4   Nuclear expression of phospho-p65 in the ST-Bre-TMA and clinical 
outcome in different luminal subtypes 
When this was subdivided into luminal subtypes, phospho-p65 nuclear expression was not 
significantly associated with breast cancer specific survival in either luminal subtype, 
although a relationship was observed in luminal B tumours, consistent with the previous 
cohort, however this did not reach significance (P=0.087, Figure 5.3B). This relationship was 
not observed in luminal A tumours, again consistent with previous clinical data (P=0.629, 
Figure 5.3A). When tumours were subdivided by luminal subtype and recurrence free interval 
was analysed, phospho-p65 was not significantly associated with recurrence free interval in 
either subtype (luminal A, P=0.842, Figure 5.4A; luminal B P=0.160, Figure 5.4B). Again, 
when recurrence on tamoxifen was considered, high phospho-p65 was not significantly 
associated with quicker time to recurrence in luminal B tumours although a relationship was 
observed (P=0.141, Figure 5.4D). No relationship was observed between phospho-p65 and 
recurrence on tamoxifen in luminal A tumours (P=0.962, Figure 5.4C). 
 
 
 
Figure 5.3: Nuclear expression of phospho-p65 and breast cancer specific survival in 
luminal subtypes in the ST-Bre-TMA. Expression of phospho-p65 in the nucleus in patients 
with luminal A tumours (A) and luminal B tumours (B) and breast cancer specific survival. 
Censor lines indicate loss to follow up or death due to other cause. 
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Figure 5.4: Nuclear expression of phospho-p65 and clinical outcome in luminal subtypes 
in the ST-Bre-TMA. Expression of phospho-p65 in the nucleus in patients with luminal B 
tumours was associated with recurrence free interval (A), but not recurrence on tamoxifen 
(C) or breast cancer specific survival (E). No relationship was observed with recurrence free 
interval (B), recurrence on tamoxifen (D) and breast cancer specific survival (F) in patients 
with luminal B tumours. Censor lines in (A-D) indicate loss to follow up and in (E) and (F) 
indicate loss to follow up or death due to other cause. 
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5.3   Expression of IKKα in the ST-Bre-TMA 
Immunohistochemistry was employed to TMAs to assess levels of IKKα. Evidence from the 
literature and our previous clinical cohort suggest IKKα is associated with ER and it was 
therefore hypothesised that expression of IKKα would be involved in the development of 
endocrine resistance. 
 
5.3.1   Cytoplasmic expression of IKKα in the ST-Bre-TMA 
Expression of IKKα was assessed in 78.8% (309/392) of the ER positive patients included in 
analysis and of these 99% (308/309) displayed cytoplasmic expression. Histoscores in these 
tumours ranged from 0 to 190 with a median histoscore of 95 (IQR = 73.3 - 116.7). The cut 
off from the previous cohort, 100 histoscore units, was applied to stratify patients into those 
with high IKKα expression and those with low IKKα expression in the cytoplasm. 181 
patients were found to have low cytoplasmic IKKα and 128 patients were classified as having 
high expression. Figure 5.2 shows an example of immunostaining showing low (Figure 5.5A) 
and high (Figure 5.5B) IKKα expression. The average standard deviation in histoscore across 
the cores from the same patient was 29.3 and the median was 26.5 (IQR= 14.1 - 37.9). 
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Figure 5.5: Cytoplasmic expression of IKKα in the ST-Bre-TMA.  (A) An example of low 
nuclear expression and (B) of high nuclear expression of IKKα in breast cancer tissue is 
shown (images taken at 400x magnification, scale bar represents 100μm). (C) Histogram 
displaying frequency of cytoplasmic IKKα histoscores.  
 
 
5.3.2   Cytoplasmic expression of IKKα in the ST-Bre-TMA and clinical outcome 
In order to investigate whether expression of IKKα was significantly associated with clinical 
outcome in the ST-Bre-TMA cohort, Kaplan-Meier survival curves were plotted and low and 
high expression compared using the log rank test. Cytoplasmic IKKα was significantly 
associated with reduced recurrence free interval (P=0.024, HR = 1.6 (1.1 - 2.4), 11.3 years vs. 
15 years, Figure 5.6A), quicker recurrence on tamoxifen (P=0.013, HR = 1.8 (1.1 - 2.9), 10.3 
years vs. 12.6 years, Figure 5.6B), and shorter recurrence free interval (P=0.016, HR = 1.7 
(1.1 - 2.7), 15.4 vs. 16 years, Figure 5.6C). 
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Figure 5.6: Cytoplasmic expression of IKKα and clinical outcome in the ST-Bre-TMA.  
(A) Expression of IKKα in the cytoplasm was associated with shorter recurrence free interval, 
(B) quicker time to recurrence on tamoxifen and (C) decreased breast cancer specific 
survival. Censor lines in (A) and (B) indicate loss to follow up and in (C) indicate loss to 
follow up or death due to other cause 
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5.3.3   Association of IKKα cytoplasmic expression with clinico-pathological 
characteristics of the ST-Bre-TMA  
In order to establish whether expression of cytoplasmic IKKα was associated with any 
clinico-pathological characteristics of the cohort, chi-squared analysis was performed. These 
factors and their association with cytoplasmic IKKα are detailed in Table 5.2.  As previously 
observed expression of IKKα in the cytoplasm was associated with invasive grade, nodal 
status and also NPI, again we were unable to determine if correlated with klintrup, as this 
wasn’t available for this cohort. In the previous cohort IKKα was associated with cell death, 
however necrosis information was unavailable in this cohort and TUNEL (as a marker of 
apoptosis) was not found to correlate, although there were small amounts of tumours with low 
TUNEL for analysis. 
 
 
 
Table 5.2: Association of cytoplasmic IKKα with clinico-pathological characteristics of 
the ST-Bre-TMA cohort. Chi-squared analysis explored the relationship of cytoplasmic 
expression of IKKα with various characteristics of the cohort. 
 
Clinico-pathological characteristic Association with cytoplasmic IKKα  
Age P=0.546 
Size P=0.272 
Grade P=0.036 
Nodal Status P=0.043 
NPI P=0.011 
PgR status  P=0.593 
HER2 P=0.738 
Ki67 P=0.212 
Apoptosis (TUNEL) P=0.427 
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5.3.4   Cytoplasmic expression of IKKα in the ST-Bre-TMA and clinical outcome 
in different luminal subtypes 
When this was subdivided into luminal subtypes, in luminal A tumours cytoplasmic IKKα 
nuclear expression was not significantly associated with survival (P=0.214, Figure 5.7A), 
recurrence free interval (P=0.137, Figure 5.8A) or recurrence on tamoxifen (P=0.110, Figure 
5.8C). In patients with luminal B tumours high IKKα was associated with poorer breast 
cancer specific free survival (P=0.018, Figure 5.7B), decreased recurrence free interval 
(P=0.031, Figure 5.8B) and quicker recurrence on tamoxifen (P=0.029, Figure 5.8D). This is 
not consistent with the previous cohort where a relationship with recurrence free interval was 
observed in patients with luminal A tumours, and further testing in a larger cohort is required.  
 
 
 
 
 
Figure 5.7: Cytoplasmic expression of IKKα and breast cancer specific survival in 
luminal subtypes in the ST-Bre-TMA. Expression of IKKα in the cytoplasm in patients with 
luminal A tumours was not associated with breast cancer specific survival (A). In patients 
with luminal B tumours (B), high IKKα was associated with reduced breast cancer specific 
survival. Censor lines indicate loss to follow up or death due to other cause. 
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Figure 5.8: Cytoplasmic expression of IKKα and clinical outcome in luminal subtypes in 
the ST-Bre-TMA. Expression of IKKα in the cytoplasm in patients with luminal A tumours 
was not associated with recurrence free interval (A) or recurrence on tamoxifen (C). In 
patients with luminal B tumours however, high IKKα was associated with shorter recurrence 
free interval (B) and quicker time to recurrence on tamoxifen (D). Censor lines indicate loss 
to follow up. 
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5.4   Discussion 
It was previously observed that nuclear expression of phospho-p65 and cytoplasmic 
expression of IKKα were both associated with recurrence in ER positive breast cancer and 
these markers were therefore tested in an independent cohort of ER positive patients. 
 
When levels of phosphorylated p65 at serine residue 536 were assessed, these were much 
higher overall than the previous cohorts. The median histoscore of nuclear phospho-p65 was 
110 with an interquartile range of 80 to 140. The cut off established in the previous cohort 
was much lower at 15 histoscore units, however only 12 patients in the ST-Bre-TMA had a 
histoscore of 15 or less meaning the previously established cut off could not be applied for 
analysis due to insufficient numbers. This highlights the variability observed with levels of 
phosphoproteins, in agreement with the study by Pinhel et al previously described [173]. 
There are several studies that have investigated the stability of phosphoproteins in tissue 
studies by examining the effect of time to fixation and levels of phosphoprotein observed. 
Expression of Akt phosphorylated at Ser 473 was lost in gastroesophageal tumour resections 
but present in biopsies [179]. Additionally, western blotting showed a greater decrease in 
levels of phospho-Akt over time with a half life of 20 minutes, in comparison to total Akt, 
which had a half life of 180 minutes [179]. Due to the often transient nature of the process, 
and the results from Baker et al and Pinhel et al, it may be expected that phosphorylation may 
be lost with delays in fixation; however increase in phosphorylation has also been reported. 
Jones et al studied the effect of a delay in fixation on markers associated with Src tyrosine 
kinase activity by assessing levels of phosphorylation of focal adhesion kinase and Paxillin, 
both downstream markers of Src [180]. No difference was observed in bladder tumours 
however, in breast cancer specimens, an increase in phosphorylation of Paxillin was observed 
over time [180]. Furthermore, another study reported an increase in certain proteins and 
decreases in others and reasoned that this is dependent on the function of the protein [181]. 
This collection of research again demonstrates the importance of time to fixation and the need 
for standardisation of procedures involved in every stage of tissue studies, particularly when 
using phosphoprotein antibodies. 
 
High levels of phospho-p65 in the nucleus were not significantly associated with breast 
cancer recurrence or recurrence on tamoxifen, inferior breast cancer specific survival was 
however observed. A more reliable marker of activation of the canonical pathway is therefore 
required. Elevated IKKα in the cytoplasm was again associated with briefer recurrence free 
interval and also decreased breast cancer specific survival, validating that IKKα is a marker of 
poor prognosis in ER positive breast cancer.  However, when subdivided into luminal A and 
 149 
luminal B tumours, unlike the previous cohort in which IKKα was associated with recurrence 
in the luminal A tumours, in this cohort IKKα was associated with breast cancer specific 
survival, recurrence free interval and recurrence on tamoxifen only in luminal B tumours.  
The results from chapter 4 and chapter 5 therefore confirm that IKKα is involved with ER 
positive disease but question whether its role is dominant in the luminal A or luminal B 
subtype, suggesting that further validation is required in a larger cohort. The results do 
however again suggest that different pathways are active in different breast tumours and 
emphasises the need to consider breast cancer a collection of distinct diseases, which should 
be treated accordingly.  
 
Validation in a similar, but independent, cohort with patients from the same geographical 
location as the discovery cohort is considered internal validation [182]. Although this 
provides valuable evidence of the reproducibility of findings from the initial cohort, external 
validation is therefore still required. Using an independent cohort of patients from outwith the 
Greater Glasgow and Clyde area would provide substantiation that these markers are 
associated with breast cancer progression in other areas and strengthen evidence for use in a 
clinical setting. Larger numbers of patients are also required to ensure each subgroup is of 
sufficient statistical power. However, rather than to propose that these be used as biomarkers, 
the primary objective of investigation in a second cohort was instead to provide validation to 
strengthen the implication of IKKα involvement in endocrine resistance and that inhibitors of 
IKKα may be beneficial to patients with ER positive breast cancer.  
 
Although there are therapies currently available for ER positive breast cancer, many patients 
develop resistance to endocrine therapy and a better understanding of mechanisms driving 
endocrine resistance is required [84]. The results from both cohorts suggest a role for NF-κB, 
in particular IKKα, in endocrine resistance, with patients who have luminal (ER positive) 
tumours that have high IKKα showing quicker time to recurrence on tamoxifen. It has also 
been found that tamoxifen resistant MCF7/HER2 and BT474 cells have enhanced NF-
[183]. This along with the findings 
in the clinical cohort indicates that inhibitors of components of the NF-ĸB pathways, 
particularly IKKα, may therefore be beneficial to patient with ER positive tumours following 
development of endocrine resistance or in combination with endocrine therapy. Mechanistic 
studies examining the effect of preventing activation of the NF-ĸB pathways are required 
examining the most efficient method of suppression, such as inhibition of IKKα and IKKβ, 
and the impact this has on cellular viability. 
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In 2005 guidelines were published for tissue studies examining prognostic markers in 
tumours. These guidelines, known as REporting recommendations for tumor MARKer 
prognostic studies (REMARK), were established with the aim of improving the reporting of  
these studies by providing clear and complete reporting of data, allowing other researchers to 
interpret how useful the results are and the context of the findings [153]. As discussed on P54, 
these guidelines were adhered to in this chapter and the previous two chapters including 
clinical tissue. The only exception was that a power calculation was not used to justify sample 
size as tissue was used based on availability, however there was around 100 events for each 
end point in both cohorts and therefore these sample numbers are sufficient for a study of this 
kind, although validation of findings in a much larger cohort would be extremely beneficial. 
 
 
This chapter has therefore shown that IKKα was associated with recurrence free interval in a 
second cohort and also with recurrence on tamoxifen, however in contrast to the first cohort 
IKKα was only associated with clinical outcome in patients with luminal B tumours. 
Validaiton in a larger cohort from a different geographical location is therefore necessary 
before any conclusions can be drawn. The variability in phospho-specific antibodies was 
highlighted by the much higher levels of phosphorylation of p65 in this cohort. This has 
therefore demonstrated that selective markers of both the canonical and the non-canonical 
pathway are required. 
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Chapter 6: 
Expression of components of the NF-κB 
pathways in breast cancer cell lines
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6.1   Introduction 
The NF-κB pathways have been reported to be elevated in cancer cell lines, and it was 
observed in the clinical cohorts that high levels of expression of certain key members of the 
pathways are associated with poor clinical outcome. Further investigation was therefore 
carried out into expression of the canonical and non-canonical NF-κB pathways in breast 
cancer cell lines. Due to the differences observed in ER positive and negative tumours, both 
ER positive MCF7 cells and ER negative MDA-MB-231 cells were utilised as model cell 
lines to reflect the different ER subgroups of breast cancer. Expression of several family 
members, from both the canonical and non-canonical pathway, was assessed in both cell lines 
after exposure to ligands in order to compare the differences in NF-κB signaling in ER 
positive and ER negative breast cancer. Additionally, as difficulties with phosphorylated 
antibodies were highlighted in the tissue study using phosphorylation of p65 as a marker of 
activation of the canonical pathway and as there is no specific marker for activation of the 
non-canonical pathway, siRNA was employed to silence the kinases in each pathway and 
observe downstream effects using qPCR. 
 
6.2   Activation of the canonical NF-κB pathway in breast cancer cell lines 
To establish that induction of the canonical NF-B pathway could be observed in a cellular 
setting, key markers of pathway activation including the phosphorylation of the p65 subunit 
and degradation of IκBα were measured. Western blotting was performed using protein 
extracts prepared from ER positive MCF7 cells and ER negative MDA-MB-231 cells.  
 
Both TNFα and IL-1β have been reported to drive activation of the canonical NF-κB pathway, 
and these ligands were selected to investigate NF-κB activation in the breast cancer cell lines.  
A pilot experiment was performed to confirm which ligand could be utilised in future 
experiments. First cells were rendered quiescent by incubation in serum free media for 24 
hours and cells were then exposed to either TNFα or IL-1β, both at 20ng/ml, for various 
incubation periods as stated below. Proteins were then extracted from cells, separated by 
SDS-PAGE and transferred to a nitrocellulose membrane before visualisation (as described in 
Section 2.3). Expression of members of the canonical NF-B pathway was then investigated 
including IκBα, p65 and its phosphorylation status at serine 536, IKKβ and IKKα. The 
expression of these proteins at various time points following TNFα or IL-1β stimulation are 
shown in Figure 6.1. In order to compare the amount of protein in each sample and allow 
proper assessment of the blotting, β-tubulin expression, a housekeeping gene independent of 
NF-κB, was used as a loading control.  
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6.2.1   Activation of the canonical NF-κB pathway in MCF7 and MDA-MB-231 
cells 
A preliminary experiment (N=1) was constructed to identify activation of the pathway 
following exposure to different ligands. This experiment was only performed once to guide us 
on future use of ligands and quantification of the blots was therefore not performed in this 
instance. In ER positive MCF7 cells, both degradation of IκBα and induction of 
phosphorylation of p65 were observed with TNFα and IL-1β exposure (Figure 6.1A). 
Compared to untreated cells, TNFα exposure resulted in a time dependent increase in p65 
phosphorylation, which remained elevated until 120 minutes. However response to Il-1β was 
more transient, returning to basal levels by approximately 120 minutes. Both agonists also 
induced a parallel stimulation of IκBα degradation with a time dependent decrease in IκBα 
from 15 minutes exposure and lowest levels at 30 minutes. After 60 minutes exposure to 
TNFα, expression of IκBα began to increase again. In ER negative MDA-MB-231 cells, 
although some degradation of IκBα was evident and slight increase is observed in p65 
phosphorylation in response to TNFα, phosphorylation is high at all time points including 
untreated control cells, showing constitutive activation of the canonical pathway in these cells 
(Figure 6.1B).  This made further induction of the pathway difficult to observe and neither 
ligand was able to induce the pathway to the same extent as that observed in the ER positive 
cells. Small levels of induction were, however, observed in response to TNFα, therefore 
TNFα was chosen as the ligand of choice for future experiments examining the canonical NF-
κB pathway. Expression of p65, IKKα and IKKβ did not change over the time course 
examined. 
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Figure 6.1: Expression of members of the canonical NF-κB pathway in MCF7 and 
MDA-MB-231 breast cancer cell lines at following TNFα or IL-1β exposure. MCF7 (A) 
and MDA-MB-231 (B) cells were exposed to 20ng/ml of TNFα or IL-1β for various time 
periods. Protein was then extracted, separated by SDS-PAGE and assessed for expression of 
IκBα, p65 and its phosphorylation status at serine 536, IKKβ and IKKα (N=1). β-tubulin was 
used as a loading control.   
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6.2.2 TNFα exposure and expression of components of the canonical NF-κB 
pathway in MCF7 cells 
TNFα was selected for stimulation of MCF7 and MDA-MB-231 cells in 3 separate 
experiments to allow quantification of expression levels of IκBα and phosphorylated p65. 
Again, cells were exposed to 20ng/ml TNFα for various time periods before protein was 
extracted, separated by SDS-PAGE and expression of members of the pathway visualised.  
Images were then quantified using ImageJ. Protein expression was normalised to the β-tubulin 
loading control and expression compared to untreated cells. Differences in expression were 
calculated using fold change to control, and graphs of IκBα and phospho-p65 expression were 
drawn. Stastistical analysis was performed using a one-way ANOVA with Bonferroni 
correction and Dunnett’s test to compare to control levels.  
 
TNFα induced IκBα degradation and phosphorylation of p65 in a time dependent manner in 
ER positive MCF7 cells (Figure 6.2). Degradation of IκBα occurred at 15 minutes incubation 
with TNFα, with an average reduction in expression to 55% of control levels (P=0.005). The 
minimal level was observed at 30 minutes stimulation, with only 17% of that of the levels in 
untreated cells (P<0.001). Expression of IκBα returned at 60 minutes. Phosphorylation of p65 
occurred earlier with around a 2.7 average fold increase at 5 minutes TNFα exposure. This 
was time dependent with a further increase in expression at 15 minutes to 4.4 times that of 
control cells (P=0.046). Expression peaked at 30 minutes with an average 5.2 fold increase 
(P=0.013). Phosphorylation remained high but began to return to basal levels with a 4.2 fold 
increase compared to control at 60 minutes (P=0.064) and a 3.3 fold at 120 minutes 
(P=0.232). Levels of p65, IKKα and IKKβ were unchanged by TNFα exposure.  
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Figure 6.2: Expression of members of the canonical NF-κB pathway in MCF7 breast 
cancer cells following TNFα exposure. MCF7 cells were exposed to 20ng/ml of TNFα for 
various time periods. Protein was then extracted, separated by SDS-PAGE and assessed for 
expression of IκBα, p65 and its phosphorylation status at serine 536, IKKβ and IKKα. β-
tubulin was used as a loading control. This is representative of 3 experiments. ImageJ was 
used to quantify expression of IκBα and phospho-p65 and levels in TNFα stimulated cells 
were compared to unstimulated cells, displayed as fold change to control in the bar graphs. 
Error bars represent standard deviation. Stastistical analysis was performed using a one-way 
ANOVA with Bonferroni correction and Dunnett’s test to compare to control levels. * 
signifies significant difference of P<0.05. ** indicates highly significant differences P<0.001. 
 
  
 ** 
   ** 
    * 
      * 
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6.2.3 TNFα exposure and expression of components of the canonical NF-κB 
pathway in MDA-MB-231 cells 
High basal levels of phosphorylation of p65 at serine 536 was observed in ER negative MDA-
MB-231 cells, but degradation of IκBα occurred following TNFα exposure (Figure 6.3).  
Phosphorylation of p65 was high at all time points indicating constitutive activation of the 
canonical pathway. Expression of phospho-p65 was increased slightly, but not significantly, 
at 15 minutes with around a 25% increase on average and at 30 minutes was 15% higher than 
unstimulated MDA-MB-231 cells. IκBα degradation was evident in the MDA-MB-231 cells 
with approximately 50 % reduction at 15 minutes (P=0.01) and a minimal level at 30 minutes, 
where expression was reduced by 63% compare to basal levels (P=0.002). Levels of IκBα 
began to return to basal levels at 60 minutes, where expression was 61% of control cells 
(P=0.044). Levels of p65, IKKα and IKKβ were unchanged by TNFα stimulation.  
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Figure 6.3: Expression of members of the canonical NF-κB pathway in MDA-MB-231 
breast cancer cells following TNFα stimulation. MDA-MB-231 cells were exposed to 
20ng/ml of TNFα for various time periods. Protein was then extracted, separated by SDS-
PAGE and assessed for expression of IκBα, p65 and its phosphorylation status at serine 536, 
IKKβ and IKKα. β-tubulin was used as a loading control. This is representative of 3 
experiments. ImageJ was used to quantify expression of IκBα and phospho-p65 and levels in 
cells exposed to TNFα were compared to untreated cells, displayed as fold change to control 
in the bar graphs. Error bars represent standard deviation. Stastistical analysis was 
performed using a one-way ANOVA with Bonferroni correction and Dunnett’s test to 
compare to control levels. * shows significant difference of P<0.05. ** indicates highly 
significant differences P<0.001. 
         
         *        
      *          
        * 
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6.2.4    Cellular location of p65 in MCF7 cells following exposure to TNFα  
Cell pellets of MCF7 cells exposed to 20ng/ml TNFα for 15 minutes show nuclear 
translocation when IHC was performed using an antibody that detects the p65 subunit or p65 
phosphorylated at residue 536 (Figure 6.4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4: Expression of the p65 subunit in MCF7 cell pellets following TNFα 
stimulation. MCF7 cells were exposed to 20ng/ml of TNFα for 15 minutes before formalin 
fixation and wax embedding. IHC was performed to assess cellular location of p65 and 
phosphorylated p65 (N=1). Images were taken at magnification of 1000x. This figure was 
previously displayed as part of Figure 4.2 to show antibody specificity. 
Untreated                         TNFα treated 
p65 
 
 
 
 
 
 
 
phospho 
-p65 
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6.3 Activation of the non-canonical NF-κB pathway in breast cancer cell lines 
Expression of members of the non-canonical NF-κB pathway was investigated including 
p100/p52, p100 phosphorylated at serine residues 866/870 and IKKα. A pilot experiment was 
performed to observe the expression of these proteins at several time points following 
treatment with various ligands. Exposure of MCF7 and MDA-MB-231 cells to IL-1β, TNFα, 
RANK-L or lymphotoxin 12 is shown in Figure 6.5. In order to compare the amount of 
protein in each sample β-tubulin was used as a loading control.  This experiment was only 
performed once to inform on future use of ligands and quantification of the blots was 
therefore not performed in this instance 
 
6.3.1 Activation of the non-canonical NF-κB pathway in MCF7 and MDA-MB-231 
cells 
In ER positive MCF7 cells (Figure 6.5A), phosphorylation of p100 did not appear to be 
increased by RANK-L but did increase upon lymphotoxin exposure in comparison to 
unstimulated cells. No increase in p52 is obvious and a method of examining nuclear 
expression such as western blots of nuclear fractions or IHC on cell pellets may be required to 
visualise changes in p52 expression. TNFα and IL-1β exposure both also appear to increase 
expression of phospho-p100 indicating IKKβ driven activation of the non-canonical pathway. 
 
In ER negative MDA-MB-231 cells (Figure 6.5B), phosphorylation of p100 appears low in 
the control cells, although β-tubulin shows less protein present in this sample. TNFα also 
increased expression of phospho-p100 in these cells. 
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Figure 6.5: Expression of members of the non-canonical NF-κB pathway in MCF7 and 
MDA-MB-231 breast cancer cell lines following TNFα, IL-1 RANK-L or lymphotoxin 
exposure. MCF7 and MDA-MB-231 cells were exposed to 20ng/ml of TNFα, IL-1 or 
lymphotoxin α1β2 (LTx) or 100ng/ml RANK-L for various time periods (N=1). Protein was 
then extracted, separated by SDS-PAGE and assessed for expression of p100/p52, 
phosphorylated p100 and IKKα. β-tubulin was used as a loading control.   
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6.3.2 Lymphotoxin exposure and expression of components of the non-
canonical NF-κB pathway in MCF7 cells 
Lymphotoxin was selected for stimulation of MCF7 and MDA-MB-231 cells in 3 separate 
experiments to allow quantification of expression levels of p100/p52 and phosphorylated 
p100. Cells were exposed to 20ng/ml lymphotoxin α1β2 for various time periods before 
protein was extracted, separated by SDS-PAGE and expression of members of the pathway 
was visualised.  Images were quantified using ImageJ and protein expression was normalised 
to the β-tubulin loading control. Differences in expression upon lymphotoxin stimulation were 
calculated using fold change to untreated cells.  
 
Figure 6.6 shows a representative image of lymphotoxin stimulation in MCF7 cells and 
graphs showing the average fold change compared to untreated cells from the three 
experiments.  On average lymphotoxin increased p52 expression 1.4 fold at 4 and 8 hours 
stimulation and 2.1 fold after 24 hours (P=0.049). Variable results were however observed 
and investigating the expression of p52 in the nucleus alone may achieve more reliable 
results. An increase in p100 phosphorylation was clearer in MCF7 cells. At 4 hours 
lymphotoxin incubation, phosphorylation of p100 increased on average 5.2 fold. A further 
increase was observed to around 6.8 fold compared to control cells after 8 hours (P=0.024). 
Phosphorylation of p100 was highest at 24 hours exposure with an average 8.8 fold increase 
in expression compared to unstimulated MCF7 cells (P=0.005). Levels of IKKα remained 
constant between unstimulated and stimulated cells. 
 
 
6.3.3 Lymphotoxin exposure and expression of components of the non-
canonical NF-κB pathway in MDA-MB-231 cells  
Figure 6.7 shows a representative image of three separate experiments investigating 
expression of p100/p52, phospho-p100 and IKKα in MDA-MB-231 cells. Constitutive 
expression of phospho-p100 is observed, with little different between control and stimulated 
cells. No increase in p52 is evident with lymphotoxin exposure. IKKα levels were unchanged 
by stimulation with lymphotoxin. 
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Figure 6.6: Expression of members of the non-canonical NF-κB pathway in MCF7 
breast cancer cell lines following lymphotoxin exposure. MCF7 cells were stimulated with 
20ng/ml lymphotoxin α1β2 (LTx) for various time periods. Protein was then extracted, 
separated by SDS-PAGE and assessed for expression of p100/p52, phosphorylated p100 and 
IKKα. β-tubulin was used as a loading control. This is representative of 3 experiments. 
ImageJ was used to quantify expression of p100, p52, phospho-p100 and IKKα. Expression 
levels in cells exposed to lymphotoxin were compared to untreated cells, displayed as fold 
change to control in the bar graphs. Error bars represent standard deviation. Stastistical 
analysis was performed using a one-way ANOVA with Bonferroni correction and Dunnett’s 
test to compare to control levels. * shows significant difference of P<0.05. ** indicates highly 
significant differences P<0.001. 
         
         * 
         
         *          
           * 
         
            * 
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Figure 6.7: Expression of members of the non-canonical NF-κB pathway in MDA-MB-
231 breast cancer cell lines following lymphotoxin exposure. MDA-MB-231 cells were 
stimulated with 20ng/ml lymphotoxin α1β2 for various time periods. Protein was then 
extracted, separated by SDS-PAGE and assessed for expression of p100/p52, phosphorylated 
p100 and IKKα. β-tubulin was used as a loading control. This is representative of 3 
experiments. ImageJ was used to quantify expression of p100, p52, phospho-p100 and IKKα. 
Expression levels in cells exposed to lymphotoxin were compared to untreated cells, displayed 
as fold change to control in the bar graphs. Error bars represent standard deviation.  
Stastistical analysis was performed using a one-way ANOVA with Bonferroni correction and 
Dunnett’s test to compare to control levels. * signifies significant difference of P<0.05. ** 
indicates highly significant differences P<0.001. 
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6.4 Inhibition of IKKα and IKKβ  
In order to block activation of the canonical and non-canonical NF-κB pathways, inhibition of 
IKKα and IKKβ was explored in breast cancer cells by reducing expression or altering 
function. 
 
6.4.1 siRNA silencing of IKKα and IKKβ in MCF7 cells 
Using a lipofection based method, small interfering RNA (siRNA) was delivered to the cells 
to reduce expression of IKKα or IKKβ. To optimise the efficiency of the siRNA, different 
concentrations of siRNA were transfected into the cells and optimal duration was established 
using both 48 and 72 hours silencing.  Non-targeting (NT) siRNA was used as a negative 
control to ensure observations were not due to the transfection procedure. Additionally, 
expression of the proteins after addition of lipofectamine alone was assessed. After silencing, 
protein was extracted from cells and protein expression assessed via western blotting. 
 
Figure 6.8 shows expression of IKKα and IKKβ in MCF7 cells after 48 hours (Figure 6.8A) 
and 72 hours (Figure 6.8B) silencing. At both 48 and 72 hours siRNA targeted to IKKα 
effectively reduced expression of IKKα at all concentrations. Similarly, reduction of IKKβ 
was observed at all concentrations at both 48 hours and 72 hours after transfection with IKKβ 
siRNA. Figure 6.8C shows the level of IKKα and IKKβ 48 hours after transfection with 
200nM siRNA. IKKα expression was reduced to 7.5% and IKKβ to 4% of expression in 
untreated cells. 
 
6.4.2 siRNA silencing of IKKα and IKKβ in MDA-MB-231 cells 
In 231 cells, expression of IKKα and IKKβ was greatly reduced after 48 hours silencing at all 
concentrations (Figure 6.9). The graphs in Figure 6.9 depict levels of IKKα and IKKβ 48 
hours after transfection with 200nM siRNA. Levels of IKKα were reduced to less than 2% 
and IKKβ expression following silencing was 3.6% of that in untreated cells.  
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Figure 6.8: Expression of IKKα and IKKβ after siRNA transfection in MCF7 cells. 
MCF7 cells were transfected with siRNA for IKKα and IKKβ at various concentrations (100, 
200 and 300nM). Non-targeting (NT) siRNA was used as a negative control. After 48 (A) or 
72  (B) hours protein was extracted, separated by SDS-PAGE and assessed for expression 
IKKα and IKKβ (N=1). β-tubulin was used as a loading control. (C) Fold change to control 
was calculated after images were quantified. Graphs show levels of IKKα or IKKβ after 48 
hours silencing with 200nM of siRNA (NT, IKKα or IKKβ). 
 C 
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Figure 6.9: Expression of IKKα and IKKβ after siRNA transfection in MDA-MB-231 
cells. MDA-MB-231 cells were transfected with siRNA for IKKα and IKKβ at various 
concentrations (100, 200 and 300nM). Non-targeting (NT) siRNA was used as a negative 
control. After 48 hours protein was extracted, separated by SDS-PAGE and assessed for 
expression IKKα and IKKβ (N=1). β-tubulin was used as a loading control. Fold change to 
control was calculated after images were quantified. Graphs show levels of IKKα or IKKβ 
after 48 hours silencing with 200nM of siRNA (NT, IKKα or IKKβ). 
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6.4.3 Infection with Adv.DN-IKKβ in MCF7and MDA-MB-231 cells 
Another method of manipulation of the pathway via inhibition of IKK function is the use of 
dominant negative (DN) versions of the kinases. DN-IKKβ is catalytically inactive and 
therefore cannot function as a kinase and overexpression results in reduction in activation of 
the pathway. Adenovirus was used to deliver DN-IKKβ to the cells.  To establish the most 
appropriate multiplicity of infection (MOI) various concentrations were used, measured by 
plaque forming units (pfu). Adenovirus expressing β-galactosidase (β-gal) was used a 
negative control. Figure 6.10 shows the expression of IKKβ in MCF7 cells and MDA-MB-
231 cells following infection with Adv.DN-IKKβ. 
 
In MCF7 cells, IKKβ expression increased in a concentration dependent manner (Figure 
6.10A). An increase of 2.6 fold compared to control was observed with 25 pfu, 2.9 fold with 
50 pfu and 3.4 fold with 100 pfu. The largest increase was observed with 200 pfu with a 4.8 
fold increase in IKKβ expression compared to control MCF7 cells.  
 
A concentration dependent increase was also observed with Adv.DN-IKKβ infection in 
MDA-MB-231 cells (Figure 6.10B). Expression of IKKβ increased only slightly (1.4 fold) 
with 25 pfu and (1.8 fold) with 50 pfu. Infection with 100 pfu Adv.DN-IKKβ increased 
expression of IKKβ 2.4 fold compared to control. The highest levels of IKKβ were observed 
with 200 pfu of Adv.DN-IKKβ, with an increase in expression of 2.9 fold compared to control 
MDA-MB-231 cells.   Unfortunately due to time constraints and availability this was not able 
to be optimised for IKKα, therefore for all further experiments in which the pathways were 
inhibited used siRNA to silence IKKα or IKKβ. This method should, however, be employed 
in studies continuing from this work to investigate the impact of loss of the IKK catalytic 
functions, while maintaining their scaffolding properties, more closely mimicking the use of 
inhibitors. It appears the breast cell lines used will be ameanable to this form of manipulation 
and further experiements should be conducted using ligands to investigate the effects 
downstream. 
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Figure 6.10: Expression of IKKβ in MCF7 and MDA-MB-231 cells infected with  
Adv.DN-IKKβ. MCF7 (A) and MDA-MB-231 (B) cells were infected with adenovirus with 
DN-IKKβ at various concentrations (25, 50, 100 and 200 pfu, N=1) for 40 hours. Infection 
with adenovirus with β-gal was used as a negative control. β-tubulin was used as a loading 
control. Fold change compared to control (shown in graphs) was calculated after images 
were quantified. 
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6.5 Effect of siRNA silencing of IKKα and IKKβ upon gene expression in MCF7 
cells. 
Due to the problems reported with phospho-specific antibodies and difference observed 
between cohorts in levels of phospho-p65 from the canonical pathways and the lack of 
specific markers of activation of the non-canonical pathway, experiments were carried out to 
identify selective markers of these pathways. In order to compare gene expression between 
control samples and samples with silenced IKKα or IKKβ and to attempt to establish selective 
downstream targets whose expression was altered following IKKα or IKKβ silencing, 
quantitative real time PCR (qPCR) was used. MCF7 cells were treated with siRNA and RNA 
extracted, cDNA made and qPCR performed. 
 
A panel of genes was selected as well as CHUK (IKKα) and IKBKB (IKKβ) to confirm 
silencing of expression at the mRNA level. The panel of genes tested contained genes that 
have been demonstrated in other cancer models to be regulated by IKKα and/or IKKβ, and 
one additional gene as a control that was reported to be IKKα and IKKβ independent.   Genes 
employed for this part of the study were CCND1 (cyclin D1, previously found to be IKKα 
dependent), NCOR2 (nuclear receptor corepressor 2, demonstrated to be IKKα dependent in 
other cancer models), CXCL10 (chemokine CXC ligand 10, dependent on both IKKα and 
IKKβ in previous studies), and CRLF1 (chemokine receptor-like factor 1, independent of 
IKKα and IKKβ). Levels of mRNA were normalised to those obtained for housekeeping gene 
18S and the comparative (ΔΔCt) method used to quantify relative gene expression compared 
to control and results are presented in fold change in the target gene relative to 18S 
endogenous control. (Fold Change = 2
-Δ(ΔCt)
 where ΔCt = Ct, target - Ct, 18S and Δ(ΔCt) = 
ΔCt, stimulated - ΔCt, control). A 2 fold change compared to control was considered as a 
relevant change in expression. 
 
Figure 6.10 shows gene expression in control cells and cells treated with NT, IKKα and IKKβ 
siRNA. Silencing of IKKα and IKKβ were confirmed at the mRNA level. Using siRNA for 
IKKα resulted in a decrease in mRNA expression levels of CHUK to 28% of control cells and 
siRNA for IKKβ resulted in a decrease in expression of IKBKB to 46% of that in control cells. 
A greater efficiency in silencing was therefore achieved with IKKα siRNA than IKKβ. In 
IKKβ silenced cells, mRNA expression of IKKα increased over 8 fold, suggesting a 
compensatory role in the absence of IKKβ. However, this was not confirmed at the protein 
level as no increase in IKKα protein is observed in lysates from IKKβ silenced cells (Figure 
6.8). No increase in IKKβ mRNA expression was observed in IKKα silenced cells. 
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Levels of CCND1 were increased 2.8 fold in IKKα silenced cells and therefore a significant 
increase in gene expression was observed. In IKKβ silenced cells this only increased 1.8 fold 
and cyclin D1 therefore appears to be a more IKKα dependent marker than IKKβ. Expression 
of NCOR2 was decreased to 45% following IKKα silencing and to 78% in IKKβ silenced 
samples, however levels in cells treated with NT siRNA were also decreased to 35% fold 
compared to control and therefore therefore it is not possible to comment using these results if 
NCOR2 is a IKKα and/or IKKβ dependent marker in breast cancer.  Therefore this experiment 
is required to be performed again before any conclusion could be drawn. 
 
CXCL10 levels increased 15.4 fold compared to controls following IKKβ silencing and to 5.6 
fold in IKKα silenced MCF7 cells. This target is therefore not selective for either IKKα or 
IKKβ but is affected by expression of both of these IKKs, although more strongly with IKKβ. 
Levels of CRLF1 were not significantly altered in IKKα or IKKβ silenced cells with 0.98 and 
1.4 respective changes observed, therefore confirming previous observations from other 
cancer models investigated within our laboratory. 
 
Unfortunately, this experiment was only completed once and only MCF7 cells were 
investigated and therefore no conclusions can be drawn from this. Several repeat experiments 
are required to ensure reliable and reproducible results are achieved and confirm if any are 
IKKα or IKKβ downstream targets in breast cancer cells.  However this does highlight that 
the markers identified in prostate cancer are not applicable in breast cancer and it appears that 
further work using a different method exploring more targets is required to identify IKKα and 
IKKβ selective markers in breast cancer. 
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Figure 6.11: Expression of IKKα and IKKβ after siRNA transfection in MCF7 cells. 
MCF7 cells were transfected with 200nM siRNA for IKKα and IKKβ (N=1). Non-targeting 
(NT) siRNA was used as a negative control. After 48 hours RNA was extracted, and used to 
make cDNA. Quantitative Real Time-PCR (qPCR) was then performed to assess gene 
expression of IKKa (CHUK), IKKβ (IKBKB) as well as four other genes, CCND1, NCOR2, 
CXCL10 and CRLF1. Levels of mRNA were normalised to those obtained for housekeeping 
gene 18S and the comparative (ΔΔCt) method used to quantify relative gene expression 
compared to control. 
    18S              CHUK         IKBKB          CCND1        NCOR2         CXCL10        CRLF1 
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6.6 Discussion 
Data from the clinical cohort suggests a role for the NF-κB pathways in the progression of 
breast cancer with differences in ER positive and negative tumours evident; in vitro studies 
were therefore performed to investigate expression of members of the NF-κB pathways in ER 
positive MCF7 cells and ER negative MDA-MB-231 cells.  
 
Expression of members of the canonical NF-κB pathway (IκBα, p65 and its phosphorylation 
status at serine 536, IKKβ and IKKα) were evaluated in the breast cancer cell lines by 
measuring protein levels via Western blotting and changes in expression following exposure 
to TNFα calculated. In MCF7 cells, TNFα exposure stimulated activation of the pathway, as 
demonstrated by degradation of IκBα and an increase in p65 phosphorylation at serine 536. 
MDA-MB-231 ER negative cells were observed to have constitutive activation of the 
canonical NF-κB pathway with high levels of p65 phosphorylation in untreated cells. This is 
in agreement with other studies that have reported elevated levels of NF-κB DNA binding 
activity in ER negative cells in comparison to ER positive cells [142]. Additionally, cellular 
location of p65 and phosphorylated p65 was examined using IHC on cell pellets and nuclear 
translocation was observed upon TNFα exposure. Although this is the required approach for 
validation of antibodies used in IHC due to cells being subject to formalin fixation, similar to 
the tissue cohorts, alternative approaches may be more appropriate for localisation studies. In 
hindsight immunocytochemistry, in which the cells are not subject to the same processing as 
in cell pellets, may have been a better method to select to study the localisation of the p65 
subunit following TNFα exposure. Other methods that could have been employed include 
immunofluorescence and Western blotting of fractionated protein samples. 
 
Similar results were observed with the non-canonical NF-κB pathway with induction of 
phosphorylation of p100 observed in MCF7 cells following exposure to lymphotoxin α1β2 and 
high levels demonstrated in MDA-MB-231 cells even before stimulation. Wang et al reported 
elevated levels of RelB, another component of the non-canonical NF-κB pathway, in a panel 
of ER negative breast cancer cells including MDA-MB-231 [184]. A difference in ER 
positive and ER negative cells is therefore evident for both canonical and non-canonical NF-
κB activity. 
  
Expression of IKKα and IKKβ was then silenced in both MCF7 and MDA-MB-231 cells and 
levels of both kinases assessed to test efficacy. Silencing reduced expression of IKKα and 
IKKβ at all concentrations in both MCF7 and MDA-MB-231 cells. Silencing was confirmed 
at the mRNA level with expression of CHUK (IKKα) and IKBKB (IKKβ) in MCF7 cells. 
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Transfection with siRNA was therefore efficient at silencing IKKα and IKKβ expression and 
optimal conditions were established.   
 
Expression of a panel of genes was also assessed in MCF7 cells using qPCR in an endeavour 
to identify selective downstream markers including CCND1, CXCL10, CRFL1 and NCOR2. 
Several reports have suggested cyclin D1, a protein involved in the G1/S transition in the cell 
cycle, as a target of NF-κB [185-186]. Expression of CCND1, which encodes for the cyclin 
D1 protein, was altered to a greater extent following IKKα silencing and to a lesser extent 
with IKKβ silencing. In knock-in mice where IKKα has serine residues that ordinarily 
undergo phosphorylation during activation of the pathway replaced with alanine, NF-κB 
activation was found to be defective and cyclin D1 expression was reduced [121]. 
Additionally, IKKα has been reported to regulate cell cycle through cyclin D1 expression in 
association with Wnt signalling [120]. This supports a role for both canonical and non-
canonical NF-κB regulation of cyclin D1 expression as observed by the present study.  As the 
literature suggests that IKKα induces cyclin D1 expression, it would have been expected that 
cyclin D1 would be reduced when IKKα was silenced. This was however not what was 
observed in this initial experiment or in studies in other cancer models in the host laboratory. 
Further experiments are however required to confirm our findings. In the host laboratory a 
gene card experiment using prostate cancer cell lines identified CCND1 as IKKα dependent 
but this does not appear to have translated to our breast cancer work as both IKKα and IKKβ 
were observed to influence CCND1 expression, albeit to much lesser extent with IKKβ 
compared to IKKα   
 
CXCL10, also known as Interferon gamma-induced protein 10 or eotaxin, is a chemokine 
whose expression has been reported to be induced by pro-inflammatory stimuli such as TNFα 
through activation of NF-κB [187]. CXCL10 expression has been demonstrated to be IKKβ, 
but not IKKα, dependent [188]. CXCL10 levels increased over 15 fold compared to controls 
following IKKβ silencing and to over 5 fold in IKKα silenced MCF7 cells. It was therefore 
found this target is not selective for either IKKα or IKKβ.  Again this gene was chosen as in 
the host laboratory this was observed to be IKKβ dependent in prostate cancer cells.  This has 
again not been translated into this initial experiment using breast cancer cell lines, although 
expression of CXCL10 appears to be affected to a greater degree by IKKβ absence. 
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Expression of CRLF1, which has to our knowledge not been reported to be associated with 
IKKα or IKKβ and was found to be independent of both in previous studies using prostate 
cancer cell lines, was assessed as an additional control. Expression was not significantly 
altered in IKKα or IKKβ silenced cells. The transcriptional coregulatory protein SMRT (also 
known as NCOR2) is phosphorylated by IKKα, contributing to its dissociation from 
chromatin. IKKβ was, however, not associated with derepression of SMRT [118]. Expression 
of NCOR2 decreased significantly following IKKα silencing but not IKKβ silencing and 
would therefore appear to be an IKKα selective marker. Levels in cells treated with NT 
siRNA were however decreased compared to control and repeated experiments are required. 
Although only conducted once and in one cell line, this preliminary study does however show 
that the markers identified as specific in prostate cancer are not likely to translate to breast 
cancer and therefore other methods to look at larger panels of genes should be explored in 
future studies. 
 
Although silencing was found to be efficient in reducing levels of IKKα and IKKβ, one 
potential problem with siRNA is off targeting effects where silencing of partially 
complementary transcripts occurs. In order to overcome this ON-TARGET plus which has 
position-specific sequence-independent chemical modifications to reduce off target effects 
was employed [189]. Additionally, compensation was evident between IKKα and IKKβ. 
When IKKβ was silenced in MCF7 cells, qPCR showed mRNA levels of IKKα increased 
over 8 fold. Furthermore, western blots show TNFα and IL-1β were able to induce 
phosphorylation of p100, therefore demonstrating IKKβ driven induction of the non-canonical 
NF-κB pathway. The role of IKKα and IKKβ appears to not solely involve IKKβ in the 
canonical and IKKα in the non-canonical NF-κB pathway, with compensation between both 
kinases apparent. IKKα has been demonstrated to play a compensatory role in the canonical 
NF-κB pathway upon IKKβ inhibition in a subtype of B-cell lymphoma [190]. Another 
method of inhibition of the IKKs is to instead use adenovirus-mediated delivery of dominant 
negative mutants of IKKα and IKKβ to inhibit activation of the pathways. This method allows 
the protein to maintain scaffolding function but as these mutants are catalytically inactive, 
they are unable to perform as a kinase and induction of the pathway is therefore blocked. 
Degradation of IκBα following TNFα exposure was inhibited in HUVEC cells following 
expression of DN-IKKβ [111]. Expression of DN-IKKα resulted in inhibition of p100 
processing and a reduction in p52 formation [191]. The use of DN isoforms of IKKα and 
IKKβ therefore appear to prevent activation of NF-κB signalling and may offer an alternative 
approach to inhibition in breast cancer cells. In both MCF7 and MDA-MB-231 cells infected 
with DN-IKKβ adenovirus, overexpression of IKKβ was observed and the breast cancer cells 
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therefore appear to be responsive to this method of inhibition.  
It has therefore been demonstrated that breast cancer cells, particularly ER positive MCF7 
cells, are amenable to manipulation of the NF-κB pathways. This was achieved either by 
exposure to ligands to drive expression of family members or by inhibiting expression of the 
kinases IKKα and IKKβ which are required for activation of the pathways. This will be 
further explored in the next chapter to investigate the impact of stimulating or inhibiting the 
NF-κB pathways on cell growth and viability. 
 
In conclusion, a difference in the NF-κB pathways is observed between ER positive and ER 
negative breast cancer in these in vitro studies assessing the expression of certain members of 
the canonical and non-canonical pathway. In ER positive MCF7 cells degradation of IκBα 
and phosphorylation of p65 (as markers of activation of the canonical pathway) and 
phosphorylation of p100 (as a marker of activation of the non-canonical pathway) were 
inducible by exposure to ligands that stimulate these pathways. In ER negative MDA-MB-
231 cells activation was observed in untreated cells indicating constitutive activation of these 
pathways.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
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Chapter 7: 
 
Phenotypic impact of stimulating or 
inhibiting the NF-κB pathways in breast 
cancer cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 178 
7.1 Introduction 
As discussed previously, we investigated the role of proliferation and apoptosis in breast 
cancer clinical cohorts and found both to be associated with clinical outcome.  In addition, we 
observed that high expression of the canonical and non-canonical pathways are associated 
with poorer clinical outcome. Furthermore, the previous chapter has demonstrated that breast 
cancer cell lines are amenable to manipulation of NF-κB signalling.  
We hypothesised that high expression of the pathways would be associated with poorer 
clinical outcome and that inhibition of the IKKs would reduce the viability of breast cancer 
cells. In order to address these hypotheses and explore the potential of the IKKs as novel 
targets in breast cancer, siRNA was employed to knock down expression of both kinases and 
the effect on cell viability and apoptosis was assessed. Due to differences in clinical outcome 
measures observed in the canonical and non-canonical NF-κB pathways between ER negative 
and positive breast cancer, and when investigating the signalling of these pathways in ER 
negative and positive breast cancer cell lines, differences in results between ER negative 
MDA-MB-231 cells and ER positive MCF7 cells were compared. 
 
7.2 Impact of stimulation of the canonical and non-canonical pathways on cell 
growth and viability 
The NF-κB pathways regulate genes involved in several aspects of cancer development and 
progression including cell death and growth [104]. In order to explore the consequence of 
activation of the pathways, cells were rendered quiescent in serum free media before 
stimulation of the canonical or non-canonical pathways by exposure to TNFα or lymphotoxin 
respectively. Using several assays the impact of activation of the pathways on cell growth and 
viability was assessed. 
 
7.2.1 Assessment of apoptosis in breast cancer cells following stimulation of 
the NF-κB pathways 
Apoptosis levels were measured using a commercially available ELISA kit to detect cell 
death after stimulation. This one step sandwich ELISA quantifies levels of DNA 
fragmentation. The amount of dye, which is proportional to the amount of DNA 
fragmentation, is then measured using a spectrophotometer and the levels of apoptosis 
calculated. 
 
Again, cells were exposed to 20ng/ml of TNFα or lymphotoxin for various lengths of time 
(24, 48 and 72 hours) and the ELISA to detect cell death was then performed. Cells were 
incubated in the vehicle used to deliver the ligand (distilled water for TNFα and PBS with 
 179 
0.1% BSA for lymphotoxin) as a negative control to ensure this was not responsible for any 
effects observed. Statistical analysis was performed on the results from three experiments 
using a one-way ANOVA with Bonferroni correction and Dunnett’s test to compare to control 
levels. 
 
7.2.1.1 Apoptosis in MCF7 cells following stimulation of the NF-κB pathways 
TNFα stimulation increased apoptosis in ER positive MCF7 cells after 24 hours incubation 
(P=4.2x10
-4, Figure 7.1A). However 48 and 72 hours TNFα incubation did not significantly 
alter apoptosis levels (P=0.065 and P=0.237 respectively, Figure 7.1A). Incubation in the 
vehicles did not affect the number of apoptotic cells. Lymphotoxin significantly increased 
apoptosis in MCF7 cells at all incubation periods examined (24 hours P=6.0x10
-6
, 48 hours 
P=0.008, 72 hours P=3.0x10
-6
, Figure 7.1B).  
 
As an additional control for the assay conditions, apoptosis was measured in cells incubated 
in full serum media for 24 hours, 48 hours and 72 hours following serum starvation. Full 
serum media rescued the cells from cell death and a decrease in apoptosis was observed at all 
time periods (24 hours P=4.0x10
-6
, 48 hours P=6.6x10
-8
, 72hours P=1.4x10
-7
, Figure 7.1C).
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Figure 7.1: Apoptosis in MCF7 cells following stimulation of the canonical and non-
canonical NF-κB pathways. Levels of apoptosis were measured using a Cell Death 
Detection ELISA kit. Cells were quiesced in serum free media then incubated in 20ng/ml 
TNFα (A), 20ng/ml lymphotoxin α1β2 (B) or full serum media (C) before the apoptosis assay 
was performed. SS = serum starved, V = vehicle (distilled water for TNFα and PBS with 0.1% 
BSA for lymphotoxin). Within each experiment an internal triplicate (3 wells per condition) 
was included and each experiment was completed independently 3 times. Stastistical analysis 
was performed using a one-way ANOVA with Bonferroni correction and Dunnett’s test to 
compare to control levels. Error bars represent standard deviation.  * shows significant 
difference of P<0.05. ** indicates highly significant differences P<0.001. 
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7.2.1.1 Apoptosis in MDA-MB-231 cells following stimulation of the NF-κB 
pathways 
In ER negative MDA-MB-231 cells TNFα did not induce apoptosis at any time point (24 
hours P=0.973, 48 hours P=1.0, 72 hours P=0.369, Figure 7.2A). Similarly, incubation in 
lymphotoxin did not affect apoptosis levels in these cells (24 hours P=0.125, 48 hours P=1.0, 
72 hours P=0.57, Figure 7.2B). Incubation in either vehicle (distilled water or PBS with 0.1% 
BSA) did not affect apoptosis. To rescue the cells from the level of apoptosis observed with 
serum starvation cells were treated with incubation in full media, but 24 hours incubation did 
not affect levels of apoptosis (P=1.0, Figure 7.2C). However, by 48 hours and 72 hours (both 
P<1.0x10
-6
) full media reduced the number of apoptotic cells. 
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Figure 7.2: Apoptosis in MDA-MB-231 cells following stimulation of the canonical and 
non-canonical NF-κB pathways. Levels of apoptosis were measured using a Cell Death 
Detection ELISA kit. Cells were quiesced in serum free media then incubated in 20ng/ml 
TNFα (A), 20ng/ml lymphotoxin α1β2 (B) or full serum media (C) before the WST assay was 
performed. SS = serum starved, V = vehicle (distilled water for TNFα and PBS with 0.1% 
BSA for lymphotoxin). Within each experiment an internal triplicate (3 wells per condition) 
was included and each experiment was completed independently 3 times. Stastistical analysis 
was performed using a one-way ANOVA with Bonferroni correction and Dunnett’s test to 
compare to control levels. Error bars represent standard deviation. * shows significant 
difference of P<0.05. ** indicates highly significant differences P<0.001. 
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7.2.2 Assessment of viability in breast cancer cells following stimulation of the 
NF-κB pathways by WST-1 
Cell viability was assessed using a WST-1 based assay. This colourimetric assay is based on 
cleavage of WST-1 to formazan. More activity of mitochondrial dehydrogenases, which 
corresponds to the number of viable cells, results in an increase in formation of formazan dye. 
The amount of dye is then measured using a spectrophotometer and the fold change compared 
to the control was calculated.  
 
Cells were treated with 20ng/ml of TNFα or lymphotoxin to stimulate the canonical or non-
canonical NF-ĸB pathway and then the WST-1 assay performed. Additionally, as a negative 
control cells were incubated in the vehicle used to deliver the ligand (distilled water for TNFα 
and PBS with 0.1% BSA for lymphotoxin). Experiments were repeated three times to allow 
statistical analysis using a one-way ANOVA with Bonferroni correction and Dunnett’s test to 
compare to control levels.  
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7.2.1.1 Cell viability, by WST-1, in MCF7 cells following stimulation of the NF-κB 
pathways 
In MCF7 cells, TNFα exposure did not impact on cell viability at any of the time points 
examined (24 hours P=0.316, 48 hours P=0.673, 72 hours P=0.972, Figure 7.3A). Incubation 
in lymphotoxin for 24 hours resulted in a slight increase in viability (P=0.020, Figure 7.3B) 
but 48 hours and 72 hours incubation did not significantly alter viability (P=0.051 and 
P=0.052 respectively, Figure 7.3B). Incubation in either vehicle did not affect cell viability. 
As an additional control for the assay conditions, viability was measured in cells incubated in 
growth media containing full serum for 24 hours, 48 hours and 72 hours following serum 
starvation. Incubation in growth media containing serum for 24 hours significantly enhanced 
cell viability (P=0.001, Figure 7.3C). A time dependent increase was observed, with highly 
significant increase in viability at 48 hours and 72 hours incubation (P=1.2x10
-5
 and 
P=1.0x10
-6
, respectively, Figure 7.3C). 
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Figure 7.3: Cell viability, assessed by WST-1, in MCF7 cells following stimulation of the 
canonical and non-canonical NF-κB pathways. Cell viability was measured using a WST-1 
assay. Cells were quiesced in serum free media then incubated in 20ng/ml TNFα (A), 20ng/ml 
lymphotoxin α1β2 (B) or full serum media (C) before the WST assay was performed. SS = 
serum starved, V = vehicle (distilled water for TNFα and PBS with 0.1% BSA for 
lymphotoxin). Within each experiment an internal triplicate (3 wells per condition) was 
included and each experiment was completed independently 3 times. Stastistical analysis was 
performed using a one-way ANOVA with Bonferroni correction and Dunnett’s test to 
compare to control levels. Error bars represent standard deviation. * shows significant 
difference of P<0.05. ** indicates highly significant differences P<0.001.  
A 
B 
C 
                                     . 
          lymphotoxin 
                                     . 
            TNFα 
 * 
    * 
        ** 
      ** 
F
o
ld
 c
h
a
n
g
e
 (
to
 c
o
n
tr
o
l)
 
F
o
ld
 c
h
a
n
g
e
 (
to
 c
o
n
tr
o
l)
 
F
o
ld
 c
h
a
n
g
e
 (
to
 c
o
n
tr
o
l)
 
Full media 
        ** 
        ** 
    
 186 
 
7.2.2.2 Cell viability, by WST-1, in MDA-MB-231 cells following stimulation of 
the NF-κB pathways 
TNFα exposure increased cell viability in MDA-MB-231 cells after 24 hours and 48 hours 
incubation (P=1.0x10
-6
 and P=3.0x10
-6, respectively, Figure 7.4A). 72 hours TNFα incubation 
did not significantly alter cell viability (P=0.998, Figure 7.4A). However, incubation in the 
vehicle (distilled water) also increased cell viability (P=0.002, Figure 7.4A). Incubation in the 
lymphotoxin vehicle (PBS with 0.1% BSA) did not affect cell viability (P=0.824, Figure 
7.4B) and lymphotoxin did not significantly affect viability in MDA-MB-231 cells at any of 
the incubation periods examined (24 hours P=0.359, 48 hours P=0.234, 72 hours P=0.995, 
Figure 7.4B). As an additional control for the assay conditions, viability was measured in 
cells incubated in full serum media for 24 hours, 48 hours and 72 hours following serum 
starvation. Incubation in growth media containing full serum for 24 hours did not significantly 
impact on cell viability (P=0.180, Figure 7.4C). An increase in viability was observed at 48 
hours and 72 hours incubation in full serum media (both P=0.001, Figure 7.4C). 
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Figure 7.4: Cell viability, assessed by WST-1, in MDA-MB-231 cells following 
stimulation of the canonical and non-canonical NF-κB pathways. Cell viability was 
measured using a WST-1 assay. Cells were quiesced in serum free media then incubated in 
20ng/ml TNFα (A), 20ng/ml lymphotoxin α1β2 (B) or full serum media (C) before the WST 
assay was performed. SS = serum starved, V = vehicle (distilled water for TNFα and PBS 
with 0.1% BSA for lymphotoxin). Within each experiment an internal triplicate (3 wells per 
condition) was included and each experiment was completed independently 3 times. 
Stastistical analysis was performed using a one-way ANOVA with Bonferroni correction and 
Dunnett’s test to compare to control levels. Error bars represent standard deviation.  * shows 
significant difference of P<0.05. ** indicates highly significant differences P<0.001.  
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7.2.3 Assessment of cell viability in breast cancer cells following stimulation of 
the NF-κB pathways using xCELLigence 
The xCELLigence machine was used to display cell growth and viability in real time [192]. 
Using special plates with microelectrodes, the impedance of each well was measured 
continuously in a non-invasive manner, allowing real time growth curves to be plotted. 
Measurements are produced using “Cell Index” which represents the number of viable cells in 
each well. Cells were serum starved for 24 hours before exposure to 20ng/ml 
TNFα/lymphotoxin or serum. The cell index for each condition was normalised at 0 hours 
treatment and experiments were continued 72 hours post treatment. For each treatment 
triplicate wells were included and each experiment was repeated independently to an N=2. 
 
7.2.3.1 Cell viability, by xCELLigence, in MCF7 cells following stimulation of the 
NF-κB pathways 
Results from xCELLigence show that lymphotoxin did not affect cell viability in MCF7 cells 
(Figure 7.5B). TNFα treatment, however, resulted in reduced cell viability from 24 hours post 
treatment, which continued to decrease at 48 and 72 hours incubation (Figure 7.5A). As 
expected, MCF7 cells incubated in media containing 10% serum had increased viability in 
comparison to cells that were deprived of serum. 
 
7.2.3.2 Cell viability, by xCELLigence, in MDA-MB-231 cells following 
stimulation of the NF-κB pathways 
Neither TNFα nor lymphotoxin appear to affect cell viability in MDA-MB-231 cells (Figure 
7.6A and Figure 7.6B). Incubation in media containing 10% serum greatly increased viability 
of MDA-MB-231 cells in comparison to cells that were deprived of serum. 
 
Results obtained from the different assays upon stimulation of the pathways with ligands 
appear to be variable. However, as expected, serum induced proliferation and reduced 
apoptosis resulting in increased cell viability. This was consistent across all assays for both 
MCF7 and MDA-MB-231 cells. Hence, comparison between cells that were grown in normal 
full serum media and those that had been starved of serum was used as a control for further 
assays. 
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Figure 7.5: Cell viability in MCF7 cells following stimulation of the canonical and non-
canonical NF-κB pathways. The xCELLigence was used to measure cell viability (expressed 
as cell index) and generate real time plots of these cells following stimulation of the NF-κB 
pathways. Cells were quiesced in serum free media then incubated in 20ng/ml TNFα (A), 
20ng/ml lymphotoxin α1β2 (B). Media with 10% serum (full media) was used as a positive 
control. V = vehicle (distilled water for TNFα and PBS with 0.1% BSA for lymphotoxin). 
Graphs shown are representative of two separate experiments. 
A 
B 
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Figure 7.6: Cell viability in MDA-MB-231 cells following stimulation of the canonical 
and non-canonical NF-κB pathways. The xCELLigence was used to measure cell viability 
(expressed as cell index) and generate real time plots of these cells following stimulation of 
the NF-κB pathways. Cells were quiesced in serum free media then incubated in 20ng/ml 
TNFα (A), 20ng/ml lymphotoxin α1β2 (B). Media with 10% serum (full media) was used as a 
positive control. V = vehicle (distilled water for TNFα and PBS with 0.1% BSA for 
lymphotoxin). Graphs shown are representative of two separate experiments. 
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7.3 Impact of silencing the IKKs on cell growth and viability 
To examine the effect of inhibition of the IKKs and further explore these as targets in breast 
cancer, we used RNA interference to knock down expression of both the kinases to observe 
the effect on cell growth and viability. Optimal conditions for siRNA transfection were 
previously established by visualisation of protein expression using western blotting, as 
discussed in chapter 6. 
 
7.3.2 Assessment of apoptosis in breast cancer cells following silencing of 
IKKα and IKKβ 
Levels of apoptosis were again assessed using an ELISA kit, which measures DNA 
fragmentation. MCF7 and MDA-MB-231 cells were transfected with 200nM IKKα and IKKβ 
siRNA, as well as NT siRNA as a negative control, and 48 hours post treatment the apoptosis 
assay was performed. Serum starvation, which as previously described induces apoptosis, was 
used as an additional control. 
 
7.3.2.1 Apoptosis in MCF7 cells following silencing of IKKα and IKKβ  
ER positive MCF7 cells treated with NT siRNA (as a negative control) did not show a 
significant difference in apoptosis when compared to untreated control cells (P=0.992, Figure 
7.9).   A significant increase was observed in levels of apoptosis when cells were treated with 
siRNA to silence expression of IKKα and IKKβ.  Compared to control cells, IKKα silencing 
resulted in a 5 fold increase on average (P=2.1x10
-5, Figure 7.7). Silencing IKKβ increased 
apoptosis almost 7 fold (P=1.0x10
-6
, Figure 7.7).  Additionally, consistent with previous 
findings, serum starvation significantly induced apoptosis resulting in over 2 fold increase 
compared to untreated cells  (P=0.038, Figure 7.7). 
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Figure 7.7: Apoptosis in MCF7 cells following silencing of IKKα or IKKβ. Using a 
lipofection based method, ER positive MCF7 cells were transfected with 200nM siRNA for 48 
hours and the ELISA for cell death was then performed to assess apoptosis levels. NT = non-
targeting siRNA, negative control. As an internal assay control, cells were serum starved to 
induce apoptosis. Within each experiment an internal triplicate (3 wells per condition) was 
included and each experiment was completed independently 3 times. Stastistical analysis was 
performed using a one-way ANOVA with Bonferroni correction and Dunnett’s test to 
compare to control levels. Error bars represent standard deviation. * shows significant 
difference of P<0.05. ** indicates highly significant differences P<0.001. 
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7.3.2.2 Apoptosis in MDA-MB-231 cells following silencing of IKKα and IKKβ  
ER negative MDA-MB-231 cells treated with NT siRNA (as a negative control) did not show 
a significant difference in apoptosis when compared to untreated control cells (P=1.0, Figure 
7.8).   A significant increase was observed in levels of apoptosis when cells were treated with 
siRNA to silence expression of IKKβ with an almost 5 fold increase on average compared to 
untreated cells (P=2.1x10
-4, Figure 7.8). Silencing IKKα expression, however, did not 
significantly affect levels of apoptosis (P=0.999, Figure 7.8).  As expected, serum starvation 
significantly induced apoptosis resulting in an 8 fold increase compared to untreated cells  
(P=1.0x10
-6
, Figure 7.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8: Apoptosis in MDA-MB-231 cells following silencing of IKKα or IKKβ. Using 
a lipofection based method, ER negative MDA-MB-231 cells were transfected with 200nM 
siRNA for 48 hours and the ELISA for cell death detection was then performed to assess 
apoptosis levels. NT = non-targeting siRNA, negative control. As an internal assay control, 
cells were serum starved to induce apoptosis. Within each experiment an internal triplicate (3 
wells per condition) was included and each experiment was completed independently 3 times. 
Stastistical analysis was performed using a one-way ANOVA with Bonferroni correction and 
Dunnett’s test to compare to control levels. Error bars represent standard deviation. * shows 
significant difference of P<0.05. ** indicates highly significant differences P<0.001. 
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7.3.1 Assessment of cell viability in breast cancer cells following silencing of 
IKKα and IKKβ using WST-1 
Similar to stimulation experiments, proliferation was assessed via a WST-1 assay.  Non-
targeting siRNA (NT) was used as a negative control to ensure results obtained were not due 
to the transfection procedure. Cells were treated with 200nM of siRNA for 48 hours before 
the assay was performed, and confirm via western blot that a decrease in expression had been 
achieved. Experiments were repeated to an N=3 to allow statistical analysis of the data. 
 
7.3.1.1 Cell viability, by WST-1, in MCF7 cells following silencing of IKKα and 
IKKβ  
In MCF7 cells treated with NT siRNA (as a negative control), cell viability were not 
significantly different to untreated control cells (P=0.773, Figure 7.9).   A decrease in cell 
viability was observed when cells were treated with siRNA to silence expression of IKKα and 
IKKβ (P=0.001 and P=6.8x10-5 respectively, Figure 7.9.  Additionally, consistent with 
previous findings, serum starvation significantly reduced cell viability compared to untreated 
control cells (P=1.0x10
-6
, Figure 7.9). 
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Figure 7.9: Cell viability, assessed by WST-1, in MCF7 cells following silencing of IKKα 
or IKKβ. Using a lipofection based method, ER positive MCF7 cells were transfected with 
200nM siRNA for 48 hours and the WST assay was then performed to assess viability. NT = 
non-targeting siRNA, negative control. As an internal assay control, cells were serum starved 
to inhibit proliferation. Within each experiment an internal triplicate (3 wells per condition) 
was included and each experiment was completed independently 3 times. Stastistical analysis 
was performed using a one-way ANOVA with Bonferroni correction and Dunnett’s test to 
compare to control levels. Error bars represent standard deviation. * signifies significant 
difference of P<0.05. ** indicates highly significant differences P<0.001. 
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7.3.1.2 Cell viability, by WST-1, in MDA-MB-231 cells following silencing of IKKα 
and IKKβ 
In ER negative MDA-MB-231 cells, cell viability were not significantly different in cells 
treated with NT siRNA than untreated control cells (P=0.954, Figure 7.10).   A decrease in 
cell viability was observed when cells were treated with siRNA to silence expression of IKKβ 
(P=0.002, Figure 7.10) but not IKKα (P=0.872, Figure 7.10).  Additionally, consistent with 
previous findings, serum starvation significantly reduced cell viability compared to untreated 
control cells (P=1.0x10
-6
, Figure 7.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10: Cell viability, assessed by WST-1, in MDA-MB-231 cells following silencing 
of IKKα or IKKβ. Using a lipofection based method, ER negative MDA-MB-231 cells were 
transfected with 200nM siRNA for 48 hours and the WST assay was then performed to assess 
viability. NT = non-targeting siRNA, negative control. As an internal assay control, cells 
were serum starved to inhibit proliferation. Within each experiment an internal triplicate (3 
wells per condition) was included and each experiment was completed independently 3 times. 
Stastistical analysis was performed using a one-way ANOVA with Bonferroni correction and 
Dunnett’s test to compare to control levels. Error bars represent standard deviation. * 
signifies significant difference of P<0.05. ** indicates highly significant differences P<0.001. 
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7.3.3 Assessment of cell viability in breast cancer cells following silencing of 
IKKα and IKKβ using xCELLigence 
Cell viability was also measured using the xCELLigence machine, as previously described. 
MCF7 and MDA-MB-231 cells were seeded in special plates with electrodes on the bottom 
and real time viability measurements recorded. Cells were treated with 200nM siRNA 
targeting either IKKα or IKKβ. NT (non-targeting) siRNA was used as a negative control to 
ensure observations were not due to the transfection procedure. Media was replaced after 8 
hours and cell index was normalised at this point. Real time plots were generated to 80 hours 
post-treatment. Although this was only performed once, the results are consistent with those 
obtained with the WST-1 viability assay and therefore add to the evidence of the role of these 
kinases in cell viability in the different ER backgrounds. 
 
7.3.3.1 Cell viability, by xCELLigence, in MCF7 cells following silencing of IKKα 
and IKKβ 
Cell viability plots following silencing in MCF7 cells is shown in Figure 7.11A. Cell viability 
in cells transfected with NT siRNA, employed as a transfection control, did not appear to be 
different to that observed for untreated cells. Both IKKα and IKKβ siRNA reduced cell 
viability in MCF7 cells. 
 
7.3.2.2 Cell viability, by xCELLigence, in MDA-MB-231 cells following silencing 
of IKKα and IKKβ 
Figure 7.11B shows cell viability in MDA-MB-231 cells following treatment with siRNA. 
Cells transfected with NT or IKKα siRNA did not display any difference in cell viability to 
untreated cells. IKKβ siRNA, however, reduced cell viability in MDA-MB-231 cells.  
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Figure 7.11: Cell viability, measured using xCELLigence, in breast cancer cell lines 
following silencing of IKKα or IKKβ. The xCELLigence machine was used to measure cell 
viability and growth in real time in both ER positive MCF7 cells (A) and ER negative MDA-
MB-231 cells (B). Cells were treated with 200nM siRNA to silence either IKKα or IKKβ. NT 
(non-targeting) siRNA was used as a negative control to ensure observations were not due to 
the transfection procedure. Media was replaced after 8 hours, results normalised and real 
time plots generated to 80 hours post-treatment. N=1. 
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7.4 Discussion 
Decreased cell growth and viability can reflect either a reduction in proliferation rates or an 
increase in apoptosis, or a combination of both mechanisms. Cell viability was measured 
through various methods including assessment of apoptosis using an ELISA, viability using a 
WST-1 assay real time growth and viability using xCELLigence. As observations from the 
clinical tissue implicated members of the pathway in the progression of ER positive breast 
cancer, the effect of stimulating the pathway or inhibiting activation through silencing of the 
relevant kinases was examined. Encouraging results were obtained when IKKα and IKKβ 
were silenced suggesting these are possible targets for exploitation in treatment of breast 
cancer. 
 
Variable results were obtained when ligands were applied to stimulate activation of the 
canonical and non-canonical pathways. Incubation with TNFα slightly induced apoptosis after 
24 hours in ER positive MCF7 cells and a reduction in cell viability was observed when 
xCELLigence technique was employed. However no change was observed using the WST-1 
assay at this time point. In ER negative MDA-MB-231 cells, TNFα increased viability 
slightly at 24 hours and 48 hour time points. Statistical analysis implied viability was also 
increased in the cells treated with vehicle. Although this effect was minimal, this however 
means that these results should be interpreted with caution. However, when the xCELLigence 
technique was employed no difference in cell viability between control cells or cells treated 
with vehicle or TNFα in MDA-MB-231 cells was observed. Although decreased viability is 
observed in MCF7 cells following exposure to TNFα, activation of NF-κB is associated with 
suppression of apoptosis. The role of TNFα in the cell is complex as it has been demonstrated 
to both induce apoptosis via activation of caspases and to aid cell survival by stimulation of 
expression of anti-apoptotic genes via NF-κB [193-194].  Therefore, although TNFα is often 
thought of as a ligand that induces apoptosis, it has a dual function and in the correct 
conditions can in fact inhibit apoptosis via NF-κB.  The anti-apoptotic role of NF-κB was first 
observed in p65 knockout mice, which die due to hepatic apoptosis mid-gestation [109].  
Further work has demonstrated activation of NF-κB induces the transcription of anti apoptotic 
genes such as X-linked inhibitor of apoptosis (XIAP), and overexpression of XIAP has been 
reported to protect cells from TNFα induced apoptosis as part of a feedback mechanism [193]. 
A complex relationship between TNFα and cell survival and apoptosis is therefore evident 
and it is likely that the reduction in cell viability that we observe in our experiments follow 
TNFα treatment is due to activation of an alternative pathway and may be completely 
independent of NF-κB. 
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Lymphotoxin was used to induce activation of the non-canonical pathway, as demonstrated in 
chapter 6. Incubation with lymphotoxin for 24 hours marginally increased both cell viability 
and apoptosis in MCF7 cells at all time points examined, although it is questionable if the 
levels observed would in fact have an overall effect as they were so small.  No difference, 
however, was observed between control MCF7 cells or cells treated with the vehicle or 
lymphotoxin using the xCELLigence method. In MDA-MB-231 cells lymphotoxin did not 
affect cell viability or apoptosis in any of the assays used. Results obtained from the different 
assays upon stimulation with ligands therefore appear to be variable at times, likely due to 
activation of various other pathways involved in cell survival and apoptosis. Nevertheless, as 
expected serum induction of proliferation and reduction of apoptosis, resulting in increased 
cell viability, was observed in all assays used, confirming that the assays were indeed reliable 
and the lack of consistency observed between assay types was more likely to be a 
consequence of the ligands employed rather than the reliability of the assays themselves. As 
use of full serum media gave consistent results across all assays for both MCF7 and MDA-
MB-231 cells this was subsequently employed as a control across all further assays. 
 
Phosphorylation of p65 was previously observed to be associated with poor recurrence free 
interval in breast cancer patients and others have reported that NF-κB activity is associated 
with reduced apoptosis and promotion of cell survival. It was therefore hypothesised that 
inhibition of the IKKs would induce apoptosis and diminish survival of breast cancer cells, 
making them possible targets for breast cancer treatment. This hypothesis was tested by 
silencing the IKKs and performing a series of phenotypic assays to assess cell viability and 
apoptosis.  Due to the complications that we observed in the previous set of experiments when 
ligands were employed to stimulate the NF-κB pathways, the experiments investigating 
silencing of IKKs utilised full serum media for pathway induction in preference to TNFα or 
lymphotoxin.  IKKβ, the kinase in the canonical pathway that is responsible for 
phosphorylation of p65 in response to certain stimuli, has been implicated in cell survival. A 
recent study in gastric cancer found expression of a microRNA that was upregulated in tissue 
and cell lines was associated with promotion of cell proliferation and prevention of apoptosis. 
This microRNA was found to be involved in regulation of NF-κB and genes induced by NF-
κB activation and inhibition resulted in a reduction in proliferation and increase in apoptosis 
[195].  In both MCF7 and MDA-MB-231 breast cancer cell lines, it was observed that 
inhibition of IKKβ using siRNA robustly induced apoptosis and reduced cell viability. 
 
In keeping with results from the clinical specimens, IKKα however only had an impact in ER 
positive MCF7 breast cancer cells. Loss of IKKα expression increased cell death and inhibited 
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cell growth resulting in reduced numbers of viable MCF7 cells. It therefore appears IKKα 
selective inhibitors would be most beneficial to patients with ER positive tumours. IKKα has 
been associated with the regulation of oestrogen-dependent genes such as cyclin D1 and  
c-myc, resulting in increased proliferation [119]. Oestrogen inhibits the Notch pathway and 
application of anti-oestrogens result in the activation of Notch [196]. Furthermore, the kinase 
activity of IKKα has been found to be associated with Notch in the activation of ER-
dependent genes [197]. Along with the finding that high cytoplasmic IKKα results in 
increased recurrence and that in ER positive MCF7 cells silencing IKKα decreased cell 
viability, this suggests that IKKα is associated with the ER and is a worthwhile target to 
pursue investigating in ER positive breast cancer. Until recently there have been no IKKα 
selective inhibitors available, but through collaboration with Strathclyde University on a 
CRUK Drug Discovery programme, our laboratory has been involved in the testing of new 
‘first in class’ IKKα inhibitors in prostate cancer and hope to employ these inhibitors as tools 
in our future breast cancer studies. 
 
Although these experiments yielded interesting results that add to the evidence that IKKα may 
be a potential target in ER positive breast cancer, there are several limitations of the in vitro 
work conducted in this thesis. The ER positive cell line used in this research was MCF7, as 
these are a widely used and well categorised ER positive cell line. These cells are caspase 3 
deficient due to a deletion in the CASP-3 gene, a critical constituent of the apoptosis cascade 
[198]. Studies investigating apoptosis in MCF7 cells have, however, found that in response to 
certain stimuli (such as PBOX-6, a microtubule-targeting agent) DNA fragmentation and cell 
death still occur despite these cells lacking caspase 3 [199]. Despite the presence of apoptosis 
in these cells in our study, investigation into the effect of IKKα and IKKβ silencing on cell 
viability and apoptosis on in another ER positive cell line, or ideally in several, would be 
extremely beneficial at strengthening the data generated in this study. Other ER positive cell 
lines have been identified that express caspase 3, such as BT-474 or T47D, and testing these 
findings in these cell lines would be beneficial for validation of results [200]. 
 
Additionally cell lines were unfortunately not authenticated, which is a necessary process to 
ensure data is not misleading if incorrect cell lines are used. Authentication is an extremely 
important verification to verify that no cross-contamination has ensued and that genetic drift 
has not occurred. This is done by short tandem repeat DNA typing [201], examining a set of 
loci and comparing the profile of the cell line to that of a reference library. Cell line 
authentication should be performed for all future work.  
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In conclusion, through various methods it has therefore been demonstrated that IKKβ 
silencing increased apoptosis and reduced cell viability in both ER positive MCF7 cells and 
ER negative MDA-MB-231 cells. IKKα silencing, however, induced apoptosis and decreased 
cell viability solely in MCF7 cells. These results suggest IKKα may be a valid target for ER 
positive breast cancer. Further investigation is needed using a second siRNA, as well as using 
dominant negative versions of the IKKs, in multiple ER positive and ER negative cell lines.  
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8. General discussion and future work  
There are several hallmarks of cancer including self-sustained proliferation, resistance to 
growth suppressors and absence of apoptosis, all of which contribute to uncontrolled cell 
growth [123]. The NF-κB pathways regulate the transcription of a wide range of genes 
involved in many of these processes, as well as inflammation and immune response, and NF-
κB is thought to represent a link between inflammation and cancer [104]. We hypothesised 
that increased activity of the NF-κB pathways contributes to the recurrence of breast cancer. 
In order to address this hypothesis we aimed to establish whether members of the NF-κB 
pathway were associated with clinical outcome and investigate the potential therapeutic 
benefit of inhibitors of the pathways in certain subgroups of patients. 
 
First it was demonstrated that use of a MIB1 antibody to assess Ki67 expression via IHC was 
successfully able to stratify patients into groups with different outcome based on proliferation 
status in two independent cohorts. Additionally, in accordance with the study by Cheang et al 
[54] and recommendations by the expert panel at the St. Gallen Conference [48], it was found 
that Ki67 in addition to HER2, ER and PgR status appeared to appropriately identified 
luminal A, luminal B, HER2 enriched and triple negative tumours, allowing the use of a 
stratified approach for further investigations. 
After specificity of all antibodies was confirmed, IHC was employed on a TMA of patients to 
assess whether expression of members of the canonical and non-canonical NF-κB pathways 
were associated with recurrence. High levels of phospho-p65 and IKKα were both associated 
with shorter recurrence free interval, possibly implicating both NF-κB pathways in the 
progression of breast cancer. When stratified by ER status, this relationship with both IKKα 
and phospho-p65 and recurrence free interval was retained in ER positive tumours but 
negated in ER negative tumours. Other studies have also reported an association with high 
NF-κB activity, assessed by p50 DNA binding activity, in ER positive tumours [139]. 
Diverging roles were observed for each pathway however, with the canonical NF-κB pathway 
associating with angiogenesis and recurrence in luminal B patients and expression of the non-
canonical NF-κB pathway associating with cell death (both necrosis and apoptosis) and 
recurrence in luminal A patients. These results add to the growing body of evidence that 
highlight the need to consider breast cancer not as one disease but a collection of breast 
diseases with different molecular profiles, allowing patients, where possible, to be treated 
based on these profiles. 
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A difference between ER positive and ER negative breast cancer was also reflected in our in 
vitro work using cell lines of different ER status. Consistent with other studies, which 
observed elevated levels of components of both the canonical and non-canonical NF-κB 
pathways in ER negative cells [142], high basal expression levels of both phospho-p65 and 
phospho-p100 were observed in ER negative MDA-MB-231 cells. In contrast, although basal 
levels of both NF-κB pathways were low in ER positive MCF7 cells, activation of both 
pathways was inducible. 
The use of cell lines representative of each subtype would be greatly beneficial to investigate 
the relationship of phospho-p65 and IKKα with the different luminal tumours, however often 
these are simply defined as luminal rather than specifying which of the luminal subtypes it 
reflects [202-203]. Suggestions of cell lines representative of the luminal subtypes have 
defined MCF7 cells as luminal A based on their profile using immunohistochemistry and 
proposed BT474 cells as representative of luminal B tumours [204]. These immunoprofiles 
include ER, PgR and HER2, and the difference between luminal A and luminal B is therefore 
defined by HER2 status. However, upon further examination of the relationship with 
phospho-p65 and luminal B tumours it was found that this relationship was most significant in 
luminal B tumours with high Ki67 rather than those that were HER2 positive, although very 
small numbers were available for analysis and caution is required in interpretation of these 
results. The use of a cell line defined as luminal B based on HER2 status therefore does not 
appear to be the most appropriate for use in future studies continuing from this project. 
Additionally, when the molecular and phenotypic relation of a panel of breast cancer cells 
were evaluated in comparison to breast tumour samples, all of the intrinsic subtypes were 
represented with the exception of the luminal A subtype [205].  Furthermore, this study found 
that MCF7 cells were most similar to luminal B tumours [205]. There is therefore conflicting 
opinions on what cell lines best represent the different subtypes and subdividing breast cancer 
cell lines into luminal A and B remains difficult. In order to investigate the use of novel 
therapies and identify which patients are most likely to respond to these, in vitro preclinical 
models need to accurately represent the profile of tumours in different patients. One 
promising approach is the use of patient derived cell lines. These more accurately replicate the 
heterogeneity observed in breast cancer and models using patient derived xenografts are likely 
to be more useful in the translation of cancer therapies [206]. 
As an association was observed with both markers in ER positive breast cancer and 
recurrence in the first 5 years in ER positive patients receiving tamoxifen as endocrine 
therapy, a cohort of ER positive patients with information on recurrence on tamoxifen was 
 206 
selected as the second independent cohort used to validate findings. In this cohort phospho-
p65 was higher overall meaning the cut off established in the previous cohort was unable 
to be used due to too few numbers in the low, highlighting the difficulty often experienced 
with phosphorylation status antibodies. Nuclear expression of phospho-p65 was not 
associated with recurrence free interval or recurrence on tamoxifen but was associated with 
poorer breast cancer specific survival. Levels of IKKα were however, were consistent with 
the previous cohort and high cytoplasmic expression was found to be more significantly 
associated with clinical outcome with quicker recurrence on tamoxifen, shorter recurrence 
free interval and reduced breast cancer specific survival. However as this was found to be 
in luminal B tumours, where in the previous cohort it was with luminal A tumours, and 
therefore further investigations are needed to strengthen the implication that IKKα may be 
associated with recurrence.  This cohort, although valuable to investigate recurrence on 
tamoxifen, unfortunately does not include patients treated with AIs. In order to determine 
whether NF-κB and the IKKs appear to be involved in resistance to AIs, examination of 
expression of the pathways in a cohort of patients treated with AIs is required. The 
Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial is a phase 3 trial with two 
arms where arm 1 was treated with the aromatase inhibitor exemestane and arm 2 was 
treated with tamoxifen for five years followed by exemestane [207]. This cohort is an ideal 
platform to test whether the pathways are also associated with recurrence on AIs and with 
tissue available for 4500 patients, it has sufficient statistical power to validate appropriate 
biomarkers. Additionally, this cohort includes patients from nine different countries, 
meaning that this would be considered external validation of the role of NF-κB in breast 
cancer progression, due to the inclusion of patients from a different geographical locations 
[182]. Work continuing on from the research presented in this thesis will investigate the 
identified markers in the TEAM trial cohort, in order to validate these initial findings and 
to further investigate them in the context of AI treatment. Investigations are needed into 
whether the relationship of these pathways with clinical outcome is due to a causative role. 
Although tamoxifen and other endocrine therapies are effective for the treatment of ER 
positive tumours, endocrine resistance remains a major clinical problem. The mechanisms 
behind progression are not yet fully understood and the Gap Analysis Working Group 
identified mechanisms driving resistance as one of the major gaps in research that if filled 
would make the biggest clinical impact [84]. Further investigation is required to examine 
the role of the NF-κB pathways in the transition from endocrine sensitive to endocrine 
resistant tumours. Studies exploring changes in other signalling pathways have used 
matched tissue of primary and recurrent endocrine resistant tumours. Using 77 matched 
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tumours, Drury et al assessed changes insulin-like growth factor receptor 1 (IGFR1) and 
the PI3K pathway in addition to ER, PgR and HER2 [208]. Through this approach the 
authors were able to confirm loss of ER and PgR as well as increase in HER2 expression in 
some of the tamoxifen resistant tumours. An increase in expression of stahmin, which has 
been identified as a marker of PI3K activation, was also detected, however no evidence of 
change in IGFR1 was observed [208]. Other studies within our laboratory in prostate 
cancer have examined the expression of the canonical NF-κB pathway, as well as aspects 
of PI3K signalling, in matched tissue from hormone naïve and castrate resistant tumours 
[135]. Expression of components of both NF-κB pathways in the transition from endocrine 
responsive breast cancer to resistant disease has yet to be assessed and investigations using 
matched tissue would be extremely valuable in assessing the role of these pathways in 
endocrine resistance. Additionally, mechanistic work is required in ER positive breast 
cancer cells that are resistant to endocrine treatment. In cellular models of tamoxifen 
resistance or oestrogen deprivation resistance, the effectiveness of a dual inhibitor of 
mTORC1/2 mTOR kinase inhibitor was assessed [209]. These cells allowed the authors to 
establish the impact of this inhibitor in acquired endocrine resistance. Use of this dual 
inhibitor was found to reduce proliferation, induce cell death and decrease migration and 
observations suggested the use of these inhibitors in combination with anti-oestrogen 
therapy may be an appropriate second-line treatment following endocrine resistance [209]. 
Use of similar in vitro models would be advantageous in the investigation of IKKα/NF-κB 
signalling in endocrine resistance and the incorporation of these models should be 
considered in future studies. 
Due to problems with phosphorylated antibodies and the lack of reliable markers of activation 
of the pathways we aimed to establish IKKα and IKKβ selective markers. Using siRNA for 
IKKα and IKKβ and qPCR, expression of a panel of markers used in previous studies in 
prostate cancer was examined. Of the genes investigated, however, no selective marker for 
either kinase was identified, although this experiment was only completed once. Markers used 
in prostate cancer were revealed using TaqMan Low Density Arrays (TLDA), which enable 
qPCR analysis of 384 markers in one experiment. The use of TLDA cards has been found to 
be a reproducible method with minimal variation when assessed for use in microRNA 
profiling [210]. The application of these arrays would be useful in future studies that 
endeavour to find both IKKα and IKKβ selective markers. 
Since the evidence from clinical specimens suggests high NF-κB may be associated with a 
poorer outcome, the potential of targeting the IKKs in breast cancer was investigated in ER 
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positive and ER negative cells. Silencing of IKKβ induced apoptosis and decreased cell 
viability in both MDA-MB-231 cells and MCF7 cells. On the other hand, increased apoptosis 
and reduced viability following silencing of IKKα was limited to ER positive MCF7 cells, 
suggesting inhibitors of IKKα would be beneficial for patients with ER positive tumours. A 
difference was observed in the luminal subtypes, with phospho-p65 associating with 
recurrence in luminal B subtype and IKKα associating with recurrence free interval and 
recurrence on tamoxifen in luminal A subtype. Patient selection may consequently be 
important in the use of NF-κB inhibitors and drugs selectively targeting both canonical and 
non-canonical arms of the NF-κB pathways may provide possible clinical benefit.  
Pharmacological intervention targeting NF-κB has already been proposed as a possible 
therapeutic option in many cancers due to its role in regulation of genes involved in cell 
growth and apoptosis. In 2006 a review of the literature revealed 785 modulators of NF-κB 
signalling at many different levels including those which stabilise and prevent degradation of 
IκB or result in upregulation of IκB expression as well as NF-κB DNA-binding inhibitors 
[211]. The present study suggests that a successful approach would be to selectively target the 
kinases IKKα and IKKβ, preventing activation of the pathway and therefore inhibiting 
downstream effects. Several compounds described as IKKβ inhibitors have been developed, 
including SC-514 from Pfizer, TPCA-1 from GlaxoSmithKline, BMS-345541 from Bristol-
Myers Squibb and ML120B from Millennium Pharmaceuticals [212]. However, many of 
these compounds also display inhibition of IKKα, although to a lesser extent and additionally, 
several of these inhibitors have displayed adverse effects [91]. There has therefore been no 
IKKα or IKKβ selective inhibitors available, but through collaboration with Strathclyde 
University on a CRUK Drug Discovery programme, our laboratory has been involved in the 
testing of new ‘first in class’ IKKα inhibitors and IKKβ inhibitors with a higher level of 
selectivity than previously available. These compounds require testing in breast cancer cell 
lines however initial studies involving prostate cancer models have yielded encouraging 
results. An exciting continuation of this project should therefore involve testing these novel 
compounds in in vitro breast cancer models.  
In conclusion, results from the current study demonstrate a possible role of both NF-κB 
pathways in the recurrence of breast cancer and expression of IKKα in the resistance to 
endocrine therapy. Additional thorough investigation, including both tissue studies and 
mechanistic work, is required to further elucidate the role of the NF-κB pathways and IKKs in 
the progression of breast cancer, though involvement of these pathways in breast cancer 
recurrence appears to exist. Inhibitors of this pathway may therefore a promising therapeutic 
approach in the future, once novel compounds are found to be selective and efficient in 
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preclinical models, and may be beneficial in the treatment of breast cancer, particularly 
following endocrine resistance.  
 
Future work  
Future studies continuing on from the research presented in this thesis should aim to validate 
results and further explore the role of the canonical and non-canonical pathways in the 
progression of breast cancer and test whether the upstream kinases are possible novel targets 
for breast cancer.     
One of the most interesting and novel findings from this study was the examination of the 
different pathways in the molecular subtypes of breast cancer. However, although IKKα and 
phospho-p65 were associated with poorer outcome in both cohorts in ER positive tumours, 
within the each cohort IKKα was associated with poorer outcome in different luminal 
subtypes. This should be further explored in a larger cohort from outwith the west of 
Scotland, information on subtypes would be extremely beneficial. The TEAM trial would be 
an excellent resource for this study, as well as to explore the association of the markers with 
endocrine resistance [207]. 
This study only used one ER positive and one ER negative cell line, and as previously 
mentioned although MCF7 cells are widely used and well characterised, these are caspase 3 
deficient [198] and may not be the most appropriate cell line to examine cell viability and 
apoptosis. Experiments should be repeated using a second ER positive cell line, for example 
T47D, which is not caspase 3 deficient or BT474, which is also not caspase 3 deficient and is 
HER2 positive, and another ER negative cell line, such as MDA-MB-330 or BT-20 cells. 
Additionally, repetition using a second siRNA for a different sequence from IKKα/IKKβ 
would improve the validity of the study. In hindsight, the time spent completing the viability 
and apoptosis assays after exposure to ligands that activate the pathway may have been better 
spent addressing some of these issues, such as testing the results obtained with both a second 
ER positive cell line and also a second siRNA. This should be performed in studies carrying 
on from the research presented in this thesis. Investigations using DN-IKKα and IKKβ should 
be carried out, as it has been shown that the breast cancer cells appear amenable to this 
manipulation but further examination of the effects on the signaling of the pathway is 
necessary. This should be followed by assays to test the affects of loss of IKKα and IKKβ in 
the presence of a ligand that drives each pathway. Additionally, the novel compounds should 
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be screened in breast cancer cells to investigate the effect these have on NF-κB signaling as 
well as cell viability. 
Other future in vitro work could also include a longer term viability assay to observe effects 
of loss of IKKα and IKKβ function, such as a clonogenic assay to measure the ability of 
single cells to form colonies of over 50 cells [213]. In order to address the lack of specific 
markers of the non-canonical pathway and the variation observed with the phosphorylation of 
p65, selective downstream markers are required. From the initial qPCR experiment performed 
in this study, it appears that markers identified as specific in other cancer models do not 
translate to breast cancer cells. Another method should be used to look at a much larger set of 
downstream markers to find ones selective for both pathways in breast cancer. This could 
include the TLDA cards, which were used previously in our laboratory to identify markers in 
other cancer models. 
 
Conclusion 
We hypothesised that high expression of the NF-κB pathways would result in poorer outcome 
in breast cancer patients and that these pathways may be involved in the development of 
endocrine resistance. Results presented in this thesis using two patient tissue cohorts suggest 
that both phosphorylation of p65, from the canonical pathway, and IKKα, from the non-
canonical pathway, may be associated with shorter recurrence free interval in ER positive 
breast cancer. Additionally, results from the second cohort also show that IKKα expression 
may be associated with recurrence on tamoxifen. Further investigation is needed in larger 
cohorts from another location in addition to studies that would provide evidence of a direct 
involvement, rather than association, of the pathways in the progression of breast cancer. It 
was also speculated that inhibition of the IKKs would reduce the viability of breast cancer 
cells. This was tested using siRNA to target IKKα and IKKβ in both ER positive MCF7 cells 
and ER negative MDA-MB-231 cells. It was found that loss of IKKβ expression resulted in 
reduced viability in ER positive and ER negative cells however IKKα silencing only reduced 
viability in ER positive cells. More mechanistic work is required, however it appears these 
may be possible targets, particularly in ER positive breast cancer, and further investigation 
into this is warranted. 
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